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1A Fresh Approach to Drugs
The UK Drug Policy Commission is an independent charity that provides objective 
analysis of the evidence concerning drug policies and practice. UKDPC is 
principally funded by the Esmée Fairbairn Foundation, and will finish its work 
in December 2012.
We bring together senior figures from policing, public policy and the media, along 
with leading experts from the medical and drug treatment fields, to encourage the 
formulation and adoption of evidence-based drug policies.
Our work has included reviews of:
• Employment issues for recovering drug users
• The extent, nature and impact of stigma towards drug users
• Support for families of drug users
• Programmes for drug-dependent offenders
• Efforts to tackle drug markets and distribution networks
• Harm reduction approaches to drug law enforcement
• Options for controlling new drugs
• The impact of drugs on Minority groups
• Impact of localism and austerity on drug interventions
• How drug policy is made in the UK.
All UKDPC reports are available for free download at: www.ukdpc.org.uk.
ISBN: 978-1-906246-41-9
Published: October 2012
Design by David Casey at dha communications.
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FOREWORD 
Drug policy is currently a mix of cautious politics and limited evidence and 
analysis. This is coupled with strident and contested interpretations, both of the 
causes of problems and the effects of policies. In fact, for as long as there has been 
a drug policy, there have been gaps in the evidence as well as uncertainty about 
how to understand and act on the evidence that we do have.
The UK Drug Policy Commission was set up six years ago as an independent 
organisation with the remit of analysing the evidence about what works in drug 
policy. We have come to the conclusion that drug policy may struggle to address 
current and emerging challenges if it carries on as it is. 
We can make some progress by improving existing programmes, for example 
through enhancing drug treatment and recovery efforts, by promoting disease 
prevention measures, and by prosecuting members of serious and organised 
criminal networks.
But we need a new approach if we are to go further.
We need to focus on the twin goals of how society and government can support 
and enable people to behave responsibly, and how they can stimulate and help 
individuals recover from drug dependence. And we need an evidence-based 
approach which puts at the forefront the need to find out what promotes such 
goals.
Our research has pointed towards a number of areas where this approach can 
help make UK drug policy better able to meet existing and future challenges.
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We all have an interest in knowing which policies work in tackling problems 
associated with drug use. Many members of the public, and many politicians, 
believe that our drug policies are not working. But the debate about how we 
address the challenges of mind-altering drugs is polarised, with an added 
emotional and moral aspect that is not seen in most other policy areas. 
The UK Drug Policy Commission was established to address these problems in a 
different way. Our aim has been to show how independent scrutiny of evidence 
can produce both better results and value for money in drug policy and practice. 
We believe that our projects - and their results - demonstrate how this can help to 
overcome the challenges which we now face.
Existing drug policies have struggled to 
limit the damage drug use can cause. 
Yet the rapid creation of new drugs is 
changing the drugs market too quickly 
for the traditional methods we use to 
control drugs. People can now use the 
internet, both to find out about new 
substances and to purchase a ready supply. The economic crisis may have an 
impact on the nature of drug use and drug problems in the UK, and with fewer 
resources, the capacity to respond will be limited further. Added to that, the speed 
and scale at which services are being devolved to a local level may mean there are 
increasing and unpredictable variations in the kind of services offered in different 
parts of the country. 
In this report we identify a fresh approach to drug policy, with both a recasting 
of how we structure our response to drug problems, and an analysis of the 
evidence for how policies and interventions could be improved. The chapters 
cover where we are now; the need for a fresh approach and what this could 
look like; potential barriers in policymaking and delivery; and finally, our 
recommendations for the future.
Our aim has been to show 
how independent scrutiny 
of evidence can produce 
both better results and 
value for money.
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WHERE WE ARE NOW 
For most people, illicit drug use is something that happens in their teenage years or 
young adulthood. As they grow up they stop using, largely without any problems. 
People who do develop drug problems do so for a range of complex reasons. 
These include their own personality traits, their personal history, their genetic/
biological makeup and their social circumstances, including how much they are 
exposed to illicit drugs and how easy it is to get hold of different substances. The 
consequences of using a substance are likewise influenced by context.
Contrary to popular opinion, levels of drug 
use have actually been declining in the 
UK over recent years. Injecting drug use, 
and the numbers with heroin and crack 
problems, have recently started to decrease 
in England. This has been driven by a fall 
in numbers in the younger age groups using heroin. Cannabis is still the most 
commonly used drug, yet its use has also been declining for several years. Overall 
stimulant use has remained steady although the drugs in fashion may change. Yet 
despite these encouraging falls in numbers, a higher proportion of people in the 
UK appear to consume drugs than in many other countries. 
At the moment, drug policy in the UK is based on taking measures to reduce 
the supply and demand for drugs, and increasing the rates of recovery of those 
dependent on drugs. There have been some important successes. For example, 
rates of HIV among injecting drug users are amongst the lowest in the world 
thanks to harm reduction approaches, such as needle and syringe exchanges. 
The number of people receiving treatment for drug problems has also steadily 
increased. 
Yet there are policies where there is very little evidence that they work or they 
have been cost-effective. This is not to say that they do not work, but that we do 
not have sufficient information to make an informed judgement. Some policies 
also end up having counter-productive effects. For example, sending drug users 
to prison without appropriate support either inside or on their release, may lead 
to a higher risk of death, reduced risk of recovery because their treatment is 
disrupted or they have nowhere suitable to live afterwards, as well as the impact 
on their families.
Levels of drug use have 
actually been declining 
in the UK over recent 
years.
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THE NEED FOR A FRESH APPROACH
While UK government drug policies have delivered some real successes in recent 
years, there is still a lot to do to address the remaining challenges, and to respond 
to new ones. The way that the UK makes and implements drug policy may also 
mean policy is not cost effective and does not manage to fully address the problem, 
especially in an era of austerity. 
The UK’s approach appears simplistic 
in several ways. Seeing all drug use as 
invariably problematic can reduce the 
cost-effectiveness of policy. Equally, drug 
problems need to be seen and addressed 
within their wider social and economic 
context; entrenched drug problems appear 
to be significantly linked to inequality 
and social exclusion. Finally, separating drugs from alcohol and tobacco use 
is difficult to justify when their relative harms are considered, and doing so 
makes it more difficult to tackle the full range of individuals’ substance use.
Taking drugs does not always cause problems, but this is rarely acknowledged 
by policy makers. In fact most users do not experience significant problems, and 
there is some evidence that drug use can have benefits in some circumstances. 
Drug policy also does not take into account the different reasons that people take 
drugs or can become addicted. In short, there is not a single drug problem and so 
we need a variety of solutions to a variety of problems. 
The debate over drugs reflects the different sets of values and professional interests 
that those engaging in it have, and thus why there are different views on what 
should be done to tackle the issues. But polarising the debate, for example over 
the relative virtues of enforcement and of treatment, is not productive. Debates 
about drug policy need agreement on goals, which can be hard, but also more 
realism about what will achieve those goals effectively. One of the most important 
factors that has impeded the introduction of more cost effective drug policies, 
and understanding the consequences (often unintended) of current policies, is 
the fact there has been inadequate collection and analysis of evidence. To address 
this we need to improve both the collection of evidence and the ways in which it 
is analysed and used.
The way the UK makes 
and implements drug 
policy may mean policy 
is not cost effective and 
does not fully address 
the problem.
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WHAT A FRESH APPROACH COULD LOOK LIKE
Drug policy is typically divided into 
three separate elements: prevention, 
treatment, and enforcement. This can 
result in duplication of work, missed 
opportunities for increased effectiveness 
through working together and feelings 
of institutional protectionism. When 
these different types of intervention operate without sufficient coordination they 
can function at cross-purposes - for example, enforcement activity near treatment 
centres can discourage people from turning up for treatment. These divisions, and 
a lack of open debate about the overall goals of drug policy, also lead to these 
interventions being seen not as tools but as goals in themselves, resulting in the 
focus being on activity rather than outcomes. That can reduce the effectiveness of 
programmes, lead to wasted resources, as well as inhibiting the development of 
more cost-effective ways of tackling drug problems.
We suggest making a clear distinction between the overall goals of drug policy and 
the tools to deliver it. Rather than starting with the traditional distinction between 
prevention, treatment and enforcement, it may be more effective to consider drug 
policy in terms of two higher level challenges. 
First, we need to look at how society and government can enable and 
support individuals to behave responsibly. This means tackling underlying 
causes of drug use, providing the information and skills necessary for people to 
make sensible choices about drug use, and ensuring that where drug use does 
occur, it is undertaken in a way that minimises the harm to the user and others. 
Second, we should focus on how society and government can enable 
and promote recovery from entrenched drug problems, whether 
for individuals or in communities. Then we can see how the practical tools of 
prevention, treatment and enforcement can help deliver this as well as how it links 
into wider social policy through the various supporting institutions, professional 
interests and social and economic programmes. 
What we mean by ‘responsible behaviour’ is that an individual should seek 
to behave in ways that allow them to achieve their potential and contribute 
positively to their families and communities and also to avoid incurring harm to 
other people in general. Behaving responsibly and limiting harm and damage to 
oneself and others are two sides of the same coin.
A lack of open debate 
about the goals of drug 
policy results in the focus 
being on activity rather 
than outcomes.
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At the heart of the goal of encouraging individuals to behave responsibly is the 
recognition that governmental policies and programmes can both facilitate and 
undermine this. Society and government need to adopt policies that seek to create 
an environment that is supportive of responsible behaviour.
For example, providing clean needles and syringes to injecting drug users to 
prevent the spread of HIV and other blood-borne viruses is a good illustration of 
how the state can help facilitate responsible behaviour, as it can also be a first 
step for drug users in a long journey of rebuilding their lives. Similarly, policies 
built on sound evidence designed to strengthen families and improve young 
people’s life skills and attachment to school can facilitate responsible behaviour 
and delay and prevent harmful drug use, even though many will still go on to 
experiment and use drugs. 
But some policies can undermine 
responsible behaviour. It is now well 
recognised that very aggressive stop and 
search tactics aimed at addressing drugs 
- employed by police in some places, 
and amongst certain ethnic groups - has 
had unintended negative consequences. 
Damage to communities’ and individuals’ trust in and their attitude to the police 
and other authorities can undermine other efforts to address the supply and use 
of drugs.
As part of efforts to encourage responsible behaviour, and our society’s 
response to it, we cannot ignore the fact that a small but significant segment of 
the population will experiment with drugs, and that some of them will continue 
to use drugs, even if they know about the risks. So we do not believe that pursuing 
the goal of encouraging responsible behaviour requires the prevention of all 
drug use in every circumstance. This is not to say that we consider drug use to be 
desirable. Just like with gambling or eating junk food, there are some moderately 
selfish or risky behaviours that free societies accept will occur and seek to limit to 
the least damaging manifestations, rather than to prevent entirely.
Drug policy needs to focus on ensuring that any drug use occurs in ways that pose 
lower risks of harm to others and to users. The bar should be set particularly high 
for children and young people given their physiological vulnerability to harm 
from drugs and because they are less able to make rational decisions about their 
own wellbeing.
Governmental policies 
and programmes can 
both facilitate and 
undermine responsible 
behaviour.
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On this basis, our approach is as follows. 
First, we conclude that the debate about 
drug policy should centre upon finding out 
how society and government can enable and support responsible behaviour, 
alongside stimulating and promoting recovery from drug addiction. Second, we 
say that focused work, looking at the evidence, is needed in order to show what 
policies we should adopt to achieve these goals. The best policy will depend on 
which users and suppliers we are talking about, on what drugs they are using 
and supplying, and on other factors relevant to their particular case as well as the 
types of harm being caused, both to individuals and to society. There are unlikely 
to be any silver bullets.
Over the past six years we have tested this approach by carrying out a wide 
variety of projects on particular problems and we have sought to make a careful 
assessment of what the evidence indicates might help address some of those 
problems. What follows here picks out the main conclusions of our work, and 
shows how the approach can be made to work.
SUPPORTING INDIVIDUALS TO BEHAVE RESPONSIBLY
There are a number of ways that society and government can foster an environment 
that supports responsible behaviour. This includes policies designed to prevent 
a range of harmful behaviours including truancy, offending and substance use, 
such as some early intervention programmes. While programmes which try to 
prevent young people from using drugs through education and information have 
generally been shown to have little or no impact - or even to increase drug use 
- some wider programmes that address children’s general behaviour and their 
attitudes to school and their beliefs about what is normal behaviour, may have an 
overall positive effect.
The evidence for traditional drug law 
enforcement efforts, which have focused 
on arrests and drug seizures with the aim of 
reducing supply, suggests that often they 
have limited or no sustained impact on 
supply. Often, they also have unintended 
consequences, resulting in an increase in 
the consequential damage that drug markets inflict on a community, for example 
where arresting one group of drug dealers leads to an increase in violence in the 
area as a result of a turf war between rival gangs seeking to fill the gap created. 
Programmes which try 
to prevent young people 
from using drugs have 
generally been shown to 
have little or no impact.
There are unlikely 
to be any silver bullets.
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But there is growing evidence that law enforcement can be effectively targeted 
to support responsible behaviour by focusing on particularly harmful groups or 
behaviours. For example, police operations that use intelligence to identify and 
prosecute drug dealers who are particularly violent or who exploit children, while 
providing to those at the lower level of drug dealing the option of support to 
change their lives, have proved successful in reducing the harms to communities 
in some areas.
Similarly, current drug laws can lead to unintended consequences, such as 
criminalising many otherwise law-abiding young adults, and is not always 
effective in encouraging people to behave responsibly. This growing disconnect 
between policy and practice, uneven application of the law, and consequent 
erosion of respect for the law, combined with evidence of benefits of alternative 
approaches, indicates that there is a need to consider modifications.
PROMOTING RECOVERY FROM ENTRENCHED DRUG PROBLEMS
Recovery from problematic substance 
use is a process that involves not only 
achieving control over drug use, but also 
involves improved health and wellbeing 
and building a new life, including family 
and social relationships, education, 
voluntary activities and employment. 
While the individual is at the heart of recovery, their relationship with the wider 
world - family, peers, communities and society - is an intrinsic part of the recovery 
process. Recovery is neither an easy nor a linear process and takes considerable 
time and effort to achieve and sustain, both for individuals and hard-pressed 
communities. 
The stigmatisation of people with drug problems and their families is a significant 
barrier to recovery. The wider community, including potential employers, 
could play a greater role in helping individuals to recover. Having contact with 
people who are in recovery from drug problems can help overcome fears and 
misconceptions based on stereotypes that can arise from the way in which drug 
problems are covered in the media and political debate. Families of people with 
drug problems are also often overlooked. Yet, not only can adult family members 
aid their relative’s recovery, but they also often need help in their own right.
 
There is scope for law enforcement and the criminal justice system to be more 
focused on supporting recovery. Programmes that seek to divert drug-dependent 
Recovery is neither an 
easy nor a linear process 
and takes considerable 
time and effort to 
achieve and sustain.
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offenders into treatment rather than simply relying on prison or probation, 
for example the Drug Interventions Programme and local initiatives such as 
Operation Reduction in Brighton, have proved successful in reducing acquisitive 
offending. In those cases where a prison sentence is necessary, the Integrated 
Drug Treatment System recently introduced in prisons has the potential to ensure 
that evidence-based treatment is more widely available for prisoners and to 
provide better links into community services so that progress in recovery can be 
maintained on release.
It is good news that there has been 
an increased focus on recovery in UK 
drug strategies. However, there is a risk 
that narrowly focusing on achieving 
abstinence from drugs does not make 
sufficient use of the evidence of the 
cost-effectiveness of a wide range of interventions and the need for flexibility 
and personalisation in service provision to accommodate the different needs of 
individuals. In short, one size does not fit all. Services such as needle exchange 
and drug consumption rooms have been shown not only to reduce harm from 
drug use, but also in some cases to provide a first step towards recovery. 
Similarly, treatment services, ranging from substitute prescribing to residential 
rehabilitation, can all contribute to recovery at different stages. Other factors, 
such as the availability of mutual aid and peer support, are crucial for sustaining 
recovery alongside a wider environment that is accepting of people trying to 
rebuild their lives, for example employers being more open and willing to give 
jobs to such people.
BARRIERS IN POLICYMAKING AND DELIVERY
Beyond specific policy proposals, there is also a need to address how drug policy 
is made and delivered in the UK. We identify several areas where the ways in 
which we make and deliver drug policy may be limiting our ability to develop and 
implement more cost effective policies. 
In general, independent research on what works in drug policy receives 
comparatively little funding in the UK. Among other bodies, this affects the 
government’s Advisory Council on the Misuse of Drugs (ACMD). Its very 
limited resources are now increasingly dedicated to investigating and making 
recommendations on new drugs, rather than a comprehensive programme of 
wider research and policy analysis.
Independent research on 
what works in drug policy 
receives comparatively 
little funding in the UK.
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A separate issue is the location of the political lead for drug policy. The UK is 
unusual among EU countries in that the Home Office is the lead department for 
drug policy; most countries situate their leadership in the Ministry of Health. It 
has been suggested that the Home Office leadership encourages a view of drugs 
as a crime issue rather than a matter of health. 
As noted previously, the debate about drug 
policy is often polarised and combative. 
This also applies in the political sphere. 
Because there appears to be such 
limited space for developing informed 
consideration of options, and reaching 
consensus, there are restrictions on the 
potential for investigating some policy alternatives.
Finally, localism and devolution are allowing greater experimentation across the 
UK, which may create the potential for the testing of innovative policies. However, 
localism may also limit the ability of the government to implement and track the 
effectiveness of a coherent national drug strategy.
RECOMMENDATIONS 
Having identified challenges, examined evidence, and suggested alternative ways of 
approaching drug policy, we conclude by making specific policy recommendations 
to address these challenges, based on our assessment of what evidence there is. It is 
crucial that the introduction of these policies is matched with significant efforts to 
monitor their impact and to extend the evidence base for what works. This will be 
valuable not only for demonstrating any successes, but is consistent with our belief 
that policy initiatives must be both evidence based and themselves be evaluated 
further; policymakers should also be transparent about what does not work. 
Supporting responsible behaviour
It is now well established that wider social 
and environmental factors contribute to 
turning someone’s vulnerability to drug 
use into actual drug use, and that use then 
becoming problematic. Equally, it is clear that there is a relationship between 
drug use and a range of other risky behaviours. This suggests that simply tackling 
drug problems and drug-using behaviour on their own is insufficient. Such efforts 
have to be integrated and coordinated with other social and economic policies. 
It is crucial that the 
introduction of these 
policies is matched with 
significant efforts to 
monitor their impact.
Simply tackling drug 
problems and drug-
using behaviour on their 
own is insufficient.
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Key opportunities for policy to support these include:
• Tackle structural problems that increase risk of drug problems
Social problems, such as income inequality, lack of a sense of community, 
feelings of exclusion and disenfranchisement, are likely to have an impact on 
whether someone develops drug problems. It is important that this is recognised 
within social policy more widely. The potential impact on drug problems should 
therefore be considered in broader social policy impact assessments.
• Develop and evaluate early interventions to help families and communities build 
resilience to drug problems alongside other problems
These programmes have the potential to provide a wide range of benefits beyond 
reducing drug problems but the evidence for their effectiveness is mixed. 
Nevertheless, there is some evidence for the cost effectiveness of some of these 
programmes, and this needs to be expanded and developed further. While it 
is likely that the overall impact on drug problems will be modest, there will be 
benefits in other areas as well.
• Provide evidence-based prevention 
programmes to support less risky choices
There is little evidence that drug-specific 
education makes a difference to the 
prevalence of drug taking. But we can 
give young people accurate information 
about drugs and other substances and 
their risks, which can influence drug-taking behaviour. Overall the evidence 
for cost effectiveness of drug-specific education is weak, although there is some 
evidence to support broader programmes that address behaviour more generally 
and build self-efficacy, help with impulse control and teach life skills, and these 
should be part of the national curriculum. Schools need to be provided with the 
necessary information to make sure they are in a position to choose cost-effective 
programmes and deliver them effectively.
• Promote interventions which reduce the harms of drug use
There is good evidence supporting a number of ways in which people who 
use drugs can be enabled to do so in such a way that harm to themselves and 
nearby communities are minimised. These include traditional harm-reduction 
programmes, such as needle and syringe exchanges and drug consumption rooms, 
and promising innovative approaches relating to recreational use of drugs, such 
as pill-testing services.
Numbers of arrests and 
amount of drugs seized 
do not necessarily reflect 
success in reducing the 
availability of drugs.
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• Involve local communities in law enforcement and assess its impacts
The evidence is weak for the efficacy of most traditional drug enforcement activity, 
especially that directed at major and middle-level drug dealers and criminal 
networks as well as border interdictions. But what there is supports interventions 
that take a problem-solving approach and that involve local communities. The 
traditional indicators, of numbers of arrests and amount of drugs seized, do not 
necessarily reflect success in reducing the availability of drugs and the damage to 
communities. All drug enforcement operations should be assessed to demonstrate 
their proven impact on communities, to allow 
for continuous improvements and better 
value for money. At the community level, 
enforcement should involve the affected 
communities in identifying problems and 
setting priorities to help focus on the most 
harmful aspects of drug markets.
Stimulating and promoting recovery from drug dependence
The new focus on recovery from drug dependence provides an important opportunity 
to increase the effectiveness of drug policy. However, as is recognised in the drug 
strategies across the UK, improved rates of recovery from dependence require the 
involvement of more than just treatment systems and government services. 
Policy opportunities to support recovery include:
• Tackle stigma towards people with drug problems and their families
Society as a whole needs to be engaged if we are to achieve the goal of reintegrating 
people with drug problems. For this to be successful, tackling the damaging stigma 
towards people with drug problems will be vital to provide a foundation and then 
an environment in which recovery is possible. This needs to be wide-ranging 
and government can set an example, including through its announcements. A 
wider stigma ‘campaign’ could improve public and professional knowledge and 
understanding of drug dependence and recovery.
• Make the criminal justice system more focused on recovery
Different policies need to work together rather than against each other to promote 
recovery. There needs to be more support for smart enforcement programmes, 
such as Operation Reduction, that divert drug-dependent offenders into the 
treatment system rather than the criminal justice system, and that work with 
communities to support them to reintegrate. Reducing the numbers of those sent 
The involvement of 
adult family members 
of people with drug 
problems can promote 
recovery for their drug-
using relative.
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to prison and improving integration between services provided in prisons and as 
part of community sentences and community-based services can also contribute 
to a criminal justice system that is more recovery focused.
• Provide greater support to families of people with drug problems
People with drug problems are more likely to achieve recovery if they have a 
supported and supportive family. The involvement of adult family members of 
people with drug problems can promote recovery for their drug-using relative, 
but they also need support in their own right. This needs to be reflected in local 
area planning processes and service development alongside the need to support 
children of drug-misusing parents. For families where substance misuse is 
intergenerational, new models of family intervention should be further developed 
and evaluated. 
• Continue to develop treatment systems, 
mutual aid networks and communities 
that support those recovering from drug 
dependence
To support recovery, a wide range of 
treatment, mutual aid and supportive 
local community approaches is required. 
Opportunities for action include promoting recovery through balanced treatment 
systems, which take account of the varied and individual nature of recovery, 
recognise diverse needs, and are underpinned by a competent workforce. The 
role of local communities including employers, faith groups and generic services 
should be enhanced, particularly if stigma among these groups is reduced. 
This requires investment in a skilled and competent workforce, as well as 
sustaining the level of spending on treatment and recovery services by the 
government and local councils. There is some evidence that mutual aid really 
helps recovery, and local groups should be supported. 
The laws on drug production, supply and possession
Our conclusions about how the law might be changed are structured in a possible 
order in which they could be introduced. We are aware that some are shorter term 
and some longer term adjustments. Of most importance is careful monitoring and 
evaluation of the impacts of any reforms.
Of most importance is 
careful monitoring and 
evaluation of the impacts 
of any reforms.
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• Review the process for classifying controlled drugs
The 40-year-old ABC classification system and the process of providing advice to 
ministers and Parliament have significant weaknesses. For many people it has 
lost credibility. There should be a wholesale review both of the Misuse of Drugs 
Act and the underpinning classification system. Such a review ought to examine 
the possibility of devolving decision-making responsibility to an expert body 
which could be accorded a statutory role to make classification decisions, with 
appropriate democratic safeguards.
• Reduce sanctions for drug possession
There are a number of reasons that support consideration of an overhaul of 
some aspects of the drug laws. These include the disconnect between policy 
and practice, negative effects of enforcement, erosion of respect for the law, and 
evidence about the impact of some law reforms in other countries.
With some 42,000 people in England & Wales sentenced annually for drug 
possession offences and about 160,000 given cannabis warnings, this amounts to 
a lot of time and money for police, prosecution and courts. On top of this comes 
the cost to the individual in terms of damage to employment prospects. Some 
people who do develop drug problems may also be put off from seeking help 
earlier because they are doing something illegal.
To address these costs, there is evidence 
to suggest that the law on the possession 
of small amounts of controlled drugs, 
for personal use only, could be changed 
so that it is no longer a criminal offence. 
Criminal sanctions could be replaced 
with simple civil penalties, such as a fine, 
perhaps a referral to a drug awareness session run by a public health body, or if 
there was a demonstrable need, to a drug treatment programme. The evidence 
from other countries that have done this is that it would not necessarily lead to 
any significant increase in use, while providing opportunities to address some of 
the harms associated with existing drug laws.
Given its relatively low level of harm, its wide usage, and international 
developments, the obvious drug to focus on as a first step is cannabis, which 
is already subject to lesser sanctions than previously with the use of cannabis 
warnings. If evaluations indicated that there were no substantial negative 
consequences, similar incremental measures could be considered, with caution 
and careful further evaluation, for other drugs.
The evidence from other 
countries is that this 
would not necessarily 
lead to any significant 
increase in use.
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These changes could potentially result in less demand on police and criminal 
justice time and resources. Given the experience of other countries, our 
assessment is that we do not believe this would materially alter the levels of use, 
while allowing resources to be spent on more cost-effective measures to reduce 
harm associated with drug use. We would expect the net effect to be positive.
• Address production and supply
We do not believe that there is sufficient evidence at the moment to support the 
case for removing criminal penalties for the major production or supply offences 
of most drugs. 
However, for the most ubiquitous drug, cannabis, it is worth considering whether 
there are alternative approaches which might be more effective at reducing 
harm. For example, there is an argument that amending the law relating to the 
growing of it, at least for personal use, might go some way to undermining the 
commercialisation of production, with associated involvement of organised crime 
and the development of stronger strains of cannabis (‘skunk’), that we have seen 
in the UK and other countries in recent years. Perhaps the most expedient course 
to take here would be to re-examine sentence levels and sentencing practice to 
ensure that those growing below a certain low volume of plants face no - or only 
minimal - sanctions. The impact of any such move would need to be carefully 
measured and evaluated so policymakers could make informed decisions about 
future actions.
• Review penalties for all drug offences
There is a case for Parliament to revisit the level of penalties applied to all drug 
offences and particularly those concerned with production and supply. Even 
though maximum sentences are rarely applied, in recent years there has been a 
clear drift upwards in the length of imprisonment for drug production and supply 
offences. This incurs costs in terms of burden on the taxpayer, yet there is little 
evidence to support the idea that this is a deterrent or, more importantly, has any 
long-term impact on drug supply. 
The priority for such a review should be to collect and evaluate evidence to ensure 
that penalties are working effectively to deliver proportionate justice for victims of 
drug-related crime, and to act as a deterrent for those whose activities are causing 
the most harm.
• Establish consistency in controls over all psychoactive drugs
Parliament should consider an integrated framework controlling the supply of 
all psychoactive substances, including alcohol, tobacco and solvents, as well as 
22 23
other drugs that are used for cognitive, appearance or performance enhancement, 
such as modafinil as a study aid or anabolic steroids for building muscle mass. 
This would provide an opportunity to remove anomalies that have grown up over 
the years.
Improving structures and processes for how we make 
and implement drug policy
• Introduce independent decision-making on drug harms
Both the Advisory Council on the Misuse of Drugs (ACMD) and the New Zealand 
Law Commission have proposed that an independent body could be empowered 
to take delegated decisions about controlling new drugs. The National Institute for 
Health and Clinical Excellence (NICE) and the Medicines and Healthcare products 
Regulatory Agency (MHRA) operate in this manner.
With appropriate parliamentary oversight and accountability, we see no reason 
in principle why decision making over the process of classification might not be 
delegated in its entirety to a new statutory body. We therefore recommend that the 
government should initiate a formal review of the powers and remit of the ACMD and 
explore different options for the assessment of harms and the classification process.
• Improve research and policy analysis
We need a better mechanism for 
embedding evidence and knowledge 
development into the drug policy process, 
incorporating evaluation of the drug 
strategy and a coordinated programme of 
research and knowledge dissemination. A 
new independent body should be set up and resourced to provide independent 
leadership, and coordination of research and policy analysis.
• Move the political lead for drug policy
The national debate about drugs needs to shift so we can foster an environment 
that values responsible behaviour, and which promotes recovery for those who 
develop drink or drug problems. This does not diminish the need to take strong 
action against those who break the law, such as those involved in serious or 
organised crime. 
Transferring responsibility for coordinating and leading national drug policy from 
the Home Office to the Department of Health would facilitate the development of a 
more active public health approach to drugs, that can improve public and political 
Fundamental questions 
about the direction of 
drug policy need to be 
considered in a cross-
party environment.
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understanding about how the UK should best respond to the drugs challenges 
over the next few decades. We do not think that transferring leadership will 
bring substantial change, at least in the short or medium term. But as a symbolic 
measure it would signal a fresh attitude to drug policy. 
• Create a cross-party political forum to progress dialogue about future policy
Fundamental questions about the direction of drug policy need to be considered 
in a cross-party environment. The most productive way of making substantial 
improvements to drug policies may be for the leaders of the main parties in 
Westminster and devolved governments to commit personally to setting up a cross-
party political forum tasked with exploring the question of ‘what next for UK drug 
policy?’ and engaging with the public to both reflect and inform public opinion.
• Evaluate local approaches
Devolution and localism should be seen as unique opportunities for natural 
experiments in drug policy which can, and should, be properly evaluated. 
Unfortunately we can find little evidence that either national or local public 
service bodies are considering this opportunity, except where they are initiated 
by central government.
If we continue to pursue national policies of devolution and localism in policing, 
heath care and education, we can no longer rely on osmosis or the market to 
ensure that the evidence about the impacts of different approaches is spread 
and acted upon. National drug strategies must pay attention to the crucial need 
to build our research and knowledge base and provide a mechanism to ensure 
this is transferred to the people that matter at local level, whether these are local 
councillors, Health and Wellbeing Boards, Police and Crime Commissioners or 
professionals in a range of disciplines. 
CONCLUSION
We think that our work has not only contributed to the development of policies 
that will be more cost effective in addressing the UK’s drug problems, but has also 
demonstrated the value of independent analysis of evidence.
Our research has identified a number of specific policy proposals which we are 
confident could be beneficially incorporated into practice. But of more value 
than the adoption of these specific 
policies would be a change in UK drug 
policy’s relationship with evidence. 
A commitment to the use of evidence 
Of most value would be a 
change in UK drug policy’s 
relationship with evidence.
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to inform which policies are adopted, combined with rigorous trials of new and 
existing policies, and a willingness to act on the results of this research, would go 
a long way towards ensuring that the UK has an effective and good value response 
to the use of mind-altering drugs. 
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KEY POINTS
>There is a widespread view that current drug policy 
is not working well
>New challenges are putting further pressure on the ability 
of existing drug policies to reduce the harm that drug 
use can cause
>Evidence-based approaches can provide a more effective 
policy that offers better value for money
>Over six years the UK Drug Policy Commission has taken 
an independent, objective view of the evidence in many 
areas of drug policy and promoted its findings in order 
to improve drug policy and practice
>This report brings together the findings from all our work 
and highlights our conclusions as to how drug policy 
and policy-making can be improved. 
Introduction
THE DOUBTS ABOUT DRUG POLICY
In June 2011, a YouGov survey asked, “In your opinion, how effective, if at all, is 
the current government’s approach to illegal drugs?”. Only 11% thought that it 
was very or fairly effective, while 53% thought it was ineffective*. The fact that for 
every person who thought the current approach is working, five considered the 
opposite, should give those concerned with the impact of drugs on society pause 
for reflection.
There are many policy makers and opinion leaders who privately express similar 
doubts about the effectiveness of the UK’s approach to controlled drugs. Many are 
hesitant to voice these publicly or act on those concerns either because they worry 
about the media and political consequences and see little political benefit in 
engaging with the issue or, perhaps more importantly, because they are uncertain 
what to do about it. 
Drug policy in the UK cannot be considered in isolation from the international 
context. We are signatories to a number of relevant international conventions, and 
most illicit drugs used in the UK originate elsewhere. However, serving political 
leaders in a number of countries, sections of the media and members of the public 
are now openly questioning the efficacy of current drug policies. 
At the sixth Summit of the Americas in April 2012, it was not only a handful of 
South American leaders calling for change. Stephen Carter, the Conservative 
Canadian Prime Minister, said: “What I think everybody believes is that the 
current approach is not working. But it is not clear what we should do.”1 President 
Obama also said: “it is entirely legitimate to have a conversation about whether 
the laws in place are doing more harm than good in certain places”, although he 
insisted legalising drugs is not the answer for the United States.2
In this country, as elsewhere, the debate about drug policy often appears to be 
polarised. On one side are the ‘drug warriors’ who argue that more enforcement 
and less tolerance are needed. On the other are the ‘drug legalisers’ who argue 
that the drug control system, with criminal penalties for possession, production 
and supply, is what is at fault and needs to be replaced. 
*In addition 25% responded ‘Neither effective nor ineffective’ and 11% ‘Don’t know’. 
YouGov Survey Results http://cdn.yougov.com/today_uk_import/ygarchives-
pol-yougov-drugs-130611.pdf [accessed 24/07/2012].
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The debate is often given an emotional and moral aspect that is not seen in most 
other policy areas. This is reflected in some of the language used to describe drug 
users, such as ‘evil’, ‘junkie’ and ‘scumbags’. The label ‘evil’ is also applied to drugs 
themselves, and not just to their use and distribution. Politicians and much of the 
public tend only to become aware of drug use when it has very severe consequences 
and makes disastrous impacts on the lives of individuals and communities. The 
impact of the policies themselves is less obvious. The consequence is that while 
some policymakers might see the current approach as imperfect, they are reluctant 
to make changes for fear of being blamed for future problems. 
Yet, despite this apparent polarisation, most people take more nuanced 
positions, at least in private, recognising that simple solutions are unlikely to 
be cost effective. In this report we set out to address how drug policies might be 
improved, without resorting to divisive ‘all or nothing’ solutions. It is possible to 
hold the view that current drug policies are not working as well as they might, 
without fully endorsing either of the polarised viewpoints described. But rather 
than simply seeking a solution in a compromise between these opposing views, 
we have sought to stand back and take a fresh look at how problems that can be 
caused by drug use might be tackled more effectively.
The benefits of doing things differently 
can be economic as well as social and 
cultural. Keynes’ observation about 
economic theory is salient: “The 
difficulty lies, not in the new ideas, 
but in escaping from the old ones, which ramify, for those brought up as most of 
us have been, into every corner of our minds”.3 
DRUGS IN SOCIETY
Throughout history, human beings have used psychoactive drugs: from 
hallucinogens in pre-Columbian America to opium in nineteenth century China, 
khat in East Africa and alcohol throughout much of the world. The majority of 
people in the world deliberately consume substances that alter their state of mind 
to varying degrees, whether as apparently innocuous as coffee and tea, or as 
damaging as heroin. Undoubtedly some users of all of these drugs may experience 
some level of harm including, for some, dependence or severe addiction. However, 
the majority pay for and use drugs, whether legal or illegal, simply to change their 
mood or their perception in ways that they consider beneficial and they consider 
the risk of harm to be acceptably low.
The difficulty lies, not in the 
new ideas, but in escaping 
from the old ones.
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A standard defence of the legality 
of alcohol cites the general benefit 
from the increased sociability that it 
induces, which is taken to outweigh 
the harm that excessive alcohol 
consumption causes to individuals, 
families and communities. It is difficult, even dangerous, to suggest that some 
illicit drugs might have similar ‘benefits’, which might be weighed against their 
harm. But we have to recognise that, for many users, drugs bring something to 
their lives that they value, be it pleasure, relief from pain, enhanced perceptions 
or performance. This perspective challenges the prevailing wisdom that all drugs 
are inherently ‘bad’ if used for non-medically authorised purposes.
The fact that a significant fraction of the population is willing to break the law 
in order to experience the effects of illicit drugs is an indication of how desirable 
they are to some, but by no means the majority of people. This use will not always 
cause harm but, because of the underground nature of the drug market, users face 
uncertain risks each time they consume drugs.
Most substances, whether food, alcohol, pharmaceutical or industrial products, 
are subject to different levels of legislative controls that govern their production, 
sale and use. Many psychoactive drugs are considered sufficiently dangerous as 
to require strict controls to suppress or, in some cases, prohibit their availability 
and use. While only around 1 in 20 people globally use an illicit drug each year, 
consumption of these drugs is regarded as a serious worldwide problem that 
requires concerted efforts to address. In the UK, the level of drug use is above 
the global average, with nearly 1 in 10 having taken a controlled drug in the last 
year.* In many countries, including the UK, policy relating to these drugs is a 
high-profile and sensitive issue which frequently absorbs much media, public 
and political attention. 
These illicit drugs and how we can best respond to their availability and use, are 
the subjects of this report. Drawing on nearly six years of work by the UK Drug 
Policy Commission (UKDPC) and other evidence, our aim is to evaluate whether 
the UK’s approach to these drugs and the problems they can cause is justified, 
and in what ways that approach could be improved.
*International comparisons need to be made with care as methods and frequency of 
data collection vary considerably as do cultural factors that may impact on willingness 
to report use. It is possible that the comparatively high level of reported drug prevalence 
and use in the UK is partly a consequence of better information systems and recording.
We have to recognise that, 
for many users, drugs bring 
something to their lives that 
they value.
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NEW CHALLENGES FOR DRUG POLICY
There can be no doubt that the use of all kinds of mind-altering drugs presents 
significant challenges in the UK. The harm that can be caused by the use of 
alcohol and tobacco are increasingly well known and are a focus of government 
attention. Likewise, and whatever one’s view of the morality of drug use or the 
impact of existing drug laws, it is clear that the use of drugs poses problems that 
require determined attention. While the drug policies pursued by successive UK 
governments over the past twenty years have limited the problems caused by drug 
supply and use, there is no guarantee that this will continue, or that the results 
could not be improved upon.
Indeed, in addition to the harms, most of which have been known for many years, 
there are increasingly important new factors that are making it more difficult for 
governments to manage the problems that drug supply and use can cause:
• The rapid creation of new psychoactive drugs is changing the drug market 
more quickly than traditional methods of drug control can respond. Between 2009 
and 2011, 114 new psychoactive drugs were identified in the EU.4 In the UK the 
Forensic Early Warning System identified 17 new substances between January 
2011 and March 2012.5 While the UK government now has powers to introduce 
temporary bans on some new drugs, it is clear that such new drugs are now being 
brought to market far more rapidly than the law or enforcement agencies can 
identify them and restrict the supply and use of those deemed harmful.
• The dynamics of the internet have meant new routes for the supply of many 
products, including controlled drugs and pharmaceuticals. Enforcement and 
regulatory bodies, including postal and delivery services are struggling to 
keep pace with this phenomenon. It also provides a readily accessible and 
uncontrolled source of information on drugs and drug use, which may have 
both positive and negative aspects.
• The economic crisis is likely to have a lasting impact on the nature of drug use 
and drug problems in the UK. The availability and nature of treatment services for 
people with drug problems are changing and may become more restricted. This 
could lead to reduced numbers succeeding in recovering from drug addiction. 
Cuts to police funding will mean some efforts to tackle the drug trade are reduced.
But in addition, wider social and economic problems may have a direct effect 
on the nature of drug use. In the recession of the 1980s, heroin use became 
widespread and entrenched in areas where there was high unemployment and 
social disadvantage. There are significant concerns that similar problems may 
recur if social and economic exclusion is not addressed.
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• A central part of the UK government’s programme is to increase local control 
over services. The reforms are far-reaching, incorporating public health, 
policing and drug treatment. Given the scale and speed of the reforms, the 
impact on drug use and drug problems is unpredictable. There may be increased 
variations between different parts of the country in terms of the level of problems 
and in the nature of the response of local services. In some respects this might be 
valuable if it enables new approaches to be explored within the limits of the law 
and if best practices are recognised and more widely promoted. However, there 
are concerns that the risks of more local control have yet to be fully explored so 
that undesirable outcomes might be avoided.
The choice of which policies we use 
to address the problems associated 
with all psychoactive substances 
is not a simple one. Not only are 
responses often expensive and time-
consuming, but policies can easily 
be ineffective, have unintended consequences and even be counterproductive. 
Some of the problems associated with controlled drugs may themselves be 
produced by aspects of drug policy and its implementation. For example, drug-
related deaths are more likely where people are obtaining drugs of uncertain 
purity from drug dealers, and the high levels of acquisitive crime by people with 
drug dependence to fund their drug use would not be necessary if heroin were 
available on prescription, as once was the practice in the UK. While there is a need 
for effective policies to address the consequences of drug use, it is inescapable that 
any response incurs costs. It is therefore essential to ensure that these efforts are 
both cost-effective and, as far as possible, avoid the many unintended costs that 
can be incurred by inappropriate, ineffective or counterproductive drug policies.
The UK has been seen as a world leader in the development of effective responses 
to the harm associated with the rapid spread of opiate use. However, in other 
areas, attempts to improve the UK’s drug policies have often struggled to make 
any headway. While there has been progress in some important areas, for example 
the expansion of evidence-based treatment for people with drug addictions, and 
some aspects of the UK’s drug problems seem to be gradually lessening, people 
in the UK still appear more likely to use illicit drugs than people in many other 
developed countries.
Drug-related deaths are 
more likely where people are 
obtaining drugs of uncertain 
purity from drug dealers.
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There are aspects of the current policy that 
can be built on, but at a time of reduced 
budgets, increased individual poverty and 
changing drug markets, we are concerned 
that UK drug policy may be reaching the 
limits of what is achievable within current 
approaches and with available funding. New ways of responding to the issues 
associated with illicit drug use are necessary.
THE WORK OF THE UK DRUG POLICY COMMISSION
The UK Drug Policy Commission was established in 2007 as in independent 
charity, funded principally by the Esmée Fairbairn Foundation, to provide 
objective analysis of the evidence concerning drug policies and practice.
The Commission has brought together senior figures from policing, public 
policy and the media, along with leading experts from the medical and drug 
treatment fields. The Commission’s aim has been to encourage the formulation 
and adoption of evidence-based drug policies through a series of evidence 
reviews, in which we have sought to involve key stakeholders to enhance the 
relevance and utility of the findings.
From the outset we decided to focus our efforts on examining domestic policies 
and interventions within the UK, while recognising many of the global influences 
underpinning drug policy. We also did not seek to examine the many parallel 
challenges in the use of others substances such as alcohol, tobacco or prescribed 
medicines although there are, of course, many similarities.
Each of the countries of the UK has its own drug policy and different mechanisms 
for responding to the problems associated with drug use and for collecting the 
information necessary for identifying such problems as well as monitoring policy 
implementation. These information and management systems are not always 
consistent, and so it is sometimes not possible to present data for the whole of 
the UK. Nevertheless we have sought to reach conclusions that can be applied 
broadly and will be useful for policymakers and practitioners throughout the UK.
Over the course of its work, the Commission has published reviews of the evidence 
across a range of issues in drug policy, including those relating to recovery from 
addiction, the families of drug users, drug policy and delivery systems, and 
approaches to law enforcement and drug control. The reports from these projects 
are available at www.ukdpc.org.uk.
New ways of responding 
to the issues associated 
with illicit drug use are 
necessary.
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The guiding principle for the work of the Commission has been to avoid 
preconceptions and to follow the evidence for what is effective, and to reach 
conclusions about how policies and interventions might be improved. We have 
sought to continue to be guided by that principle in the development of this final 
report. Our aim is that this report will not only be useful for those interested in 
the issues relating to illicit drug use, but that it will also demonstrate the value of 
evidence-based approaches to public policy more generally 
Throughout the report, we show 
how policy can make better 
use of research and evidence 
in order to produce better 
results and value for money. 
We identify where the evidence 
suggests specific improvements to existing policies can be made, and where it 
indicates that we should take a different approach altogether.
THE STRUCTURE OF THIS REPORT
In recent years, there have been several highly-regarded and wide-ranging 
inquiries into UK drug policy that have provided important and detailed 
conclusions. Among others, these include: the 2000 Police Foundation 
Independent Inquiry into the Misuse of Drugs Act; the government’s Foresight 
Drugs Futures 2025 project (2005); the 2007 RSA Commission on Illegal Drugs, 
Communities and Public Policy; the Academy of Medical Sciences’ 2008 report 
“Brain science, addiction and drugs”; and reports from the Advisory Council on 
the Misuse of Drugs. Parliament has also produced significant reports over the last 
decade, including the Home Affairs Select Committee’s 2002 report and the Science 
and Technology Committee’s 2006 report.6
A consistent theme in these reports has been that some policy reform is necessary. 
While most reform of drug policy will be evolutionary in nature rather than 
revolutionary, it is worrying that many of these recommendations have gone 
unheeded. But in addition to the new factors identified above, there is now a wider 
global recognition that all is not well with drug policy. The UK cannot insulate 
itself from this debate.
We begin with a review of where we are now, in Chapter One. This introduces 
readers to the current levels and nature of drug use and drug problems in the UK, 
and to the existing policy responses.
Policy can make better use 
of research and evidence in 
order to produce better results 
and value for money.
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Chapter Two provides a different 
perspective on drug policy. It 
identifies some of the current barriers 
that are restricting progress in 
drug policy, and suggests ways of 
overcoming these. It evaluates the 
current approach to making drug 
policy, covering all illicit drug use, as well as the way evidence and evaluation 
are, and are not, used to inform policy making. It suggests a fresh way in which 
drug policy can be approached.
Building on this, Chapter Three looks in more detail at how the approach 
identified by the previous chapter could be applied in practice. It adds a structure 
designed to encourage fresh thinking about ways of tackling drug problems. 
It makes use of the evidence available to evaluate the effectiveness of existing 
policies and to identify where improvements are needed. 
Chapter Four identifies issues in existing systems of policymaking and delivery 
that could be limiting the introduction of more cost-effective drug policies. It 
covers scientific advice, policymaking structures, and delivery mechanisms.
Finally, Chapter Five draws on the findings of the other chapters to make 
specific recommendations on how drug policy can evolve over the next decade. 
It covers the Commission’s conclusions on promoting responsible behaviour, 
encouraging recovery, the laws on drug possession, and how drug policy could 
be made in the future.
There is now a wider global 
recognition that all is not 
well with drug policy. The 
UK cannot insulate itself 
from this debate.
Chapter 1  Where we are Now
CHAPTER 
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WHERE WE ARE NOW
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KEY POINTS
>The UK appears to have higher levels of drug use than 
many comparable countries, although overall levels 
of use have been declining over recent years
>Drug problems develop for complex reasons, including 
an individual’s genetic/biological make-up, personality 
traits, personal history and social circumstances
>The level of harm caused by drug use is dependent 
on the context in which the drug is used
>UK drug policy has traditionally been organised 
under the three pillars of prevention, treatment 
and enforcement. More recently there has been 
an increased focus on recovery from dependence
>While there have been some successes in UK drug policy 
there are also costs, including unintended consequences.
Chapter 1  Where We Are Now
There is a tendency for people to talk about ‘the drug problem’ as if it was a 
simple, coherent issue, yet the picture is far more complex. UKDPC focused its 
attention on illicit drugs, which are the main focus of UK drug policy, but drawing 
distinctions among the wide variety of psychoactive substances is difficult (see 
Box 1).
Box 1: 
WHICH DRUGS ARE ILLEGAL?
In the UK, the 1971 Misuse of Drugs Act is the principal legislation for 
controlling certain substances. The Act categorises substances into classes 
A, B and C, according to their levels of harm; this in turn provides the level 
of punishment for breaches. The Act also provides a scale of varying levels 
of severity of control, known as Schedules, which reflect each substance’s 
suitability for medical or research purposes.
It is not the case that possession of substances controlled under the Act 
is forbidden or prohibited in all circumstances. Even those subject to the 
strictest level of Scheduling may still be used under a Home Office licence 
for research. Others have Schedules that allow them to be used medically: 
for instance opiates, which are categorised as class A, are widely employed 
for pain relief.
Therefore, while the term ‘illegal drugs’ is commonly used, it can be 
misleading. It is the way the drugs are produced, supplied and possessed, 
rather than the drugs themselves, that may be illegal. A further problem is 
that the term ‘illegal’ does not cover the harmful use of prescribed or other 
pharmaceutical drugs, nor the use of new psychoactive drugs that are not 
(yet) subject to legal control (known as ‘legal highs’).
An alternative, which we will use to describe all of these psychoactive 
substances, except when used medically or for research, is ‘illicit drug 
use’. The substances themselves can be described as ‘illicit drugs’ 
when they have been produced, trafficked, or possessed against UK or 
international laws.
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EXTENT AND NATURE OF DRUG USE
Estimating the number of people who use illicit drugs is not straight-forward.7 
Nevertheless, in the UK we have better sources of information on numbers of drug 
users than most other countries. These, despite limitations, provide some robust 
information on trends in use over recent years.
In thinking about drug use and 
associated problems people often 
distinguish between ‘problem drug use’ 
and ‘recreational drug use’. While any 
substance use may cause significant 
problems, in the UK problem drug use 
is most often defined as heroin and/
or crack cocaine use, which is often 
associated with dependence or addiction to these drugs and harmful consequences 
for health and crime problems.* 
So-called ‘recreational’ drug use, on the other hand, generally involves less 
frequent use often in nightlife settings and has some similarities to alcohol use. 
In these circumstances it often involves ‘club drugs’ such as powder cocaine, 
ecstasy, amphetamines, ketamine and the newer drugs, sometimes called ‘legal 
highs’. Cannabis is also most often used recreationally and in a wider range of 
settings, and is sometimes also used for therapeutic purposes. 
In addition, there is the group of drugs that are termed ‘enhancers’8, which are 
used to enhance cognitive or physical performance. Of course caffeine has been 
in widespread use for many years to help people keep going longer, but in the 
US there is increasing concern about the use of drugs such as methylphenidate 
(Ritalin) as a study aid, and in the field of sport the use of steroids and other 
methods of enhancing performance is a constant issue worldwide. These 
distinctions are not absolute. There is overlap between the groups, and all of 
these substances can cause problems of varying levels of severity in different 
individuals and circumstances.
*The definition tends to vary from country to country as it is a term of convenience used 
to define the most common and most harmful drugs in that country to provide a focus 
for policy. In Scotland it is defined as problem opiate or benzodiazepine use, in Northern 
Ireland where rates of drug use are lower it includes opiates and any cocaine use, while in 
Wales it is long duration or regular use of opioids, cocaine powder and/or crack cocaine.
While any substance use 
may cause significant 
problems, in the UK 
problem drug use is most 
often defined as heroin 
and/or crack cocaine use.
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Levels of problem drug use 
Until recently, the main focus of UK drug policy has been on the most severe end 
of the spectrum of drug problems: problematic heroin and/or crack users and 
injecting drug users. Estimating the numbers of people who have this level of 
problem is particularly difficult since the chaotic nature of the lifestyle of many 
of them means they are not included in most general population surveys. Other 
indirect methods of estimation, which make use of the fact that many people in 
this group have contact with treatment or the criminal justice system at some 
time, have to be used. In the UK, such methods have been developed and used 
regularly over recent years to give estimates of different types of problematic 
drug use. 
Within the UK the patterns of problem drug use vary between the constituent 
countries, as illustrated in Table 1 which shows the most recent and most 
comparable estimates of problematic use by country. Northern Ireland has much 
lower rates of problem drug use, particularly of opiate use, and their concerns 
are more with powder cocaine use. Scotland has higher rates of problematic use 
and also has had a greater problem with misuse of benzodiazepines, which is 
included in their estimates rather than crack use. 
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Table 1: 
ESTIMATED PREVALENCE OF PROBLEM AND INJECTING DRUG USE 
ACROSS THE UK
ADULTS AGED 15 TO 64 YEARS
Source: UK Focal Point on Drugs United Kingdom Drug Situation 2011 edition
Country Problem Drug Use Injecting Drug Use
Estimate Rate/1000 Estimate Rate/1000
England 306,150 8.93 103,185 3.01
Northern Ireland 1,395 1.28 470 0.41
Scotland 55,328 16.16 23,933 6.99
Wales 16,389 8.46 5,524 2.85
United Kingdom 379,262 9.31 133,112 3.27
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Although comparisons are difficult, the available data suggest that the UK has 
relatively high rates of problem drug use. For example, the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) reports that recent national 
estimates of problem opiate use tend to vary across Europe between one and eight 
cases per 1,000 population aged 15-64.9 The most recent estimate for England in 
2009/10 was 7.7 per thousand. However, the EMCDDA report also provides some 
comparative rates for other countries, with Russia and Ukraine having markedly 
higher rates than England (16 per thousand and 10-13 per thousand respectively) 
with rates for Australia (6.3), Canada (5.0) and the USA (5.8) all being slightly 
lower.
In England, the prevalence of 
injecting drug use and of problem 
drug use have recently started to 
decline due to a reduction in problem 
opiate use. Since the decline in 
problem drug use is driven by a 
decrease in both the prevalence rate 
and number of drug users in the younger age groups, it appears the number of 
new users is also decreasing (see Figure 1). The other side of this coin is that there 
is a growing cohort of older dependent users with changing needs associated with 
aging and the consequences of long-term opiate use.
In Scotland, problem drug use is taken to include problematic use of 
benzodiazepines. Some trend data is available and the decrease in problem 
drug use seen in England is not replicated: the number of users appears to be 
approximately stable. Wales and Northern Ireland have only so far had one 
estimate of problem use so there is no robust information on trends available.
The UK has relatively high 
rates of problem drug use. 
Estimates of problem opiate 
use for England in 2009/10 
was 7.7 per thousand.
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Figure 1: 
TRENDS IN PROBLEM DRUG USE IN ENGLAND BY AGE GROUP10
Adults aged 15 to 64 years. Rates per 1,000 population
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Cannabis: the most commonly used drug
Cannabis is much the most commonly used illicit drug in the UK, as in most of the 
world. In England & Wales in 2011/12, 31% of adults11 said they had used cannabis 
at some time in their lives, 7% had used it in the last year and 4% in the last 
month. In Scotland figures are similar but slightly higher with 8% reporting use 
of cannabis in the past year.12 Northern Ireland has slightly lower rates with 5% of 
adults reporting last year use of cannabis.13 In both these cases the figures relate 
to 2010/11. Across Europe prevalence of last year use of cannabis varies widely, 
ranging from less than 1% to about 14%.14 
Cannabis use in the UK has been declining 
for several years, and the decline has been 
greatest in younger age groups, although 
recently there has been a levelling off (see 
Figure 2).15 The decline in cannabis use is 
seen in surveys of both schoolchildren and 
adults and also appears to be occurring, 
although less markedly, in Scotland, as well 
as in England and Wales. In other European 
countries trends vary. Data from ESPAD (the 
European School Project on Alcohol and other Drugs: a survey of schoolchildren 
conducted across much of Europe) also shows the marked decline in prevalence 
of cannabis use among 15 to 16 year old schoolchildren in the UK between 2003 
and 2011, which is also seen in Ireland and Italy. However, in the Netherlands, 
Portugal and Sweden, prevalence is more or less stable over the same period.16 
 
Cannabis is much the 
most commonly used 
illicit drug in the UK. In 
2011/12, 31% of adults 
said they had used 
cannabis at some time 
in their lives.
19
96
20
11/
12
20
10
/1
1
20
09
/10
20
08
/0
9
20
07
/0
8
20
06
/0
7
20
05
/0
6
20
04
/0
5
20
03
/0
4
20
02
/0
3
20
01
/0
2
20
00
19
98
55 – 59
45 – 54
35 – 44
30 – 34
25 – 29
20 – 24
16 – 19
30%
25%
20%
15%
10%
5%
0
45Chapter 1  Where We Are Now
Figure 2: 
TRENDS IN CANNABIS USE IN THE LAST YEAR IN ENGLAND & WALES 
BY AGE GROUP
Source: Drug Misuse Declared: Findings from the 2011/12 Crime Survey for England 
and Wales
46 47
The wide range of other drugs used
The UK also has relatively high rates of use of other ‘recreational’ drugs, with new 
drugs creating a particular challenge for policymakers.17 Most of these drugs are 
stimulants and are used alongside alcohol in nightlife settings, such as clubs, bars 
and parties. Assessing the extent of, and trends in, use of such ‘party drugs’ is 
complicated by people using more than one type of drug (so-called ‘poly-use’), 
and also switching drugs depending on quality and availability.18 For example, 
Figure 3 shows trends in use of the most common stimulant drugs in recent years 
among adults in England and Wales. While cocaine use rose between 1996 and 
2008/09, at the same time amphetamine use declined and ecstasy use remained 
more or less stable. As a result, overall stimulant use has remained essentially 
steady.19 
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Figure 3: 
TRENDS IN LAST YEAR STIMULANT USE IN ENGLAND & WALES 
ADULTS AGED 16 TO 59 YEARS
Source: Drug Misuse Declared: Findings from the 2011/12 Crime Survey for England 
and Wales
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In recent years, the quality (ie purity) of 
the stimulant drugs on the market has 
been declining, and in an illicit market it 
is impossible for the user to know what 
they are buying. Partly in response to this, 
novel drugs have been appearing in this 
market, including a range of new synthetic 
substances. These drugs initially have the 
appeal of being available legally, via the 
internet or ‘head shops’, and, reportedly, 
with consistent quality, at least until legal 
controls are applied to restrict their sale. The 
most well-known of these was mephedrone (‘meow meow’) which very rapidly 
increased in prevalence so that in 2010/11 1.4% of adults said they had used it in 
the past year. Mephedrone, along with a number of drugs with a similar structure, 
was controlled in 2010. In 2011/12 the proportion of adults who reported using 
mephedrone had declined slightly, to 1.1% of the population, but a wide range of 
other substances have come on the market. Studies of groups of drug users have 
also indicated that since mephedrone became a controlled drug, its use may have 
decreased but in many cases users have simply switched to other substances, 
such as ecstasy.20 
The majority of people who use these drugs do so only occasionally and report few 
problems. Nevertheless, there are some users attending clinics for help. Problems 
that can arise include the development of symptoms of dependence and for some 
there are associated mental and physical health harms. For example, on rare 
occasions their use, particularly mixed with other substances, may cause death; 
ketamine is linked to bladder problems; and the uncertainty about what is being 
taken can lead to overdose and other problems. The often uncontrolled mixing of 
drugs and alcohol is a particularly important potential cause of harm.
As well as new manufactured synthetic substances which are coming onto the 
market at an increasing rate (17 between January 2011 and March 2012 in the 
UK),21 there are many other legal and controlled substances that some people 
use and which can sometimes cause problems. These include steroids and other 
enhancers, khat, prescription and over-the-counter medicines. The inhaling of 
various volatile substances, such as glues, gas and solvents, is the second most 
common type of drug use reported by 11 to 15 year olds (in 2011, 3.5% reported it 
in the last year) and for those aged 11 to 13 it is the most common.22 All of these 
substances pose different challenges for drug policy. 
In recent years, the 
quality (ie purity) of 
the stimulant drugs 
on the market has 
been declining, and in 
an illicit market it is 
impossible for the user 
to know what they 
are buying.
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Drugs and diversity
Another aspect of the diversity of drug use is the variation in the extent of drug 
use among different groups of people. In general men are more likely to use illicit 
drugs than women and young adults are more likely to do so than older ones.23 
The extent and nature of drug use also varies by ethnicity. There is considerable 
diversity within Black and Minority Ethnic (BME) communities although most 
surveys do not have large enough samples or collect the relevant information to 
be able to provide robust evidence about drug use in many of these groups. 
However, a UKDPC evidence review24 found that, in general, overall drug use 
is lower among minority ethnic groups than among the White population, 
although reported drug use prevalence was highest among those from Mixed 
Ethnic backgrounds in a number of studies, largely as a result of high levels of 
cannabis use. However, when the younger average age of this group was taken 
into account, their drug use levels were similar to those in the White population. 
Lowest overall levels of drug use are reported by people from Asian backgrounds 
(Indian, Pakistani or Bangladeshi).
Cannabis is the most commonly used drug across all ethnic groups and age 
groups. Rates of class A drug use are higher among people from White and 
Mixed Ethnic backgrounds than among other ethnic groups. Poly drug use is 
most common among White groups, compared with other ethnic groups. In some 
ethnic communities, khat use is particularly prevalent. Although khat use is legal, 
concerns have been raised regarding its potential negative health impacts.
The types of drugs that cause individuals to seek help also vary between different 
communities. Among the Asian community the most common reason for seeking 
treatment is problematic use of heroin. Asian drug users also appear to be more 
likely to use smoking or chasing as their method of administration while those in 
White communities are more likely to inject drugs. Drug users from Black groups 
are most likely to seek treatment for crack cocaine and cannabis use. 
Some lesbian, gay, bisexual and transgender (LGBT) people have a lifestyle 
that incorporates high rates of illicit drug use. A UKDPC review of the evidence25 
indicated that drug use among LGBT groups is higher than among their 
heterosexual counterparts.* ‘Recreational’ drug use is comparatively high among 
LGBT groups, and thus they may use new drugs before they are widespread in 
*This holds true even after the generally younger age distribution of the LGBT population 
compared with the general population is taken into account, and for both men and women.
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the general population. LGBT people, particularly gay men, may also be at risk 
of misusing other drugs, such as steroids and Viagra. Some types of drug use 
may also be associated with risky sexual behaviour, including exposure to HIV 
infection. Strong links have been reported between Viagra use and sexual risk, 
with Viagra used to counteract negative physical effects of other stimulant drugs.
It is important to recognise that LGBT people are not a homogeneous group, but 
the published evidence often fails to distinguish between sub-groups or has a very 
narrow focus on one particular group. In particular, it should be noted that most 
of the evidence available relates to gay men only. Gay men report higher overall 
rates of use of drugs than lesbian women, largely due to higher rates of stimulant 
use, particularly amyl nitrite (‘poppers’). Cannabis is the most commonly used 
drug among lesbian women, with prevalence rates similar to those reported for 
gay men.
There are other groups within the population who may have particular types of 
drug problem, but because evidence is not collected in such a way as to allow 
their identification their problems remain hidden. For example, some disabled 
people may be at increased risk of drug problems since inequality, disadvantage 
and feelings of isolation may exacerbate drug use and drug problems. In addition 
some people with particular health problems find cannabis use therapeutic. 
However, at the moment routine data sources do not allow the extent of drug use 
among such groups to be identified. 
FACTORS ASSOCIATED WITH DRUG USE AND DRUG PROBLEMS
For most people illicit drug use is something that happens in teenage years or 
young adulthood and which they ‘grow out of’. More than one in three adults 
say they have used an illicit drug at some time in their life but less than one in 
10 report (8.9%) having done so in the past year and only one in 20 (4.8%) in 
the past month.27 Although a few people may continue to use drugs throughout 
their lives, for most people illicit drug use is something that naturally ceases and 
was most likely an enjoyable phase that was largely unproblematic. Therefore, 
it is important to consider not only the reasons people choose to use drugs in 
the first place but also why, for some people, this use becomes problematic. Both 
involve a complex interplay of factors including social, environmental, genetic 
and biological factors.
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Factors underpinning drug use and the development 
of drug problems
There is much debate about whether drug addiction is a disease, a moral failing or 
a social construct. In the end there is probably no one single answer, just as there 
is not a single type of drug problem. Both non-problematic and problematic drug 
use arise from a complex interaction of a variety of factors, some of which may 
increase risk while others are protective, with the mix varying from individual to 
individual. 
For example, a recent evidence 
review found that the likelihood of 
initiating substance use is related 
to: personality traits such as 
propensity for sensation-seeking, 
self-control and extroversion; 
mental health factors such as 
self-esteem and depression; social 
factors, such as peer influence and social activities; parenting styles and levels of 
parental monitoring; family breakdown and negative life events; and environmental 
factors, such as access to drugs. 
Continued use and the progression to problematic use and addiction depend on 
many of the same things. But it also depends on the quality of the experience 
of use, which is influenced by biological factors relating to the reward receptors 
in the brain, as well as the circumstances in which use takes place.28 The extent 
of social and material support available will also have an impact, with lack of 
support increasing risk and positive experiences sometimes able to mitigate some 
of the worst effects. Hence the strong relationship between disadvantage and 
social dislocation and drug problems.29 
Researchers are increasingly paying attention to this interplay between the 
individual and environmental factors that can influence the development of drug 
problems for both the individuals and society, and to how these vary over time. 
For example, a recent review of the evidence concerning both risk and protective 
factors concluded that an individual’s vulnerability to drug use and drug problems 
results from a mix of genetic, neurobiological and behavioural factors. But these 
predisposing factors are also dependent on external factors, such as social and 
environmental experiences, for such behaviour to occur.30 The experience of drug use 
itself may also have a role in determining whether the user continues to take drugs. 
There is much debate about 
whether drug addiction is 
a disease, a moral failing 
or a social construct. In the 
end there is probably no one 
single answer.
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There is growing evidence to suggest that 
the immaturity of the brain in adolescence 
leads young people to be impulsive, with 
tendencies to ignore the possibility of 
negative consequences, and prone to 
experimentation and novelty-seeking. At 
the same time it appears that they may get a 
greater, more pleasurable social effect from 
alcohol and other substances than older 
people. These differences may make them 
more likely to try, and then continue to use substances. Since the adolescent 
brain is still developing it may also be more susceptible to long-term damage from 
substance use, such as reduced IQ.31 
This evidence of risk and protective factors applies to substance use generally, 
and not just illicit drug use. It also supports the notion of a common liability to 
addiction, rather than the ‘gateway hypothesis’ that sees the development of 
addiction problems as a sequential process of stages where use of a ‘soft’ drug, 
usually cannabis, leads an individual on a trajectory to addiction to ‘hard’ drugs. 
A recent review of the evidence makes it clear that the gateway theory is not 
supported by empirical evidence, as the sequencing of substance use is variable 
and can most readily be explained by common underlying factors, rather than by 
any deterministic process of progression. The gateway hypothesis also includes 
no mechanism for explaining why some people progress from use to addiction. 
In contrast, the theory of a common liability to addiction is well supported by the 
evidence, including emerging findings relating to the genetic and neurobiological 
underpinnings of addiction. It therefore provides a much better basis for 
developing prevention and intervention programmes.32
Understanding why people use drugs is also important for developing effective 
prevention programmes. People use drugs for a wide range of reasons. For 
example, a study of young poly drug and alcohol users found the most commonly 
selected reasons were: relaxation (given by 97% of participants); intoxication 
(96%); to keep awake while socializing (96%); to enhance an activity (88%); and 
to alleviate depressed mood (87%).33 Similarly a study of long-term cannabis users 
in Australia34 found the most common reasons given for use were for relaxation 
or relief of tension (61%) and enjoyment or to feel good (27%). Studies in people 
with different medical conditions35 have reported they use drugs for coping with 
a range of symptoms and conditions, including multiple sclerosis, neuropathy, 
chronic pain, loss of appetite, nausea, anxiety and depression.
Since the adolescent 
brain is still developing 
it may also be more 
susceptible to long-
term damage from 
substance use, such as 
reduced IQ.
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This variety of factors is discussed further in Chapter Two, with reference to its 
implications for policy.
The range and nature of drug-related harms
Another question is whether different substances are more or less likely to cause 
harms. As will be discussed further in Chapter Two, there have been a number 
of attempts to compare the harms from different psychoactive substances, 
and although the exact rankings vary, studies consistently find that the legal 
substances, alcohol and tobacco are associated with more harm than many 
illicit substances. This is partly due to the greater number of people using these 
substances, but that does not account for all of the differences. 
A recent World Health Organisation study sought to estimate the amount of 
disease in different parts of the world that was caused by a range of major risk 
factors, in 2000. This estimated that the proportion of the total burden of disease 
in the Western European region, which includes the UK, that was attributable 
to tobacco was 12.1%, to alcohol was 6.6% and to illicit drugs was just 2.1%.36 
This suggests that our policy responses to licit and illicit substances may be 
disproportionate and inconsistent.
It is also clear that the extent of any harm (or indeed benefit) from using a 
substance is very dependent on context. For example, heroin, as pharmaceutical 
diamorphine, provides huge benefits and cost-effective pain relief for many ill 
people when prescribed by doctors. But the same drug sourced from criminal 
gangs and used by a vulnerable individual may be associated with a wide range 
of harms to both the individual user and to wider society. 
This complexity is also reflected in the wide range of harms that can be related to 
drug problems. The UKDPC report Refocusing Drug-related Law Enforcement to 
Address Harms includes a harm matrix (Table 2) which illustrates the breadth of 
these harms by considering: 
•  Harm at different levels: individuals; families; neighbourhoods, national and 
international level 
•  Harms from use, supply, production, and the unintended consequences of 
interventions; as well as
• Different types of harms: health; social/structural; economic; environmental.
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Table 2:
SUMMARY MATRIX OF EXAMPLES OF DRUG RELATED HARMS AT DIFFERENT LEVELS
Source: UKDPC, 2009: Moving towards Real Impact Drug Enforcement
Individual (user or dealer) Family and peers
HEALTH HARMS
Physical/diseases
Mental 
Overdose/death
Risks from cutting agents
Risk of accidents
Poor child welfare
Mental/emotional stress
More likely to use drugs
SOCIAL/STRUCTURAL HARMS
Spiralling criminality
Impact of CJS (e.g. time in prison)
Victim of crime/ intimidation
Exclusion and vulnerability
Loss of support networks
Poor life skills
Poor/no accommodation
Distrust of authority
Victim of crimes (e.g. theft)
Fear of safety
Domestic violence
More likely to commit crime
Exclusion
Family breakdown
Poor life chances
Negative role model
Poor parenting
Loss of confidence in authorities
ECONOMIC HARMS
Unemployment
Poverty/debt
Poor prospects
Poverty/debt
Loss of breadwinner
Cost of being victim of crime
Cost of help/support for user
ENVIRONMENTAL HARMS
Degradation of neighbourhoods, e.g. discarded 
paraphernalia
Hazards from illicit production, e.g. labs/farms
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Local community National International
HEALTH HARMS
Disease transmission
Normalisation of drug use and easy 
access to drugs
Disease transmission
Normalisation of drug use 
and easy access to drugs
Harms caused by crop 
spraying
Risk of death for drug mules
Production health risks
SOCIAL/STRUCTURAL HARMS
Victim of crimes (e.g. theft)
Fear of safety
Domestic violence
More likely to commit crime
Exclusion
Family breakdown
Poor life chances
Negative role model
Poor parenting
Loss of confidence in 
authorities 
Fear of crime/anti-social behaviour (ASB)
Victim of crime/ASB
Attraction or recruitment to criminal life
Related crime (prostitution, gangs, 
corruption etc.)
Strain on local services
‘No go’ areas
Local reputation
Lack of social cohesion
Loss of amenities
Corruption
Fear of crime
Increased crime statistics
Growth in organised crime
Underclass of vulnerable 
people
Lack of social cohesion
Corruption
Loss of respect for law
Loss of confidence in 
authorities
Strain on NHS
Overcrowded prisons
Conflict/violence
Growth in organised crime
Exploitation of vulnerable 
people
Corruption
Destablised communities/ 
governments
Loss of respect for law/
confidence in authorities
ECONOMIC HARMS
Cost of help/support services
Cost of crime
Cost of enforcement and the criminal 
justice system
Property devalued
Barrier to regeneration
Loss of business
Increased unemployment
Cost of help/support services 
and welfare
Cost of crime
Cost of enforcement/CJS
Loss of tax revenue
Cost of help/support services 
Cost of crime
Cost of enforcement/CJS
Loss of tax revenue
Dependency on drug 
revenues stifling economic 
development/investment
ENVIRONMENTAL HARMS
Deforestation
Chemical waste
56
Quantifying and putting a cost on such 
diverse types of harm is methodologically 
challenging. Nevertheless, the annual 
cost to society of class A drug use in 
England and Wales has been estimated 
at over £15bn, mostly through drug-
related crime.38 The equivalent estimate 
for Scotland is £3.5 billion.39 Furthermore 
a UKDPC study estimated that at least 
1.5m adults in the UK are affected by a 
relative’s drug use and the costs of the harm they experience as a result amounts 
to about £1.8 billion a year.40 
Such a broad range of harms clearly requires a multi-faceted response from a wide 
range of agencies. There are no simple solutions and drug policy and the debate 
around it need to reflect this complexity.
Two key areas which have been the focus of much drug policy because of their 
major contribution to the above costs are drug-related crime and health harms.
The link with crime
Drug use is linked to crime in two main ways. Firstly, there are the drug offences, or 
crimes against the drug laws: drug possession, supply, production and trafficking. 
This is where organised crime is involved as drugs represent an important source 
of income and a commodity for criminal gangs both in the UK and internationally, 
providing them with the strength to undermine communities as well as public 
and private institutions. Internationally the trade in drugs has led to appalling 
levels of violence in some places on drug-supply routes, for example in Mexico, 
where organised crime is estimated to have killed 12,903 people in the first nine 
months of 2011.41 
Then there is also the crime committed by drug users, either to obtain money 
or drugs to feed their addiction, mainly acquisitive crime such as burglary or 
shoplifting, but also crime committed while under the influence of drugs, such as 
disorder and vandalism.
Identifying the extent of both these types of drug-related crimes is difficult, since 
they depend on the crimes being notified to the police and, in the case of crime by 
drug users, being able to attribute the offence to drug use. 
A UKDPC study 
estimated that at least 
1.5m adults in the UK are 
affected by a relative’s 
drug use and the costs 
amounts to about £1.8 
billion a year.
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The number of drug offences recorded is very much a reflection of how much time 
and effort the police devote to dealing with drugs. The most recent published 
figures for drug offences in England & Wales cover the financial year 2011/12. They 
show a total of 229,103 drug offences: 6% of all crimes recorded in the period.42 As 
can be seen from Figure 4, the majority of these offences, 86% in 2011/12, relate 
to drug possession, mainly possession of cannabis (70% of all drug offences). 
In 2011/12 there were 77,914 cannabis warnings and 15,930 penalty notices for 
disorder relating to cannabis issued.43
The overall number of drug offences 
increased markedly up to 2008/09 
but has since stabilised. However, 
the increase has been greatest in 
respect to cannabis possession, 
the numbers of which have almost 
doubled since 2004/05. This 
illustrates the fact that drug offences are a measure of the level of activity by 
police rather than reflecting the extent of the problem, since over this period the 
prevalence of cannabis use has been declining.
The number of drug offences 
recorded is very much 
a reflection of how much 
time and effort the police 
devote to dealing with drugs. 
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2010/11  
Total:232,922
160,733
38,711
32,336
1,142
2009/10  
Total:235,584
162,800
38,439
33,223
1,122
2008/09 
 Total:243,536
167,950
44,578
29,885
1,123
2007/08  
Total:229,913
158,254
42,519
28,323
817
2006/07  
Total:194,233
130,395
36,608
26,550
680
2005/06 
 Total:178,479
119,917
32,685
25,276
601
2004/05 
 Total:145,837
88,263
32,603
24,190
781
2011/12  
Total:229,103
160,169
36,469
31,339
1,126
Figure 4: 
TRENDS IN RECORDED DRUG OFFENCES
Source: Crime statistics: Appendix tables 2011-12 - Crime in England and Wales, 
Quarterly First Release to March 2012 
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These figures are dominated by the 
large number of warnings and penalty 
notices for disorder associated with 
cannabis that do not come to court. For 
those offences that do come to court, the 
sentencing statistics provide information 
on the penalties that are applied for those 
convicted of different types of drug offences and for offences relating to drugs in 
different classes.45 
Table 3 shows that in England and Wales a fine is the most common punishment, 
used for about two-fifths of those convicted for drug offences. About a fifth (21%) 
are given community sentences, and 16% an immediate custodial sentence. This 
divide reflects the fact that possession offences make up over two-thirds (70%) 
of the total in 2011. The vast majority (93%) of those convicted for importing or 
exporting drugs were sentenced to immediate custody as were almost half of 
those sentenced for trafficking offences, such as supply or possession with intent 
to supply, but this was true for only 3% of those convicted of possession offences. 
They were most likely to receive a fine (52%) or a community sentence (19%) 
or another punishment (24%), usually a conditional discharge (this excludes 
summary offences, of which there were about 2,000 in 2011).
The vast majority (93%) 
of those convicted for 
importing or exporting 
drugs were sentenced to 
immediate custody.
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Table 3: 
DRUG OFFENDERS CONVICTED AND SENTENCED AT ALL COURTS, 
ENGLAND AND WALES 2011
Source: Criminal Justice Statistics Quarterly Update to December 2011. 
Supplementary tables Vol 5.
Type of 
disposal
Import/
export
Trafficking Possession Other Total
No. % No. % No. % No. % No. %
Immediate 
custody
618 93% 7740 46% 1247 3% 76 13% 9681 16%
Suspended 
sentence
29 4% 3376 20% 655 2% 125 21% 4185 7%
Community 
sentence
6 1% 4156 25% 8136 19% 194 32% 12492 21%
Fine 7 1% 974 6% 21862 52% 108 18% 22951 38%
Other 
disposal
5 1% 489 3% 10167 24% 105 17% 10766 18%
Total 
sentenced
665 100% 16735 100% 42067 100% 608 100% 60075 100%
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Sentences vary due to the class of drug involved, which is to be expected, but 
this is most marked when it comes to importation and trafficking. In 2011 98% of 
those convicted of unlawful importation or export offences relating to a class A 
drug received an immediate custodial sentence. This compares with 86% for class 
B drugs and 61% for class C. The equivalent figures for trafficking offences were 
76% for class A drugs, 31% for class B and 16% for class C. However, there was less 
difference over possession: 45% of those convicted of possessing a class A drug 
received a fine compared with 54% of those possessing class B drugs and 49% of 
those caught with class C drugs, while 27% of class A possession cases were given 
a community sentence compared with 17% for class B and 13% for class C. 
Stop and searches for drugs by the police 
are responsible for about half of all stop 
and search activity. In 2010/11 there were 
587,790 stop and searches for drugs in 
England and Wales out of just over 1.2 
million in total.46 Of these, only 7% resulted 
in an arrest. But in 20009/10 Black people 
were seven times more likely to be stopped 
and searched (per 1,000 population) than 
White people,47 and the negative impact 
that this can have on community relations 
is well documented.48 
As at 30th June 2012, there were 12,314 people in prison for drug offences, 15% of 
the total prison population.49 Most of these (87%) were sentenced prisoners, ie 
people who had been convicted and given a prison sentence rather than people 
held on remand while awaiting trial. 
It is much more difficult to estimate how many offences are carried out by people 
with drug addictions in order to obtain drugs or while under the influence of them, 
and such estimates can often be overstated.50 Many offenders are drug users, but 
just because someone has used drugs does not mean that their offending is caused 
by drug use; and it is also likely that someone who is predisposed to offend is also 
predisposed to use illicit drugs. 
Nevertheless, many people with opiate and crack addiction do resort to crime to 
enable them to buy drugs, but they are not the only people committing acquisitive 
crimes, and there are many other common offences that they very rarely commit. 
The Arrestee Survey, which was undertaken in a random sample of custody suites 
throughout England and Wales between 2003 and 2006, showed that while the 
In 2009/10 Black people 
were seven times more 
likely to be stopped and 
searched (per 1,000) 
population than White 
people; the negative 
impact on community 
relations is well 
documented.
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most common reason for arrest in 
2005/06 was assault (29% of all 
arrestees) only 4% of this group 
were considered problem heroin 
or crack users (ie using heroin and 
crack at least once a week). And while 9% of arrests were for criminal damage, only 
1% of these used heroin or crack at least weekly. By way of contrast, shoplifting 
accounted for 10% of arrests, and burglary for 8%, while the proportion of 
arrestees for these offences who used heroin and crack at least once a week was 
45% for shoplifting, and 23% for burglary.51 
So while drug problems may be considered an important driver of some types of 
crime, particularly lower-level acquisitive crimes, these make up quite a small 
proportion of offences dealt with by the criminal justice system. We need therefore 
to keep the debate about the link between drugs and crime in perspective.
Health harms
A recent report attempted to summarise the range of health harms associated with 
different licit and illicit drugs.52 Some of the most severe are considered here.
Each year there are in the region of 2,000 drug-related deaths in the UK, although the 
exact number depends on how drug-related deaths are defined. Using the EMCDDA 
definition*, there were 1,930 drug-related deaths in the UK in 2010 (a decrease of 
7.7% from 2,092 in 2009) 53. Decreases were also evident in data sources using other 
definitions. As can be seen in Table 4, opiates are the main drugs mentioned on 
death certificates and this has been the case for the last 10 years. Between 2009 
and 2010 there was a sharp fall in ecstasy-related deaths (72%) and deaths in which 
cocaine was mentioned fell by nearly one quarter. It has been suggested that this 
may be related to the sudden increase in mephedrone use during this time, as well 
as reduced availability and hence lower purity of ecstasy and cocaine. 
*Identifying and deciding what constitutes a drug-related death is difficult and different 
definitions are used in different places. To some extent the numbers identified depends 
on whether coroners and doctors certifying the deaths consider and investigate for the 
presence of drugs. The EMCDDA definition refers to deaths caused directly by the consumption of 
at least one illegal drug. The Office for National Statistics uses two definitions for reporting 
drug-related deaths in England and Wales. One includes all deaths relating to drug 
poisonings whether accidental or intentional, which includes legal drugs. They also report 
deaths from drug misuse, which are those where the underlying cause is drug abuse, 
drug dependence, or poisonings where any of the substances scheduled under the 
Misuse of Drugs Act 1971 are involved. 
We need to keep the debate 
about the link between drugs 
and crime in perspective.
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The average age of death has risen in recent years from 32 in 1996 to 39 in 2010, 
which is consistent with the increasing age of opiate users. Deaths associated 
with volatile substance abuse (VSA), that is abuse of gas and solvents, also occur, 
although these have been declining in recent years, particularly among people 
aged under 15. In 2008 there were 36 VSA deaths in the UK down from a peak of 
152 in 1990.54 
Table 4: 
DRUG MENTIONS ON DEATH CERTIFICATES IN THE UNITED KINGDOM, 
2002 TO 2010
Source: UK Focal Point report, 2011
Drug Year
2002 2003 2004 2005 2006 2007 2008 2009 2010
Heroin/ 
Morphine
1,118 883 977 1,043 985 1,130 1,243 1,210 1,061
Methadone 300 292 300 292 339 441 565 582 503
Cocaine 161 161 192 221 224 246 325 238 180
Amphetamine 55 41 47 57 55 62 68 46 50
Ecstasy 79 66 61 73 62 64 55 32 9
Diazepam** 356 282 217 205 186 223 489 300 315
Temazepam 89 114 87 55 55 56 55 48 38
**A revised data collection form was introduced in Scotland in 2008 which has 
resulted since then in more specific drugs being identified than in previous years.
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One of the key times when drug users are at risk of overdosing on opiates is when 
they are released from prison, probably as a result of loss of tolerance. A study 
of prisoners released in 1999 found that in the week following release they were 
about 40 times more likely to die than people in the general population, and 90% 
of the deaths in this period were from drug-related causes.55 There is similarly an 
elevated risk of death immediately after leaving treatment.56 
Those who inject drugs face an array of potential harms. Infections are common: 
about one-third of injecting drug users report having symptoms of a bacterial 
infection (such as a sore or abscess) from injecting themselves in the past year. 
These include infections with a range of common bacteria, such as Staphylococcus 
aureus, that can cause severe illnesses and since 2000 there have been 163 cases of 
wound botulism, 93 of Clostridium novyi infection, 52 confirmed cases of anthrax 
and 35 of tetanus associated with injecting drug use in the UK.57 
Injecting drugs also carries a high risk of transmission of a number of blood-borne 
viruses, most commonly Hepatitis B and C and also HIV. The prevalence of HIV 
among those who have injected drugs remains comparatively low in the UK: in 
2010 the HIV prevalence among injecting drug users (IDUs) in the UK was 1.1%. 
There is some evidence that on-going HIV transmission amongst IDUs within the 
UK may be somewhat higher than a decade ago, and in particular this may be 
increasingly amongst those who started injecting recently.58 
Around one-half of those in the UK who inject drugs have been infected with 
hepatitis C and one-sixth with hepatitis B. However, sharing needles and syringes 
(the main way these infections are transmitted) is lower than a decade ago, 
although one-fifth of people who inject drugs continue to share.
People who use drugs and alcohol 
have an increased likelihood of mental 
health problems, and vice versa. In 
a survey of adults living in private 
households in Great Britain in 2000 
people with symptoms of common 
mental disorders, such as anxiety and depression, were more than twice as likely 
to have used drugs in the last month as those without (12% compared to 5%), 
and to have signs of drug dependence. There was also a significant association 
between drug dependence and probable psychosis, although the numbers with 
that diagnosis were very small.59  
People who use drugs and 
alcohol have an increased 
likelihood of mental health 
problems, and vice versa.
66 67
Similarly a study of people attending community mental health and substance 
misuse services found that 31% of those attending reported using drugs in the 
past year and 75% of those attending a drug service had a psychiatric disorder in 
the past year.60 However, it is not clear whether there is any causal relationship 
between the two and if so how much and in what direction. 
There has been particular concern about 
the relationship between cannabis use and 
psychotic disorders, such as schizophrenia. 
While there is strong evidence that 
cannabis use may be associated with 
transient psychotic symptoms, such as 
hallucinations and paranoid delusions, 
the strength of the relationship between 
cannabis use and the development of 
serious mental illness is still the subject 
of debate. Despite a marked increase in the prevalence of cannabis use in the 
latter part of the last century, there was no similar increase in psychotic disorders. 
Nevertheless, recent reviews of the evidence61 indicate that cannabis use most 
probably does increase the risk of psychosis, although this is an increase in what 
is overall a very low risk, with a strong genetic component. However, the reviews 
found the evidence was weak for a link to affective disorders, such as depression. 
It also appears that the risk is related to the use of larger amounts of cannabis and 
early initiation. Since adolescence is a period of rapid brain development this 
may make young people particularly vulnerable.62 
However, the picture is also complicated by the fact that cannabis contains 
a mix of psychoactive substances and while some, particularly THC (tetra-
hydrocannabinol), appears to increase the risk of psychotic symptoms, another 
one, CBD or cannabidiol, may be protective and be of benefit in treating psychotic 
symptoms.63 In general the newer varieties of herbal cannabis have two to three 
times more THC than those available 30 years ago but the balance between THC 
and CBD also varies within different strains of cannabis and this may further 
complicate the picture. 
There are also a wide range of problems that may be associated with ‘recreational’ 
use of substances. Some of these relate to the individual susceptibility and some 
to the specific action of the drugs, for example the potential for serious bladder 
problems resulting from ketamine use. Other problems arise from the context 
in which the drugs are taken and how they are taken, for example the potential 
Despite a marked 
increase in the 
prevalence of cannabis 
use in the latter part of 
the last century, there 
was no similar increase 
in psychotic disorders. 
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harms that may be associated with the smoking of cannabis, which are the same 
as or greater than for as smoking tobacco.64 Another important factor is whether 
the drugs are mixed with other drugs or alcohol; when cocaine is taken with 
alcohol, it leads to the formation of cocaethylene which is more harmful than the 
substances on their own. In addition some of the cutting agents used to bulk out 
some drugs are themselves harmful, eg phenacetin has been used to cut cocaine 
and is suspected to be carcinogenic.65
CURRENT POLICY RESPONSES
We will now briefly describe the structure of policy that responds to these 
challenges. However before looking in detail at the ways in which we approach 
drug policy, the term itself should be clarified: see Box 2.
Box 2: 
WHAT IS DRUG POLICY?
In the traditional sense, drug policy is about dealing with problems 
directly associated with the non-medically authorised use of drugs that 
might cause serious harm to users and to society. For historical reasons, 
this excludes some, such as alcohol and tobacco, which logically fall into 
this category. This interpretation implies that the overall goal is to reduce 
problems but this is an issue that is often not clarified or discussed. 
Policies are enacted through a range of different types of interventions, 
which include legal controls and their enforcement, but also encompass 
treatment and recovery for people with drug addictions; information and 
education programmes aimed at dissuading people from using drugs; and 
policies designed to reduce the harms caused by each drug user, producer 
or supplier. Some parts of drug policy are about how the drug laws, such 
as the Misuse of Drugs Act, are framed and implemented. Other aspects, 
such as policing and healthcare, are underpinned by the legal system 
but are largely shaped by organisational structures, administrative and 
professional interpretation, and funding arrangements.*
*The drug legislation is a ‘reserved’ Westminster power but with the 
implementation delegated to the devolved UK countries..
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The overall structures and goals of drug policy across the UK are guided by 
drug strategies, which are intended to coordinate the work of different 
government departments. The first comprehensive Strategy was published 
in 1995 and between then and 2002, leadership and coordination was 
handled through the Cabinet Office. Since 2002, national drug strategies 
have been coordinated and led by the Home Office, with many local health 
and preventive responsibilities transferred to the devolved administrations. 
In Scotland coordination and leadership is effected through the Minister 
for Community Safety and Legal Affairs; in Wales through the Minister for 
Local Government and Communities, and in Northern Ireland through the 
Minister for Health, Social Services & Public Health.
Drug policies are shaped also by the UK’s European and global 
commitments. There are a number of international treaties that the UK 
has signed up to, which have been influential in framing the drug laws in 
the UK over the past century. More recently, collaboration through the EU 
has created a range of drug policies, especially in the justice sphere. While 
there is convergence between countries on a number of issues, for example 
drug-related money-laundering, other policies are decided at a national or 
local level, for example prevention and health care policies.66
So drug policy is not solely the responsibility of Westminster politicians and 
civil servants. Some aspects are governed from the centre: in London, these 
are led by the Home Office. But other aspects are decentralised across the 
UK and to the devolved governments. Decisions about which drug markets 
to intervene in, which offenders to pursue, which modes of treatment to 
fund, which educational programmes to apply, or what sentence to apply 
to someone convicted of a drugs offence, are all part of drug policy, and 
should be subject to efforts to build the most cost-effective responses, 
regardless of whether policies are decided locally or nationally. 
Within the recent reform of the NHS as part of the Health and Social Care 
Act, much more responsibility for setting priorities and implementing 
drug policy in England is being devolved to local areas. Responsibility 
for commissioning drug treatment is shifting to Directors of Public Health 
within local government, with priority setting being done by local Health 
and Well-Being Boards. Police and Crime Commissioners will have 
responsibilities and resources to support services to promote community 
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safety and, through their budget making duties, have an indirect influence 
on how the drug laws are enforced locally. In Scotland, Wales and Northern 
Ireland, local public service partnerships are the key vehicle through which 
drug policy is implemented and delivery bodies held to account.
HOW DRUG POLICY IS ORGANISED
For more than two decades, drug 
policy in the UK has been based 
around a series of drug strategies 
and organised under the three main 
‘pillars’ of prevention, treatment 
and enforcement.67 Prevention 
includes school education, mass 
media campaigns and preventive 
interventions targeting specific risk factors for drug problems, such as parenting. 
Treatment includes a range of medical and psychosocial therapeutic interventions, 
and also can include so-called public health ‘harm reduction’ responses such 
as providing injecting addicts with clean syringes and needles. Enforcement 
includes local, national and international interventions, including direct and 
indirect action to seize drugs, along with suppliers and traffickers such as through 
border security. It also encompasses local and wider intelligence operations 
both in the UK and in other countries to prohibit supplies, activities to control 
precursor chemicals, as well as working through international aid programmes, 
such as crop diversification efforts in producer countries. These three pillars are 
sometimes grouped under the broader headings of supply reduction (largely 
enforcement) and demand reduction (including both treatment and prevention).
More recently, drug policy has embraced an increased focus on recovery and social 
re-integration for those with drug dependency.68 There has also been a move to 
address the use of a wider range of drugs rather than focusing mainly on opiates 
and crack, and in some instances to have joint drug and alcohol strategies.69
Although the main focus of the work of UKDPC and of this report is on drug policy 
within the UK, drugs are a global challenge and UK drug policy does not exist 
in isolation. The UK is signatory to a number of international conventions of 
relevance to drug policy which are described in Box 3.
Drug policy in the UK 
is based around a series 
of drug strategies and 
organised under the 
‘pillars’ of prevention, 
treatment and enforcement.
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Box 3: 
INTERNATIONAL COLLABORATION
Collaboration between the UK, national governments and internationally 
is effected at many different levels and through a number of treaties and 
bodies. These include:
1. Three United Nations Drug Conventions:
The 1961 Single Convention on Narcotic Drugs was set up as a 
universal system (replacing the various treaties signed until then) to control 
the cultivation, production, manufacture, export, import, distribution 
of, trade in, use and possession of narcotic substances, paying special 
attention to those that are plant-based: opium/heroin, coca/cocaine and 
cannabis. More than a hundred substances are listed in the four schedules 
of the convention, placing them under varying degrees of control.
The 1971 Convention on Psychotropic Substances, in response to 
the diversification of drugs of abuse, introduced controls over the licit 
use of more than a hundred-largely synthetic psychotropic drugs, like 
amphetamines, LSD, ecstasy, valium, etc, again divided over four schedules. 
An important purpose of the first two treaties is to codify internationally 
applicable control measures in order to ensure the availability of narcotic 
drugs and psychotropic substances for medical and scientific purposes, 
while preventing their diversion into illicit channels. 
The 1988 Convention against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances was agreed in response to the 
increasing problem of drug abuse and trafficking during the 1970s and 
1980s and provides for comprehensive measures against drug trafficking. 
These include provisions against money laundering and the diversion of 
precursor chemicals, and agreements on mutual legal assistance.
The UN Drug Conventions are not self-executing. The implementation of 
the provisions in the Conventions is left to the signatory parties themselves. 
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This leaves room for interpretation, allowing countries to develop a 
differentiated national drug policy. However, this latitude or ‘room for 
manoeuvre’70 is not unlimited. In general, the Conventions anticipate 
application and enforcement by the parties. 
2. European Union decisions:
The 2004 Framework Decision on penalties for trafficking lays 
down minimum provisions on the constituent elements of criminal acts 
and penalties in the field of illicit drug trafficking and has led to more 
harmonisation on penalties across the EU. 
 
The 2005 Council Decision on new psychoactive substances, 
which is being reviewed in 2012, provides for the information exchange, 
risk-assessment and control of new psychoactive substances and has led to 
the setting up of an EU wide ‘early warning system’. 
3. International and EU bodies:
 
The International Narcotics Control Board (INCB) is the quasi-judicial 
control organ for the implementation and oversight of all three United 
Nations drug conventions.
 
The World Health Organisation (WHO) is responsible for the medical 
and scientific assessment of all psychoactive substances and advises the 
Commission on Narcotic Drugs (CND) about their classification into one of 
the schedules of the 1961 or 1971 treaties.
 
The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) exists to provide the EU and its Member States with a factual 
overview of European drug problems and a solid evidence base to support 
the drugs debate.
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The evidence presented within this chapter 
illustrates the many types of drug use and 
drug problems within the UK. Drug problems 
arise from a complex mix of factors so there 
is no simple solution to address them. There 
has been considerable investment in drug 
policy and drug-related interventions over 
recent years but there continues to be a lack 
of evidence concerning effectiveness and 
value for money in many areas of drug policy. Although there have been benefits 
from some areas of policy there are also considerable costs, many of which are 
generally not measured. 
 
While ‘traditional’ drug problems appear to be stable or reducing in the UK, new 
drugs and patterns of use are appearing that pose new challenges. What this 
means for drug policy is considered further in the next chapter.
While ‘traditional’ drug 
problems appear to 
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KEY POINTS
>The way that drug policy is made and implemented may 
be limiting the effectiveness of attempts to address the 
consequences of drug use
>Drug problems can only be fully understood in their 
social and economic context
>The distinction between use of drugs and use of alcohol 
and tobacco is not always helpful
>Drug use is not always problematic, yet this is rarely 
acknowledged by policymakers
>Drug policy takes insufficient account of the different 
reasons underlying drug use and drug problems, and 
of the differing consequences of use
>Debates about drug policy, and policy itself, can be more 
productive when based on shared goals and taking account 
of all the consequences of policies
>It is not clear why drug policy appears to prioritise some 
goals over other legitimate aims
>Inadequate collection and analysis of evidence has been 
an important factor restricting the introduction of more 
cost-effective drug policies.
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Drug policy in the UK has produced some significant and under-recognised 
successes over the past quarter century. For example, the public health harm 
reduction approach has delivered rates of HIV among injecting drug users in the 
UK that are among the lowest in the world71 and saved thousands of lives. Greater 
investment in different types of drug treatment services and in programmes within 
the criminal justice system to divert drug-using offenders into treatment have 
also increased the numbers of people accessing these services and remaining in 
treatment long enough to help many people overcome drug dependence.
Yet, as highlighted in Chapter 
One, there remain considerable 
problems. Compared with other 
EU countries, use of some drugs, 
including cocaine, is particularly 
high in the UK. Total drug-related deaths are higher in the UK than in any other 
EU country.72 We continue to have nearly 400,000 people with major dependency 
problems. Profits from organised crime work their way through our financial 
institutions. Large sums of money are spent on enforcement which leads to 
considerable costs to the criminal justice system in processing possession offences 
(mainly cannabis), while in some areas having a negative impact on community 
relations.
While there has been some progress over the last two decades, this progress has 
been slow, and took place largely in a benign environment. Unemployment was 
relatively low, and funding was available for a rapid and significant expansion of 
harm reduction and drug treatment services, as well as money for enforcement, 
largely predicated on the need to reduce crime. Now we are in a long-term period 
of austerity, there can be real concerns that existing policies may not be able to 
achieve further progress, while significant sections of the public, politicians, 
media and drug sector professionals are not convinced that our current approach 
to drug policy is the best we can do. Alongside this are the challenges associated 
with new drugs and new routes of supply.
It may be that incremental changes to some policies will produce some benefit. 
The Westminster and devolved governments’ focus on improving the prospects of 
recovery for people with addictions is a good example of this. However, there is 
also a need to address the question of whether the way that drug policy in general 
is made and implemented is itself limiting the cost effectiveness of attempts to 
address the consequences of drug problems, or even making them more severe.
Total drug-related deaths are 
higher in the UK than in any 
other EU country.
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We are concerned that some aspects of the 
way we have traditionally responded to the 
problems associated with illicit drug use 
may be ultimately unhelpful and the UK’s 
current approach does not fully recognise 
the complexity of the challenges.
This chapter takes a high-level view of 
how we approach drug policy, and points to ways this could be reformed. It does 
not seek to make specific policy recommendations - these are developed later 
in this report - but it aims to show that there could be benefits in taking a fresh 
perspective.
THE LIMITS OF ADDRESSING DRUGS IN ISOLATION
Despite the apparent wide-ranging scope of drug policy, there are reasons to be 
concerned that the approach it takes is simplistic. Conceiving of and addressing 
drugs in isolation from other social, economic and cultural issues, and from other 
substances, restricts the ability of policymakers and practitioners to produce cost 
effective and long-lasting change.73
Drug use should not be seen simply as a cause of problems
As discussed in the previous chapter, evidence has accumulated about the 
range of genetic, neurobiological, behavioural and environmental factors that 
are associated with risk of drug problems. Fundamental socio-economic issues 
such as income inequality are significantly associated with levels of drug use, as 
indicated by the international correlation between income inequality and levels 
of illicit drug use shown in Figure 5:74 
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Figure 5: 
INTERNATIONAL LEVELS OF DRUG USE AND INCOME INEQUALITY
Source: The Equality Trust
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A comparison of inequality with levels of drug addiction and deaths from drug 
overdose in the 50 states of the US has shown a similar pattern: the most unequal 
states had higher death rates.75
In the UK this was reflected by the way some forms of drug use grew in the 1960s, 
a cultural trend that was followed in the 1980s by the growth of entrenched drug 
problems, particularly among heroin users. The development of higher rates of 
addiction in the 1980s appears to fit the pattern of entrenched drug problems 
developing in association with increasing inequality.
This is not to say that all drug problems 
were caused by inequality or that they can 
be explained by income inequality alone. 
Cultural factors influence the desirability 
of drugs, their availability fluctuates 
over time, and treatment systems affect 
how well people are able to overcome 
drug problems. Yet, the strength of the 
international and historical correlations 
between inequality and drug problems, 
and the analysis that has pointed to 
inequality having a causal link with a range of other social ills, such as trust, 
social cohesion and mental illness, indicates that this is a relationship that should 
not be ignored. 
Studies indicate that problems that are related to social status get worse when 
social status differences are increased. Greater inequality increases social 
evaluation anxieties: concerns about how one is seen and judged, which affects 
self-confidence, self-esteem and social anxiety.76
This connection has been acknowledged to some extent in policy. The 2010 Drug 
Strategy includes a chapter on early intervention for young people and families to 
help those who may be at risk of involvement in crime and anti-social behaviour. 
But it may be missing the point to attempt to address these drivers of drug use 
with interventions that relate only to criminal and anti-social behaviour. If it is 
correct that levels of harmful drug use are closely linked to levels of inequality, and 
perhaps to other factors such as unemployment, lack of housing, poor educational 
achievement and family breakdown, as well as social dislocation, disempowerment 
and hopelessness, such efforts in isolation may be unlikely to produce significant 
and lasting change. Without tackling some of the underlying problems, it may not 
be possible to significantly reduce the most harmful drug use. 
Cultural factors influence 
the desirability of 
drugs, their availability 
fluctuates over time, and 
treatment systems affect 
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Indeed, some of these wider 
problems may themselves have 
other consequences that are at least 
as damaging as drug use, especially 
when taking into account the 
relatively small proportion of the 
population that suffers or causes 
harm because of illicit drug problems. Consequences include poorer health and 
reduced life expectancy. In this respect, it is neither possible nor wise to isolate 
drug policy entirely from other parts of public policy.
A recent analysis of why Scottish people die younger than those in other parts 
of the UK concluded that the patterns of poor health and social problems that 
emerged from the 1980s were influenced and shaped by the consequences of the 
UK’s political and economic policies from the late 1970s. The researchers argued 
that “[a]ny analysis which only refers to tobacco use or alcohol, or even to ‘early 
years’, massively significant as these factors undoubtedly are, will inevitably fail 
to identify the overall causality of this profoundly troubling phenomenon, and 
will be liable to generate, at best, partial policy interventions, which are, in turn, 
most liable to prove disappointing in their outcomes.”77
The greatest risk in efforts to address drug problems is that a focus on drug use 
directs attention away from the causes of problems, and onto the symptoms 
of those problems. By separating drug policy from other areas of social policy, 
unrealistic expectations are created that lasting progress can be made through 
drug-related interventions such as treatment and recovery programmes or 
enforcement actions to disrupt drug markets.
While there should be continued efforts to improve drug policies where this is 
possible, some of the problems associated with illicit drugs are best recognised 
as a facet of socio-economic and other factors. This is one of the key principles 
of this report. This is not to say drug policies are not needed or that they do not 
have many positive impacts. The challenge we are raising is whether an approach 
that focuses just on the drugs or even drug problems, rather than the factors 
underlying those problems, is likely to achieve a significant, lasting and cost-
effective reduction in harms that can be caused by drug use. 
Without tackling some 
of the underlying problems, 
it may not be possible to 
significantly reduce the 
most harmful drug use. 
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A more consistent approach to all substance use is needed
We are also concerned by the focus on illicit drugs at the exclusion of other 
potentially harmful psychoactive substances, notably tobacco and alcohol. Many 
argue there are economic benefits from the alcohol trade, for example in the 
drink-producing and hospitality industries, as well as taxes for the Exchequer. 
But, as is becoming more evident, the use of those substances may cause even 
greater harms than much illicit drug use, measured in deaths, ill-health, and 
social breakdown.
This is certainly true when taking into 
account the much greater numbers using 
tobacco and alcohol: in England, 26% of 
men report drinking more than 21 units 
in an average week, while 18% of women 
report drinking more than 14 units in 
an average week. Meanwhile there are 
around 10 million adults in the UK who 
smoke cigarettes.78 Each year, smoking 
causes around 115,000 deaths, while 
alcohol causes 35,000. 
In comparison, illicit drugs cause about 2,000 deaths a year in the UK.79 Of 
course, illicit drugs have other associated costs, such as acquisitive crime and 
instability in other countries. Legal controls over illicit drugs are a factor in these 
costs, although they may also be a factor in reducing the numbers who use them. 
But even taking into account other costs involved in the production and use of 
illicit drugs, the harms caused by use of alcohol and tobacco remain of at least 
comparable significance.
There is also a strong case that alcohol and tobacco can be more harmful to each 
individual user than some illicit drugs, although this has been contested (see Box 
4). Yet, however one measures and compares total harms, there can be no serious 
challenge to the fact that we have inconsistent control and regulatory frameworks 
governing the availability of different psychoactive substances. The separation 
between these drugs and the illicit ones is entirely artificial and historical. In a 
world where policy could be made without reference to current behaviour and 
past decisions, that separation would probably not exist.
Each year, smoking 
causes around 115,000 
deaths, while alcohol 
causes 35,000. In 
comparison, illicit drugs 
cause about 2000 
deaths a year. 
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Box 4: 
COMPARING HARMS CAUSED BY DIFFERENT SUBSTANCES
Many experts are sceptical of the value of comparative rankings of harms caused 
by different substances, because of the impact of individual and contextual 
factors on the harms associated with any drug use, and also the impact of 
legal status on the prevalence of use. Nevertheless, drug control is justified on 
the basis of harm to individuals and society, and the Misuse of Drugs Act 1971 
established a classification system for drugs in order to prescribe the maximum 
penalties associated with offences relating to drugs in that class. Implicit in this 
is that the hierarchical classification reflects the level of harm or dangerousness 
associated with the drugs in each class.
A number of attempts have been made to compare the harms associated with 
different psychoactive substances. These include comparisons of the harms 
associated with use at a single point of time, such as the WHO global burden of 
disease estimates, attempts to compare the severity of health effects for heavy users 
of different substances and measures of lethality as a poison. What all these have 
in common, with the exception of the lethality measure, is that legal substances, 
tobacco and alcohol, were found to be among the most harmful substances.80 
Recent attempts at ranking have sought to develop systematic and, as far as 
possible, evidence-based approaches. The most recent attempt in the UK was 
led by Professor David Nutt, a former chair of the Advisory Council on the Misuse 
of Drugs, and involved other experts in a multi-criteria decision-making process 
to review harms caused by different drugs, including alcohol and tobacco as 
well as those controlled by the Misuse of Drugs Act.
The process assessed physical, psychological and social harms to users, and 
harm to others. The results, shown in Figure 6, reinforce the view that the current 
classification system is inconsistent, since several class A drugs are among 
those with the lowest levels of harm. It also suggests that alcohol is the most 
harmful of all the psychoactive substances considered, while tobacco ranks 
sixth, making it more harmful than cannabis, mephedrone (‘meow meow’), and 
ecstasy. Although the method has been criticised on several grounds,81 it is hard 
to dispute the conclusion that alcohol and tobacco are at least as harmful as 
some illegal substances.
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Yet the fact that this separation between licit and illicit drugs is currently made is 
inescapable, and ignoring this would produce an analysis that would have little 
application in the real world. It is also important that we learn from different 
approaches of controlling each substance. For example, alcohol prohibition in 
the USA in the 1930s famously had costs, such as the explosion of organised crime 
and widespread flouting of the law, but it also had benefits, such as improvement 
in certain health conditions. More recently - without prohibition, but with taxes - 
we have seen the growth in the UK of illicit alcohol production and the increasing 
avoidance of customs and revenue controls.83 Counterfeit and smuggled tobacco 
also present control and health challenges.
It is important also to recognise that the use 
of illicit and licit drugs is often influenced 
by similar and overlapping challenges. 
These include the reasons people use 
substances, the extent to which they might 
substitute one substance for another, 
and why and how substance use turns to 
dependency for some people. These factors suggest that the various substances 
should be tackled with the recognition that their use is often closely connected. 
This relationship has been acknowledged to some extent in drug policy and 
practice. The 2010 Drug Strategy recognises the harm caused by severe alcohol 
dependence; local structures increasingly cover both alcohol and drugs (eg 
Drug and Alcohol Action Teams or Community Safety Partnerships in England 
and Wales, and Alcohol and Drug Partnerships in Scotland); treatment services 
often provide treatment for both drug and alcohol addiction; and people with 
serious drug problems are often also addicted to alcohol and tobacco at the same 
time. But these usually relate only to those whose use is the most harmful. There 
continues to be a distinction between less extreme levels of alcohol consumption, 
and moderate drug use, which may not be justified by evidence of the harms 
associated with use of each substance.
Without prohibition, 
but with taxes, we have 
seen the growth in the 
UK of illicit alcohol 
production. 
Chapter 2  The Need for a Fresh Approach
THE RISKS OF MAKING GENERALISATIONS ABOUT DRUG USE
Since the early 1990s, the UK’s 
approach to drug policy aims to ensure 
public departments and bodies support 
one another to achieve common 
goals. However, while coordination is 
necessary, we are concerned that there 
are risks in seeking to base drug policies 
on generalisations about drug use and associated problems. The current 
approach may be counter-productive, in two different ways.
Drug use is not always problematic and may bring 
perceived benefit
First, many people enjoy taking drugs. As discussed in Chapter One, some people 
choose to take drugs for pleasure, in much the same way as many people use 
other mind-altering substances such as alcohol. In other cases people may self-
medicate, consciously or unconsciously using illicit drugs to deal with mental or 
physical problems. For many in both of these groups, drug use may not be a cause 
of significant other problems for themselves or others around them, for much of 
the time (see Box 5).
There are risks in seeking 
to base drug policies on 
generalisations about 
drug use and associated 
problems.
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Box 5: 
DO PEOPLE EXPERIENCE BENEFITS IN DRUG USE?
The question of whether people experience any benefit from drug use is 
controversial. There is no doubt that many people feel that they receive 
some benefit through using drugs, such as relaxation, relief of mental 
or physical pain or other symptoms, increased sociability, or feelings of 
energy. However, some people dispute whether these perceptions should 
be considered meaningful, as they argue that the negative consequences of 
drug use will always outweigh any of these benefits.
It may be impossible to calculate such costs and benefits in a way that would 
be widely accepted. However, two points can be made with confidence. 
Firstly, many people participate in other activities that have short-term 
benefits and long-term costs, such as drinking alcohol or eating fatty foods. 
In these cases there is widespread acceptance that such short-term benefits 
can be acceptable.
Secondly, survey data of personal experiences of drug use suggest that 
positive experiences are widespread. For example, a recent survey of 
schoolchildren in England84 found that of those pupils who reported that 
they had ever taken drugs, 45% said they felt good the first time they took 
them, a similar proportion (44%) said they felt no different and only 11% 
reported that they felt bad. Boys were more likely than girls to report that 
they felt good after taking drugs the first time (50%, compared with 40% 
of girls).*
In addition, the value of cannabinoids for relieving symptoms in some 
medical conditions is well-established and ‘Sativex’, a mouth spray that 
contains cannabis extracts, is licensed for prescription in the UK.85 However, 
it has not yet been assessed by NICE and not all health authorities will fund 
its prescription, and there is anecdotal evidence that some doctors are 
advising patients to obtain illicit supplies of cannabis. 
* Conversely, girls were more likely than boys to say they felt no different 
(48%, compared with 40% of boys). Similar proportions of boys and girls said 
they felt bad the first time they took drugs (10% of boys, 12% of girls).
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It is striking how rarely this point is acknowledged by policymakers. Where it has 
been mentioned, such as in the national Anti-Drug Coordinator’s introduction to 
the 1998 Drug Strategy,86 this has generally been in passing, with little attention 
to its wider implications. Yet, these implications are profound.
Millions of people in the UK use drugs each year, simply because they expect, 
often based on experience, to get pleasure from them. Communications about 
the negative consequences of drug use have little credibility if they do not 
acknowledge many people’s positive experiences of drugs.
Another implication of the high levels of use is that the argument for tightly 
restricting availability of certain drugs cannot rest on an assertion that drug use 
necessarily causes significant problems. This is not to say that drug controls 
should necessarily be relaxed, but there is a need to provide alternative reasons 
for these continued controls and, if they are to have widespread acceptance, these 
will need to recognise that there are positive experiences of drug use which need 
to be weighed against the risks.
The diversity of drug use
A further concern is that the nature 
of drug use and drug problems may 
be a too diverse phenomenon to be 
subjected to a single overarching set 
of goals. This diversity operates in 
several dimensions, each of which 
increases the difficulty of making 
generalisations about drug use.
Reasons for starting drug use vary widely. For some, drugs such as 
heroin offer an opportunity to suppress mental or physical pain. Others choose 
to consume drugs such as mephedrone or ecstasy as part of a social group or 
at nightclubs, and often these young clubbers grow up, hold responsible jobs 
and have families, and choose to stop taking drugs. Cocaine use may provide a 
stimulant for well-heeled users in business and the cultural industries. Crack on 
the other hand typically manifests itself in disadvantaged communities. Cannabis 
use can be a response to physical pain, or simply a means of relaxing with friends 
at home. For a limited and relatively small number of people, occasional use of 
any drug can descend into dependency and addiction. Broad approaches to drug 
policy can find such variations awkward to deal with. 
The nature of drug use and 
drug problems may be a 
too diverse phenomenon 
to be subjected to a single 
overarching set of goals.
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Consequences of drug use and supply are similarly diverse. While the use of 
some drugs have a higher likelihood of leading to serious problems, others are much 
less likely to be harmful, particularly if used in moderation. As discussed above, 
occasional drug use appears more likely to lead to serious entrenched problems 
for those who already are experiencing social and economic exclusion. There is 
also considerable variation in consequences according to how they are used, for 
example whether clean needles and syringes are available for injecting drug users.
The impact on communities of drug supply 
and use reflects similar variations. In some 
more affluent communities, drug problems 
may have relatively little obvious impact 
beyond the user and their close family and 
friends. But more deprived communities 
appear to be the most vulnerable. Drugs 
provide both a commodity and a source of 
income for criminal gangs. The potential for 
young people to gain status, desirable goods 
and money through joining these gangs 
as junior dealers is particularly attractive 
where there are few other prospects. Reducing the availability of the drugs may 
provide some respite but will not solve the social problems in those localities.
Ease and reasons for stopping use also vary significantly. Clearly some 
substances are more addictive and harder to give up than others. But some people 
and groups of people are able to stop using even the most addictive drugs much 
more easily than others can. The experience of many heroin-using US soldiers 
in Vietnam, whose drug use stopped on their return to America,87 indicates the 
importance of the context of drug use in influencing users’ decision and ability to 
stop taking drugs.
The stigma experienced by many people with drug problems can also make it more 
difficult for some to overcome addiction. This stigma does not affect different groups 
equally, with heroin and crack users more stigmatised, as well as female users.
The impact on policy of a generalised approach
This wide variety in drug use underlies the difficulties involved in applying 
generalised goals to drug policy. Since the nature and impacts of drug use are so 
diverse, a goal that may be relevant for one aspect of drug policy may be counter-
productive in another aspect.
In more affluent 
communities, drug 
problems may have 
relatively little obvious 
impact beyond the user 
and their family and 
friends; more deprived 
communities appear to 
be the most vulnerable. 
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It is possible to identify several possible circumstances where basing policies on 
broad generalisations that do not take account of the diversity described above 
may lead to less cost-effective policies. For example:
•  A goal of reducing drug use overall, rather than a more nuanced focus on 
the quantity used or the relative harms of different substances may be less 
effective at reducing drug problems. Efforts to stop someone who occasionally 
uses drugs, such as ecstasy, in a low-risk way may deflect resources away from 
working with someone with an established crack or heroin addiction. But the 
associated harms are very different. A general goal of reducing overall drug use 
provides an incentive to treat all drug use equally or focus on those easier to 
affect, regardless of the relative levels of harm involved. 
•  A fall in the number of people using 
particular illicit drugs would not 
necessarily lead to better health and 
reduced crime if it masked a switch 
from less harmful drugs to more 
dangerous alternatives. One example 
of where this could happen is in the 
stimulants market, where a tightening of controls over some substances that 
might be relatively less harmful, such as mephedrone, could create an incentive 
for users to switch to other potentially more harmful drugs such as powder 
cocaine and untested new drugs.
•  A goal of encouraging people to stop taking drugs altogether may also have 
unintended consequences. For example, the current focus on abstinence as a 
treatment goal creates strong incentives to encourage heroin users to stop taking 
the drug or a prescribed opiate alternative. If this occurs before they are ready 
to stay drug-free, there is a risk that this will increase the chances of relapse, 
overdose and death. Equally, creating strong pressures for those who are 
convicted of a crime and test positive for drugs, to enter treatment regardless 
of whether their crime was drug-related or of the nature of their drug use, may 
damage the treatment system for other patients by overloading it as well as 
potentially wasting resources.
We conclude that some aspects of the way we make drug policy may now be 
creating more problems than they solve. The disparate factors that influence and 
govern different aspects of drug use and the competing goals that underlie drug 
policies make it unrealistic to expect that it can be approached in isolation from 
other issues, with goals that do not take into account the diversity in drug use.
The stigma experienced 
by many people with drug 
problems can also make it 
more difficult for some to 
overcome addiction. 
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Over the remainder of this report, we 
examine the policy implications of these 
conclusions. However, there remain two 
key issues outstanding in this review of 
how we approach drug policy: the need for 
open debate, and the value of evidence.
THE NEED FOR OPEN DEBATE 
As there is not a single drug problem it would be wrong to expect a single 
solution. It is also important to recognise the limitations of drug policy, given the 
complex range of factors that underpin drug problems. It is important that there is 
discussion of what can be achieved through any drug policy so that expectations 
are realistic. For example, it is clear from the evidence that drug education will 
never stop all drug use, neither will enforcement activity completely prevent all 
drug supply nor treatment prevent all acquisitive crime.
Drug problems are complex but there can be shared goals
The debate about drugs is highly polarised reflecting different sets of values and 
professional interests. Hence drug policy is best viewed as a ‘wicked issue’: a 
social problem characterised by resistance to resolution over long periods of time, 
being fractured by different deeply held values and by being connected to other 
similarly complex and unresolved issues.88 
The 2010 Drug Strategy is built around three goals: reducing demand, restricting 
supply, and building recovery in communities. While it was announced as a 
“fundamentally different approach to tackling drugs”, there was in fact a great 
deal of continuity and overlap with the previous strategies. As with previous 
strategies, the goals and interventions were built around the pillars of prevention, 
treatment and enforcement.
The first UK-wide Drug Strategy, for 1995-1998, was also built around three goals. 
These were similar to those in the 2010 Strategy: helping young people to resist 
drugs; increasing community safety from drug-related crime; and reducing the 
health risks of drug misuse, which included a focus on drug-free recovery from 
addiction. These goals are, in reality, designed around the paradigm of a single 
drug market dynamic (demand and supply) and the activities and interests of the 
main departments of state: Home Office (enforcement); Health (treatment and 
recovery); and Education (prevention), similarly reflected in Wales, Northern 
Ireland and Scotland.
Some aspects of the way 
we make drug policy 
may now be creating 
more problems than 
they solve.
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While the goals of the Drug Strategies have been largely consistent since 1995, 
there is relatively little explicit evaluation of, firstly, why these goals should be 
chosen and, secondly, whether such generalised and discrete goals are helpful 
for drug policy. 
Addressing the first of these issues, it is not self-evident what the overall purpose 
of drug policy should be. There are competing goals that could be prioritised, and 
while each of these is legitimate, they would lead to different approaches that 
may not always be compatible, for example:
•  Increasing the safety, wellbeing and prosperity of the general public, including 
families and neighbours of those involved in drug production, supply and use
• Improving the safety of those using or considering using drugs
•  Minimisation of restrictions on the liberty of individuals to seek potential 
benefits from drug use
•  Facilitation of individuals’ ability to address physical and psychological distress.
The tensions between these potential 
goals present challenges for drug policy; 
this is particularly relevant for the debate 
about whether, and to what extent, 
restrictions on controlled drugs might be 
changed. However, recent drug policy has tended to prioritise the first and second 
goals, protection of safety and prosperity, at the exclusion of the other goals.
This is not surprising, since there is almost always more pressure on governments 
and parliament to prevent or minimise drug-related disease, deaths and crimes. 
The safety of those using drugs or considering doing so is an important goal also. 
Young people and other vulnerable groups, who are over-represented among 
drug users, are particularly in need of protection.
But the other goals, of minimising restrictions on liberty, and facilitating 
individuals’ ability to seek pleasure or address distress, cannot legitimately be 
dismissed without further consideration. These goals can apply to drugs just as 
they do to alcohol, and it seems anomalous that the harms caused by drugs are 
taken into consideration in policymaking, but their benefits are not. 
The potential for competing goals of drug policy presents challenges for 
policymakers, and the balance between them needs to be agreed before effective 
policy can be developed. 
It is not self-evident what 
the overall purpose of 
drug policy should be.
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Research by UKDPC with Demos, which 
addressed this question, used a ‘soft systems 
approach’ to consider the challenge posed 
by new psychoactive substances.89 It showed 
how people with very different perspectives 
on the drug problem could nevertheless 
reach agreement on actions that could make 
progress against intermediate objectives. 
(see Box 6).
Box 6: 
CASE STUDY: IDENTIFYING SHARED GOALS TO OVERCOME 
POLICY CONFLICTS
In seeking approaches to the control of new psychoactive substances, 
UKDPC and Demos held two workshops with participants who were 
selected for their diverse experience, and to span the range of opinions on 
drug policy. Through a structured approach that allowed each participant 
to explain their perspective on the issues and then, rather than challenging 
these or endeavouring to reconcile them, the workshops focused on 
identifying opportunities for action that everyone could agree on, regardless 
of their underlying values or beliefs about the nature of the issue.
For example, one of the themes that emerged concerned the need for better 
information to be made available about the new drugs. This information 
was seen as necessary whether to prevent use, reduce the likelihood of 
harms associated with use, help with treatment of problems or to assist 
in enforcement of drug control measures. To achieve this, it was agreed 
that the most important step was the collection and collation of accurate 
information on new drugs. 
These workshops demonstrated that alternative approaches to problems 
with apparently intractable differences can produce solutions that are not 
available to traditional methods. Minimising the impact from substance 
misuse on well-being90 or health inequalities91 could provide an overarching 
goal that might offer a starting point for identifying action to address the 
problems associated with use of both licit and illicit substances. 
Young people and other 
vulnerable groups, who 
are over-represented 
among drug users, are 
particularly in need 
of protection.
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The potential consequences of policies need to be acknowledged
One aspect of open dialogue is the need to recognise the potential harms and other 
unintended consequences from the policies or interventions themselves. Whether 
a policy is deemed a success or failure may also depend on what the perceived 
policy goal is. If the overall aim of recent drug policy has been to prevent all drug 
use and drug production, then it has clearly failed. But if lower level and more 
pragmatic goals are considered, it is clear there have been successes in a number 
of policy areas, as outlined above.
The wide range of unintended consequences that can arise from drug control 
and enforcement has been highlighted by the former Director of UNODC, Antonio 
Maria Costa among others.92 Some examples are highlighted in Box 7.
Box 7: 
TYPES OF UNINTENDED CONSEQUENCES OF DRUG CONTROL 
AND ENFORCEMENT
• A large criminal black market, with associated violence and other crime
•  Policy displacement: due to the opportunity costs of the high expenditure 
on enforcement
•  Geographical displacement: markets shift to new areas or use different 
supply routes
•  Crime-type displacement: users and user-dealers turn to other types of 
crime or to more crime if dealing becomes too risky or if they need to raise 
more money
•  Tactical displacement: dealers develop new ways of dealing or 
distributing drugs, such as the use of the internet or mobile phones, or 
new techniques of concealment
•  Target displacement: dealers seek to open new markets in different sub-
groups of the population if existing markets are hit
• Substance displacement: new drugs are developed all the time
•  The stigmatisation of people suffering from addiction, which may impede 
access to treatment and rehabilitation. 
Adapted from: UNODC, 2008; and National Police Improvement Agency 
analysis guidance 
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However, the potential for unintended 
consequences applies to the whole 
range of interventions. For example, 
it has been found that some drug 
education interventions are not only 
ineffective in preventing or stopping 
drug use, but sometimes even have a negative impact. There is evidence that some 
public education campaigns, or public service announcements (PSAs), can, in 
fact, increase the likelihood of drug use. For example, in 2006 the US Government 
Accountability Office recommended removal of funding from the $1.2 billion 
National Youth Anti-Drug Media Campaign because an independent evaluation 
showed it had no impact on either cannabis initiation rates or curtailing use 
among people who were already using, despite the fact that young people could 
remember the advertisements and commented favourably on them. Indeed the 
only significant finding in relation to cannabis initiation was of small increases in 
likelihood of initiation among some sub-groups in some data collection periods. 
It was suggested that this might be because the campaign led to young people 
believing that drug use was more widespread than was the case.93 This finding 
is not unique. A systematic review of anti-drug campaigns aimed at young people 
found that “multiple studies have noted the potential of anti-drug PSAs to weaken 
anti-drug norms among youth, which may in turn lead to increases in the prevalence 
of drug use among this population”.94 This will appear counter-intuitive to people yet 
remains a powerful finding.
In a similar counter-intuitive vein, from around 2000, the UK government sought 
to reduce waiting times for drug treatment, to increase the numbers entering 
treatment through the criminal justice system (CJS), and to get greater numbers 
remaining in treatment for a minimum period in order to reduce drug-related 
crime. The rapid expansion of treatment services, which focused on prescribing 
substitute medication did succeed in engaging a large proportion of people with 
opiate problems, stabilising their lives and reducing the offences they committed. 
However, the focus on crime reduction encouraged services to emphasise 
bringing people into and keeping them in treatment, rather than on promoting 
their recovery. 
It is also important to recognise that some of the tough talking about drugs can 
itself have negative consequences. The stigma associated with drug problems 
may delay people from seeking help, or cement drug-using identities. Research by 
UKDPC demonstrated how constant repetition of messages representing people 
There is evidence that 
some public education 
campaigns can increase 
the likelihood of drug use.
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with drug problems as ‘junkie scum’ and 
‘once a junkie, always a junkie’ can make 
people reluctant to acknowledge their 
problems and seek treatment. It can also 
make employers reluctant to give them 
jobs, make landlords reluctant to give them 
tenancies, and result in communities being 
opposed to the establishment of treatment centres. As a result, drug problems 
remain entrenched rather than overcome.95 It is noteworthy that in the United 
States, both the President and his drug ‘czar’ now openly talk about the ‘illness’ 
of addiction. As the ex-head of the United Nations Office of Drugs & Crime now 
argues, those with drug dependency problems should be helped by the health 
care system rather than through criminal justice.96 Yet the prevailing public and 
political narrative is one of responding to drug dependency and addiction in order 
to achieve crime reduction rather than helping people get better. Of course both 
are important reasons but this can skew consideration of, and public support for, 
examining different approaches.
When Portugal adopted a more treatment-focused approach towards drug 
users, there was an open and constructive dialogue which facilitated major 
developments in drug policy. The change in the drug law was preceded by a public 
debate about the issues, led by the president who used his position to promote 
public awareness, influence politicians and to build support for a new pragmatic 
approach.97 Similar developments have taken place in the Czech Republic and are 
happening also in a growing number of South American countries. Our research 
has identified leadership, which is open to the evidence, seeks consensus on 
proposals, and fosters open dialogue as the key characteristics of the ‘good 
governance’ of drug policy.98 
Recognising the complexity of the problem and the potential for unintended 
consequences could provide the beginning of a policy process that is more open 
to learning from evaluated innovation and can acknowledge where a policy has 
not worked as intended. In a period of austerity it is particularly important that 
money is not wasted on cost-ineffective interventions.
The stigma associated 
with drug problems 
may delay people from 
seeking help, or cement 
drug-using identities. 
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THE USE OF EVIDENCE 
So far in this chapter, we have focused on the structure of the UK’s response to 
illicit drug use. We have concluded that drug policy should take more account of 
other social and economic factors, should recognise the limitations of overarching 
strategies with broad goals, and needs to be steered by more open debates.
However, while we believe that addressing the structure of policy making is 
important, the approach does not tell us anything about what particular mix of 
drug policies we should adopt: how illicit drugs should be regulated; what should 
be done to address drug dependence; how the harms associated with drug use 
can be reduced; and other questions that make up drug policy. To do this requires 
much closer attention to the building of a solid evidence base and promoting 
awareness of the findings amongst professionals and policymakers, something 
often referred to as ‘knowledge management’.
The collection and promotion of evidence
Throughout the work of UKDPC, our studies have evaluated the evidence 
about different drug policies, and some of the barriers in responding to drug 
problems. We have noted where independently verifiable evidence for a policy or 
intervention is strong, where it is mixed, and where it is poor. However, too often 
we have had to conclude that there is not enough evidence, or examination of the 
evidence, to make a judgement of the effectiveness, let alone cost-effectiveness, 
of existing or potential drug policies. We simply have no way of knowing what the 
overall impact of such policies and programmes are, other than the superficial 
headlines. And that is simply not good enough in the 21st Century and in tough 
economic times. 
We spend at least £1.2bn on drug policy each 
year - about £400 for each taxpayer99- there 
is a powerful case for systematically testing 
whether this money is being spent well 
and whether policies could be improved or 
alternatives trialled. 
As the House of Commons Science and Technology Committee noted in 2006, 
“UK investment in addiction research is woefully inadequate. The Government’s 
failure to ensure that sufficient resources are devoted to building the evidence 
base to underpin drugs policy is at odds with its commitment to adopt an evidence 
We spend at least 
£1.2bn on drug policy 
each year - about £400 
for each taxpayer.
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based approach.”100 This was not a new 
observation. A Home Office Research 
Study in 1988 stated “The fundamental 
problem facing the Government in its 
deliberation on drug control measures 
is the paucity of information on the 
subject”.101 
In order to ensure that money and time 
are better spent throughout drug policy, 
it is essential that we develop a pre-requisite for knowledge. Our research has 
highlighted a number of areas where there are considerable gaps in the evidence 
base for interventions that are underway (see Box 8). 
Box 8: 
EXAMPLES OF AREAS OF DRUG POLICY WHERE EVIDENCE IS LACKING
In a 2008 review, we looked at interventions for drug-dependent offenders 
within the criminal justice system (CJS)102 and concluded that while the 
principle of using CJS-based interventions to encourage engagement 
with treatment is supported by the evidence, there were no evaluations 
of effectiveness of many of the specific interventions, such as CARAT 
(Counselling, Assessment, Referral, Advice and Throughcare), the range 
of programmes based on cognitive behavioural therapy, conditional 
cautions, diversion from prosecution schemes and Intervention Orders. 
Where programmes had been evaluated, the evidence was often 
weak. Since then there have been some significant changes in policy, 
particularly in treatment and support within prisons with the roll-out of 
the Integrated Drug Treatment System (IDTS), which is the subject of an 
on-going evaluation, and pilots of drug-recovery wings. It is important 
that evaluations are properly resourced and the results acted upon when 
available. 
Another area where evidence for effectiveness and value for money is 
lacking, is drug law enforcement. Part of the reason for this is that the 
traditional measures of enforcement activity - arrests and seizures - 
In order to ensure that 
money and time are better 
spent throughout drug 
policy, it is essential that 
we develop a pre-requisite 
for knowledge.
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provide no information on the impact on drug problems. Work by UKDPC 
in collaboration with the Association of Chief Police Officers (ACPO) and 
the Serious Organised Crime Agency (SOCA) suggested that focusing on 
the most important drug-related harms in an area, involving communities 
in identifying these harms, developing enforcement interventions that 
targeted these harms and identifying a wider range of measures of 
outcomes, is most likely to have an impact.104 
In our response to the 2007 drug strategy consultation, which we developed 
through a process that included engagement with key academics, we 
called for the establishment of a ‘knowledge pillar’ within the new strategy 
in order to address the underdeveloped knowledge base for much of 
the strategy.105 Although a cross-departmental research programme has 
been put together, this essentially works to co-ordinate, and is limited to 
government-funded research. The need identified in 2007 still remains 
and any strategy should include a framework for regular and independent 
evaluation of the drug strategy,* as well as commissioning new research 
and programme evaluations, and should be funded appropriately. We 
also felt that consideration should be given to the establishment of an 
independent body charged with leading this work. This conclusion is 
discussed further in Chapter Five.
Although building processes that aid learning and development into a strategy 
is always good practice, it is now particularly important to ensure that policy is 
able to adapt to changes in the future, given the rapid development of new drugs 
and new supply routes. A 2012 Cabinet Office paper on randomised controlled 
trials argued for their routine introduction throughout public policy in the UK.106 
We share the view that such trials can both improve policy and save money. The 
Medical Research Council’s Guidelines for Good Clinical Practice in Clinical Trials 
provides further details on how such research should most effectively 
be conducted.107 
*The 2010 Drug Strategy promised the development of an evaluation 
framework but one year on this has yet to be completed.
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It is our view that the way we collect, 
analyse and use evidence in UK drug 
policy has often been inadequate, and 
that this has held back cost-effective 
policies that could have improved the 
lives of millions of people who are 
directly and indirectly affected by drug 
problems. While a randomised control 
trial is not needed to prove the efficacy 
of every piece of policy, too often we 
have slipped to the other extreme and 
relied simply on anecdote. It is essential to recognise that, as Campbell points out, 
reforms, such as the current development of Payment by Results for a wide range 
of services, are essentially experiments and those supporting and delivering these 
programmes must be open to unbiased appraisal of success or failure, and be 
prepared to take a different approach should the evaluation prove negative.108 It is 
also important to replicate these studies to build clear evidence of cost-effectiveness 
and identify the conditions under which a particular approach works. 
International collaboration is invaluable for building the evidence base. The work 
of the Campbell Collaboration,109 a research network that produces systematic 
reviews of the effects of social interventions, is a good example of how evidence 
can be brought together to answer questions in social policy. However, it has 
been less influential than the comparable Cochrane Collaboration in the field of 
medicine, due to the paucity of international support and funding. It is important 
that drug policy research is adequately funded and is able to take advantage of 
funding streams such as the Public Health Research Programme of the National 
Institute of Health Research.110
We also need to change how we make use of evidence. In the process of making 
drug policy, evidence is often treated as a stakeholder whose interests should be 
taken into account, rather than as a tool that is useful for all participants. To make 
progress on tackling the problems associated with illicit drug use, we need a new 
and more mature relationship with evidence.
The way we collect, 
analyse and use evidence 
in UK drug policy has 
often been inadequate, 
and this has held back 
cost-effective policies that 
could have improved the 
lives of millions of people.
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Analysis and use of evidence 
is currently limited
It is not just a question of more and 
better evidence. We also need to ensure 
the evidence is analysed and used 
appropriately. We have identified five areas 
as examples where such improvements are 
necessary.
1. Willingness to be guided by evidence
Even where good evidence is available, 
the willingness to act on it may be limited 
if the implications are politically difficult. Equally, there is a danger that evidence 
collection can be used as a tool to verify pre-existing beliefs, with challenging evidence 
being discarded. Such ‘cherry-picking’ has to be resisted if policy is to learn from 
uncomfortable findings. This is one of the greatest difficulties and requires not only 
political courage but also a greater willingness in other groups, including the media 
and third sector, to be persuaded by evidence that challenges their expectations.
2. Recognition of different forms of evidence
There also needs to be greater recognition and understanding of the different 
forms and levels of evidence. The reality of complex issues is that evidence is 
often incomplete, imperfect or suggestive of only relatively small effects. It is 
crucial that policymakers are able to distinguish between better and worse quality 
evidence. Anecdote may be important for suggesting issues that need further 
exploration, but it is not a substitute for thoroughly evaluated and evidenced 
assessments.
3. Clarity on the objectives of policy
When analysing evidence, we need to be able to identify whether a particular 
intervention is achieving specific objectives - and whether it is producing 
unintended consequences. Careful setting of specific objectives is crucial if 
evidence is to be valuable to policymakers. For example, evidence might indicate 
that long prison sentences for heroin possession would reduce acquisitive crime 
in the short term. But if the aim of policy is not just to reduce crime in the short 
term, but also to help people with heroin problems to overcome addiction and 
build productive and fulfilling lives, the policy conclusions might be different.
To make progress 
on tackling the 
problems associated 
with illicit drug 
use, we need a new 
and more mature 
relationship with 
evidence and providing 
an environment that is 
supportive of recovery.
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4. Overcoming desire for trials to produce positive results
A related challenge is the political sensitivity of trials. There is a risk that they are 
seen not as honest attempts to understand what does or does not work, but as the 
first wave of new government policies. The consequence is that policymakers are 
less willing to test policies that they are not confident about, and when a trial is 
started, negative results are seen as a government failure. Instead, there should 
be recognition of the value of negative results: knowing what does not work can 
sometimes be as useful as knowing what does work. A further challenge is to 
recognise that the results of trials may not always accurately reflect the impact of 
a policy when it is implemented on a wider scale.
5. Awareness of alternative policies
Equally, there is often too little attention paid to alternative approaches and 
opportunity costs. It may be the case that evidence suggests a particular 
intervention is effective, but its costs may be greater than the costs of other 
approaches. Greater overall benefits might be achieved with these other policies.
Inadequate collection and thorough 
analysis of evidence has been one of the 
greatest limiting factors for drug policy 
in the UK. As the report of the Science 
and Technology Committee went on to 
say, “[t]he Government has been remiss 
in failing to conduct a proper evaluation 
of the impact of its policy decisions in 
this area and has, as a result, missed out on opportunities to gather valuable data 
to improve policy making in the future.”111 
As long as there continues to be inadequate collection and analysis of evidence, 
public money spent on drug policy will not be used as efficiently as it could be. 
This inefficiency would be unethical at any time, but it is particularly so when 
reduced resources mean that more sacrifices in public spending are necessary. 
Tackling this would provide an important tool to overcome the barriers that 
currently restrict more cost effective policy.
In order to begin to achieve this, our first step is to identify what we know so we 
can act on it, and what we do not know so we can plan evidence collection and 
analysis. The third chapter will now evaluate the evidence in order to identify 
opportunities for improvements to drug policy in the UK. 
Inadequate collection 
and thorough analysis 
of evidence has been one 
of the greatest limiting 
factors for drug policy 
in the UK. 
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KEY POINTS
>The division of drug policy into prevention, treatment 
and enforcement unnecessarily separates policy areas 
that cannot effectively work independently
>An approach to drug policy that would facilitate an 
integrated approach, both across departments and with 
other social policy areas, focuses on the twin overarching 
goals of supporting individuals to behave responsibly, 
and promoting recovery from entrenched drug problems.
Supporting individuals to behave responsibly
>Evidence supports some early interventions that reduce 
a range of problems
>Drug-use prevention programmes are generally not 
supported by evidence, although some wider programmes 
may have a positive effect
>For those people who nevertheless decide to use drugs 
there is evidence that a range of interventions can encourage 
them to do so in less damaging ways
>Law enforcement can be better targeted to support 
individuals to behave responsibly 
104 105
w
>Current drug laws lead to unintended consequences and 
may not be cost effective in encouraging individuals 
to behave responsibly.
Promoting recovery from entrenched drug problems
>Recovery from problematic substance use is a process that 
involves not only achieving control over drug use, but also 
improving health and well-being and building a new life, 
which includes family and social relationships, education 
and employment 
>Communities have an important role in supporting 
individuals’ recovery
>Law enforcement and the criminal justice system 
can be more focused on supporting recovery
>Families of people with drug problems can not only aid 
recovery, but often also need help in their own right
>There is evidence showing ways in which the broader 
treatment system can be changed to improve rates of recovery 
by providing a range of different types of treatment options 
and linking in wider support services, including mutual aid.
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The purpose of Chapter Two was to evaluate the principles governing the UK’s 
approach to drug policy and to suggest how these could be improved. This chapter 
applies those conclusions to the evidence of what we know works in drug policy, 
in order to identify where policy can be improved.
With few exceptions, drug strategies and policy are divided into a three-part 
structure of prevention, treatment and enforcement. While we are cautious of 
breaking a convention that is so dominant, and reflected in political, professional 
and practical institutional structures, nevertheless we are concerned that this 
approach has significant limitations. Creating clear divisions between the 
different areas of drug policy may create the misleading impression that each 
area can operate independently of the others. Yet in practice, this is not the 
case. Furthermore, it may inhibit the development of more efficient and effective 
approaches to tackling drug problems. At times such areas can function at 
cross-purposes, for example where enforcement activity near treatment centres 
discourages people from engaging with treatment.
These divisions and a lack of open debate about the overall goals of drug policy, 
also leads policymakers to treat the interventions not as tools but as goals in 
themselves. This results in a focus on activity rather than outcomes. So this may 
reduce the effectiveness of programmes, waste resources, and inhibit development 
of more cost effective ways of tackling drug problems.
We have therefore taken a different tack, and in this chapter, we consider the 
evidence for policy interventions to address two broad high-level goals. The tools 
of prevention, enforcement and treatment can be used to achieve these, as can 
broader social policy. 
First, we look at how society and 
government can enable and support 
individuals to behave responsibly. This 
includes not only policies designed to 
discourage people from taking harmful 
substances, but also law enforcement 
approaches that focus on the behaviour 
and markets that cause the most harm, 
as well as other policies intended to limit 
the risks and harm associated with both 
occasional and more problematic use.
Which policy is best will 
depend on which users 
and suppliers we are 
talking about, on what 
drugs they are using and 
supplying, and on other 
factors relevant to their 
particular case.
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Second, we consider policy that can enable and promote recovery from 
entrenched drug problems, both for individuals and communities. This looks 
at evidence around drug treatment systems, as well as wider support including 
housing and employment policies. It also includes aspects of policy around 
law enforcement and how we deal with people who are convicted of crimes 
associated with drug use.
Our intention is that this approach will help foster a greater focus on the overall 
goals of drug policies and how the different components of policy interact 
with each other, which often appears to be insufficient in current drug policy 
structures. Which policy is best will depend on which users and suppliers we are 
talking about, on what drugs they are using and supplying, and on other factors 
relevant to their particular case, as well as the types of harms being caused, both 
at individual and societal levels. There are unlikely to be any silver bullets.
AN ENVIRONMENT THAT SUPPORTS RESPONSIBLE BEHAVIOUR
The term ‘responsible behaviour’ risks meaning different things to different 
people as it is, to some extent, a moral judgement. Terms such as ‘personal 
responsibility’ also come with a certain amount of baggage attached. Box 9 shows 
what we mean by the phrase. 
Our analysis of the evidence has identified a number of opportunities for action to 
encourage responsible behaviour and in this way reduce the harms from drug use 
and other social problems.
Box 9: 
WHAT DO WE MEAN BY RESPONSIBLE BEHAVIOUR?
What we mean by ‘responsible behaviour’ is that an individual should seek 
to behave in ways that allow them to achieve their potential, and contribute 
positively to their families and communities as well as to avoid, in general, 
incurring harms to others. Behaving responsibly, and limiting harm and 
damage to self and others are two sides of the same coin.
At the heart of the goal of encouraging individuals to behave responsibly is the 
recognition that governmental policies and programmes can either facilitate 
or undermine this. Society and government need to adopt policies that seek 
to foster an environment that is supportive of responsible behaviour.
With respect to drug use therefore, policy should be primarily directed 
towards enhancing pro-social behaviours and reducing the harm that drug 
use and supply can cause to users and the people around them.
This includes seeking to:
- Reduce deprivation, disadvantage and inequalities
- Ensure that people have accurate information about the risks associated   
 with drug use on which to base decisions
- Prevent people from developing serious drug problems
- Act so that drug markets cause less harm to communities and individuals
- Enable those who take drugs to do so in ways that cause themselves less harm
- Protect children and young people from drug use and roles in drug supply
- Prevent drug-related crime, particularly violent and acquisitive crime.
Providing clean needles and syringes to injecting drug users to prevent the 
spread of HIV and other blood-borne viruses is a good illustration of how 
the state can facilitate responsible behaviour in part, as it can also be a first 
step in a long journey of rebuilding their lives. Similarly, policies built on 
sound evidence that strengthen families and improve young people’s life 
skills and attachment to school can facilitate responsible behaviour, and 
delay and prevent harmful drug use, even though many will still go on to 
experiment and use drugs.
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But some policies can undermine responsible behaviour. For example, 
it is now well recognised that very aggressive stop and search tactics 
employed by police in some places and amongst certain ethnic groups 
aimed at addressing drugs has had unintended negative consequences. 
Damage to communities’ and individuals’ trust and respect for police and 
the authorities more generally can undermine other efforts to address the 
supply and use of drugs.
A small but significant segment of the population will use drugs. We do 
not believe that pursuing the goal of encouraging responsible behaviour 
means seeking to prevent all drug use in every circumstance. This is not 
to say that we consider drug use to be desirable. Just like with gambling 
or eating junk food, there are some moderately selfish or risky behaviours 
that free societies accept will occur and seek to limit to the least damaging 
manifestations, rather than to prevent entirely.
Drug policy should focus on ensuring that any drug use occurs in ways 
that pose lower risks of harm to others and to users themselves. The bar 
should be set particularly high for children and young people, given their 
physiological vulnerability to harm from drugs and the fact they are less 
able to make rational decisions about their own wellbeing.
Once someone is addicted, they may have less ability to make rational 
choices. Therefore, while we should ensure that anyone who continues to 
use drugs does so in a way that minimises harm, support should go beyond 
this to help them recover in the longer term by working with them to build 
the hope, aspiration and skills required to be a full member of society. This 
is why we separate the goal of supporting responsible behaviour from that 
of promoting recovery. For those with serious drug problems, recovery may 
be the necessary first step to responsible behaviour: it may be counter-
productive to demand significant behaviour change from them before the 
recovery process has begun.
Tackle risk factors that predispose people to drug problems
No-one seriously doubts that use of psychoactive substance carries some risk. But 
it is also clear that the degree of risk varies between individuals. In adolescence, 
an increase in risk taking is a normal part of development and for many young 
people drug use is just one of a range of risky behaviours that they undertake. 
Usually such experimentation is short-lived. However, it is also a time when 
the brain is developing rapidly, which can increase the potential for harm.113 
Whether experimental or occasional drug use develops into more harmful use 
or dependence is associated with a range of personal, social and environmental 
factors, some of which are fixed and some of which can benefit from intervention. 
The wide range of factors that make people vulnerable to drug problems and 
influence whether or not these develop was discussed in Chapters One and 
Two, as were the specific risk factors which vary over an individual’s life.114 The 
challenge is to identify effective interventions that can address the relevant 
factors at each stage. 
Drug use is just one factor impacting 
on people’s health and well-being, and 
contributing to health inequalities. The 
approach highlighted in the Marmot 
Review, which indicates the need for 
tackling socio-economic factors in order 
to provide more inclusive and cohesive 
communities, may also be valuable for 
preventing drug use and providing an 
environment that is supportive of recovery for those who do develop problems.115 
Drug use is one of a number of behaviours posing a risk to adolescent health, 
which tend to cluster together and have been shown to be associated with the 
same risk and protective factors that may be amenable to intervention, such as 
those relating to poor parenting. 
Intervening early may help to avoid problems in families who have multiple 
disadvantages by helping them to become more resilient, and develop social 
capital. Examples in the UK include the Family Intervention Projects (FIPs) and 
more general support programmes such as Sure Start. FIPs “aimed to reduce 
anti-social behaviour (ASB) perpetrated by the most anti-social and challenging 
families, prevent cycles of homelessness due to ASB and achieve the five Every 
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Child Matters outcomes for children and young people. FIPs use an ‘assertive’ 
and ‘persistent’ style of working to challenge and support families to address the 
root causes of their ASB.” There is some evidence that these might be effective 
and cost-effective116 although there are concerns about the design of these studies 
and the robustness of the findings.117 Their impact on future substance misuse 
is unclear given the long-term nature of that outcome. If similar approaches are 
to be adopted under the Coalition’s Troubled Families programme, it will be 
necessary to establish good evidence of the effectiveness and sustainability of 
these programmes.
Other programmes providing support to vulnerable young people and their 
families at a later age, such as Targeted Youth Support, may also be valuable,118 
although they depend on identifying young people experiencing problems 
as early as possible, and having an evidence-based model underpinning the 
intervention and integration of provision. Therefore how these programmes are 
delivered is likely to have a big impact.119 There is also some evidence that the 
Strengthening Families Programme, which has been adapted for use in a range 
of countries including the UK, can have a positive impact on substance use and 
a range of behaviours.120 But assessing the likely impact and cost effectiveness 
of these programmes is made more difficult by the number of interventions that 
might have an effect on outcomes, as well as the range of outcomes and the long 
time-frame over which impacts are looked for.
It is important to recognise that drug use 
affects people from all social groups, 
but those with more resources at their 
disposal may be better placed to manage 
the problems and overcome them. 
However, high-profile cases such as that 
of Amy Winehouse and Eva Rausing 
show that, unfortunately, the difficulty 
of overcoming such problems means that 
this is not always possible. It is also the 
case that, while those from the most disadvantaged backgrounds have a higher 
than average risk of developing problems, they make up only a comparatively 
small proportion of the population. For example, the Troubled Families initiative 
is expecting to engage with 120,000 families yet there are over seven million 
families with dependent children in the UK, so reducing drug problems among this 
group may in fact have a comparatively small impact on overall drug problems.
Drug use affects people 
from all social groups, 
but those with more 
resources at their disposal 
may be better placed to 
manage problems and 
overcome them.
Support sensible choices
There is extensive literature on behaviour change121 that illustrates the array of 
factors, both at individual and society level, that underpin decisions about what 
people do. Whether the decision is to buy or not to buy a new dress, have another 
helping of dessert, or have an alcoholic drink or use drugs, the choice depends on 
a complex trade-off between the perceived benefits and any potential problems. 
People vary in many ways that affect how this trade-off is perceived. Simply 
knowing something is bad for you in the long term is often not enough to prevent 
you from doing something that brings you some sort of immediate reward. Factors 
that may impact on behaviour include: values, beliefs and attitudes; norms and 
identity; sense of agency, self-efficacy and control; habit and routine; and how an 
individual feels at a particular moment.
However, external factors that encourage or inhibit an action may also be 
important. Cultural factors that encourage hedonism and the use of substances 
such as alcohol, or that present drug use as an acceptable part of a celebrity 
lifestyle also have an impact. The recent interest in achieving changes through 
choice architecture - so-called ‘Nudge’ theory - reflects the significance of 
external factors. 
In the field of preventing drug use, the evidence for the effectiveness of most 
programmes is very limited. However, it has been argued that inexpensive 
universal programmes that have a very small positive effect may nevertheless be 
cost effective122 and those that are not specifically drug-related but seek to build 
general self-efficacy and social skills have the potential to make an impact on 
many kinds of risky behaviours, thus multiplying the benefits. 
The evidence that drug-related mass media 
campaigns work is limited and some 
have been shown to actually increase the 
likelihood of drug use. What evidence 
there is supports school-based drug 
education programmes that are aligned 
with models of behaviour change and that 
aim to build self-efficacy and social or life 
skills generally.123 However, the impact on 
drug use is not likely to be large. 
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Importantly, there are a number of drug 
education programmes that are quite widely 
used, including the Drug Abuse Resistance 
Education (DARE), but which have been 
shown to be ineffective.124 At a UKDPC seminar 
looking at the potential impact of current 
reforms in a period of austerity, concerns were 
raised that as schools become increasingly free 
from Local Authority controls and responsible 
for their own budgets, there is likely to be an 
increased use of ineffective programmes that are widely marketed and distributed 
freely.125 Equally, a review of prevention interventions in non-school settings 
found very little evidence of their effectiveness.126 The assessments included 
motivational interviewing and some family interventions.
In contrast, other more general programmes such as the Good Behaviour Game, 
aimed at primary school age children, appear to be effective at increasing 
attachment to school and improving a range of behaviours, which included 
reducing substance use. Such programmes that seek to influence behaviour more 
generally, rather than focusing solely on substance misuse, may be more cost-
effective and beneficial because of their wider impact.
Although some people would prefer that no-one uses drugs, the experience of 
more than 50 years of global efforts to prevent drug use indicates that this is not 
an achievable objective, at least with the tools currently available. Given this, 
there is good evidence to support a range of interventions that will encourage 
those who do use drugs to do so more safely or responsibly. 
As Room points out, “drinking, smoking and drug use can symbolize freedom and 
autonomy, providing youth with a seemingly adult status.” Telling young people 
not to undertake these activities, which in the case of alcohol and smoking are 
acceptable adult behaviours, seems hypocritical and is therefore often ignored.127 
Recreational drugs are generally seen as little different to the licit drugs, and their 
use by celebrities and other groups such as the media and city workers is perceived 
to be widespread. So for young people who use drugs, recreationally, there is a 
good justification for the provision of credible non-judgemental information on 
ways of using drugs that are particularly risky, such as mixing drugs and drugs and 
alcohol, using alone, and re-dosing. In the Netherlands, a confidential pill testing 
service is available which overcomes a key problem with these drugs: uncertainty 
about what they actually contain. If this service is shown to have benefits, it 
There are a number 
of drug education 
programmes that 
are quite widely 
used, but which have 
been shown to be 
ineffective.
should be considered for the UK. The need for these types of approaches is now 
even more salient with the increasing number of new psychoactive substances 
becoming available, with little certainty about their content.
The value of needle exchange 
programmes in reducing the spread of 
infectious diseases is well established, 
and there is also sufficient evidence to 
support the provision foil.128 There is also 
considerable evidence showing the value 
drug consumption rooms (DCRs) have in 
both reducing drug-related deaths, and 
harm to health for injecting drug users, 
as well as reducing nuisance from users injecting in public in local communities. 
In 2006 an Independent Working Group convened by the Joseph Rowntree 
Foundation concluded that DCRs offer a unique and promising way to work with 
the most problematic users to reduce the risk of overdose, improve their health 
and lessen the costs to society. It recommended that pilot DCRs should be set up 
and evaluated in the UK. This has not happened but the evidence in support of 
them from other countries has continued to build. So although injecting drug use 
appears to be declining in the UK, the potential benefits of DCRs should again be 
considered. It is disappointing that the UK government recently stated its view 
that the provision of DCRs would be a criminal offence.129 
The widespread provision of take-home Naloxone, a safe drug that can reverse 
the effect of heroin overdose, is also well supported by the evidence.130 Both 
Scotland and Wales have programmes to extend the provision of Naloxone packs 
and there are pilot projects underway in England. Concerns have been expressed 
that this will encourage heroin use by providing a ‘safety net’, but there is no 
evidence that this occurs and by contrast it may well encourage individuals to 
take responsibility for helping others.
While these harm reduction programmes can help promote safer or more 
responsible drug use, they can also provide a first step in the process of recovery.
Focus enforcement and control on supporting responsible behaviour
The legal controls on psychoactive substances have an impact on the behaviour 
of those who use drugs, but the evidence concerning that impact is mixed. 
Making the use or possession of particular substances illegal clearly does not 
stop people using them completely, but does almost certainly deter some people 
Harm reduction 
programmes can help 
promote safer or more 
responsible drug use and 
provide a first step in the 
process of recovery.
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from using. But as criminologists have long observed, the deterrent impact of 
any law lies in the risk and probability of detection rather than the simple fact 
something is illegal.
Traditional drug enforcement efforts, which have focused on arrests and drug 
seizures with the aim of reducing supply, often have limited or no sustained 
impact on supply, because most drug markets are large, resilient and quick to 
adapt. The risk of detection is, in reality, quite limited and the costs associated 
with improving detection rates are disproportionately high and expensive. 
Enforcement can also have unintended consequences, resulting in an increase in 
the damage that drug markets inflict on a community, for instance, by triggering a 
‘turf war’.131 When drugs are illegal, it also reduces the options for enacting controls 
that can make their use less harmful, for example quality-control measures and 
labelling requirements, as well as restrictions on who may sell or purchase them. 
Balancing the delivery of justice with effectiveness and value for money is not an 
easy consideration for policy makers in this area.
These issues are exemplified in the new 
psychoactive substances, the so-called 
‘legal highs’, which appear with increasing 
frequency. The current approach appears 
neither to be targeting clear, desirable 
outcomes, nor to be based on evidence of 
effectiveness.132 Criminalising supply of all 
new psychoactive substances is likely to 
have negative unintended consequences, for example leading to the development 
of other more harmful substances, increasing uncertainty over what is supplied, 
and increasing enforcement costs. An approach that targeted the outcome of 
reducing harm to young people might draw on other legal responses such as 
using enhanced consumer protection powers, eg trading standards, to regulate 
the availability and nature of certain new substances. It appears from other 
countries and the experience of better regulation of solvents under the Intoxicating 
Substances (Supply) Act 1985 that there is potential for using the wider legal control 
system to improve health and wellbeing, and public safety.133
Within the current legal framework there is only limited international or UK 
evidence of the effectiveness of any enforcement activities. But what there is tends 
to support partnership approaches that involve the community. The evidence 
suggests that identifying problems and setting priorities at community level 
should be done in collaboration with the community affected.134 Neighbourhood 
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policing community meetings could provide an opportunity for this, while 
engaging the community through structured, deliberative processes could help 
to develop a stronger understanding of the problems caused by drug markets and 
the options available to alleviate them.
There is also evidence that enforcement 
approaches that target particularly 
harmful behaviours may be effective at 
reducing the harm to communities and 
the environment. Our review that looked 
at the potential for improving the impact 
of enforcement135 identified three broad 
and potentially overlapping approaches 
that could be used to deliver an overall reduction in harms:
1. Targeting specific individuals or groups identified as being particularly 
harmful, eg using schemes such as Integrated Offender Management, or one-off 
targeted operations 
2. Targeting areas where drug problems are particularly damaging, eg seeking to 
displace a market to another area, where it will have less impact, or ‘closing’ open 
markets 
3. Targeting particularly harmful behaviours, eg addressing the use of violence 
and intimidation, or the use of young people as lookouts and couriers.
Examples of the first group are assertive outreach schemes such as Operation 
Reduction in Brighton & Hove, and Operation Iceberg in Kent. In these schemes, 
street-level dealers, who have been identified as user-dealers, are approached and 
offered the opportunity to enter a programme of treatment and rehabilitation as 
an alternative to arrest and prosecution. An independent evaluation of Operation 
Reduction suggested that it was successful in rehabilitating individuals and 
reducing their offending, and also reduced the costs associated with arrest, 
prosecution and incarceration.136 
The Drug Market Intervention (DMI) initiative in the US is quite similar to this and 
seeks to tackle open-air drug markets that are causing particular problems within 
a neighbourhood. The most violent offenders are targeted, and prosecuted as 
examples. The strategy then targets low-level offenders and stages an intervention 
with families and community leaders with the aim of encouraging them away from 
crime.137 This appears to have been effective in some areas138 but not in others and 
research is underway seeking to identify the characteristics of neighbourhoods 
and drug markets that are associated with good outcomes.139
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Other projects have targeted gangs, such as the Boston Gun Project, and a similar 
approach which is being tested in Glasgow. Recently there has also been an 
increase in operations that seek to ‘follow the money’ and use asset recovery 
to try and hit the organised crime leaders who benefit most from the drug trade 
and thus reduce their ability to fund the trade. While some high-profile groups 
have been brought to justice in this way, these are long-term operations requiring 
specialist skills.
The Proceeds of Crime Act (POCA) has been increasingly used in drug crime cases. 
Some research suggests that it may be a deterrent, but the evidence is mixed. The 
potential for providing additional revenue for police forces or communities makes 
it appealing, but there is anecdotal evidence of unintended consequences from 
indiscriminate use of the act, such as when the family of a person who has been 
convicted of growing a few cannabis plants may lose their house.140
Communicating with the public about 
enforcement activities can help to address 
people’s concerns and demonstrate that 
such strategies deliver results. However, the 
typical media images of a police ‘crackdown’ 
- smashing in doors and making arrests - may 
have a downside in that they may create a 
demand for a style of enforcement that is not 
always the most cost effective. It is also the case 
that what may be reassuring to one part of the 
public might heighten the concerns of others. There needs to be more innovative 
ways to engage the public and reassure people that action is being taken; the 
cases presented above illustrate examples of such approaches. 
Some enforcement practices can alienate communities and hence potentially 
increase the likelihood of drug use within the community. Stop and search for 
drugs is responsible for about half of all stop and search activity and fewer 
than 1 in 10 result in drug arrests. The differential impact of stop and search 
on ethnic minorities is well documented and can have a negative impact on 
community relations.141
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Ensure that drug laws support 
responsible behaviour
Whether drug laws are effective in 
supporting responsible behaviour is 
difficult to assess. On the one hand, the 
low overall levels of use of controlled 
drugs compared with alcohol could be 
evidence of the power of the law as a 
deterrent. In surveys the fact that drugs 
are ‘illegal’ is often cited as a reason 
why people do not use them. However, the fact that an estimated 11 million people 
across the UK have at some time in their life used drugs might also be seen as 
evidence of its ineffectiveness. Equally, the fact that an estimated three million 
have used at least one illicit drug in the past year suggests the law has, at best, a 
limited deterrent effect. 
With about 42,000 people in England & Wales sentenced every year for possessing 
drugs and about 160,000 given cannabis warnings, this amounts to a lot of time 
and money for the police, prosecution service and the courts. On top of this comes 
the cost to the individual in terms of damage to employment prospects. Some 
people who do develop drug problems may also be put off from seeking help 
earlier because they are doing something illegal.
There are a number of reasons for amending the law in relation to the possession 
of drugs for personal use:
The Misuse of Drugs Act is over 40 years old
Since the 1971 Misuse of Drugs Act was passed, the nature of drug use in the UK 
has changed radically. The Act was not designed to deal with such high levels of 
use nor the rapid development of new drugs.
The ABC classification system (see Box 1, page 37) and the associated schedules of 
drugs which are at the heart of the legislation were created both to designate the 
status of the substances, and to provide a guide to the courts when sentencing. 
In recent years, the emergence of new psychoactive drugs, now at a rate of 
one a week, has created a rate of change in the drugs market that is beyond 
anything anticipated by the designers of the Act. This is something the New 
Zealand government recognised when they commissioned the New Zealand Law 
Commission to review their Misuse of Drugs Act.
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In addition, the ABC classification system has become increasingly discredited 
because a drug has never been reclassified downwards (with the exception of 
cannabis, which was then reclassified upwards). When experts and scientists 
have suggested reclassifying drugs such as ecstasy and cannabis downwards in 
the past, this has been rejected by ministers. Some experts have suggested that 
the system has outlived its usefulness, that politicians and the public do not 
fully understand its purpose, and that with the advent of the Sentencing Council, 
there is an argument for de-coupling the assessment of harm from the legal and 
sentencing framework. 
Disconnect between policy and 
practice
The current laws also bear little 
relationship to what actually happens 
in practice. Over the years the police 
and courts have used their judgement 
to the extent that relatively few people 
receive a prison sentence simply 
for possessing a controlled drug. Many people addicted to drugs who commit 
acquisitive crimes are dealt with through other provisions in law. In effect, 
simple drug possession offences have increasingly become depenalised, except 
for repeat offences, and in a few relatively isolated instances. It is not clear why 
the law should be so disconnected from custom and practice, yet it is clear that 
the police and prosecution authorities do not consider such offences to be a high 
priority. There are also legitimate concerns that the law is applied unevenly, with 
some groups of users appearing to be subject to more strict action and penalties 
than others, most notably those from ethnic minorities.
Growing de jure decriminalisation of some drugs
In recent years, new legislation has introduced powers for the police to issue 
warnings and penalty notices for the possession of small amounts of cannabis. 
Yet the possession of class C anabolic steroids for personal use does not 
attract a criminal sanction. More recently, the new Temporary Drug Class 
Orders do not result in criminal sanctions for those found with small amounts 
of the temporarily controlled drug. In effect we are seeing a gradual de jure 
decriminalisation for the possession of small amounts of some drugs. Yet 
there is no clear explanation about why this should apply to users of these 
drugs, but not to users of other drugs. 
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Negative effects of enforcement
Many thousands of people each year are cautioned or given criminal records for 
possessing drugs. We need to ask whether this is a proportionate response, 
particularly since enforcement tends to be focused on certain groups, 
particularly the young and some ethnic groups in particular localities. There 
are also legitimate concerns that drug control laws lead to greater risks for 
each drug user, as substances are sold with less predictable dosages, and more 
uncertainty about content or possible contaminants. The ex-head of the UNODC 
is not alone in calling for the decriminalisation of the consumption (possession 
in the UK) of drugs.142
Over recent years there has been a clear drift upwards of length of imprisonment 
for drug production and supply offences, even though maximum sentences are 
rarely applied.143 These appear disproportionate in comparison with some other 
countries,144 and it is not clear that these tougher sentences provide any greater 
deterrent for those who might break the drug laws.
Erosion of respect for the law
The risk of being caught possessing 
drugs is very low compared to the 
prevalence of drug use overall. As 
criminologists know, the perceived risk 
of detection is an essential component 
of deterrence,145 and the point has been reached where drug laws are largely 
seen as an irrelevance by those who break them. Opponents of depenalisation 
and decriminalisation raise concerns about the message that a change in the 
law would send to the public, particularly young people. We recognise that the 
law expresses the sort of society we wish to live in. But the law relating to the 
possession of drugs has become discredited to such an extent that any usefulness 
in setting a moral position has in many situations become largely ineffectual. One 
example of the disconnect between law and behaviour is the reclassification of 
cannabis. After reaching a peak in 2001, the prevalence of cannabis use in the 
UK has been broadly declining. This has been in spite of the classification and 
punishments for possession being eased in 2004 and then increased again in 
2007. As noted by the Chair of the Advisory Council on the Misuse of Drugs in 
relation to the changes in classification of cannabis, “It is as if cannabis users 
either do not know or do not care”.146
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Acceptability of other approaches
Many people are concerned that if the law were to be changed so that possessing 
controlled drugs was no longer a criminal offence, then use, especially by 
young people, would increase. This is understandable. But what evidence there 
is indicates that changes in drug laws do not necessarily lead to changes in 
individuals’ decisions about drug use. In the UK, the reclassification of cannabis, 
both downwards and subsequently upwards, coupled with an increasing use of 
other penalties by the police, took place at the same time as a steady decline in 
reported use of cannabis, with no apparent impact on levels of use caused by the 
changes in legal status. 
Some other countries have gradually moved towards a more decriminalised 
approach to personal possession of small amounts of all drugs. This has been seen 
for example in Portugal, Czech Republic, and Switzerland, and for cannabis in 
parts of Australia, the US, and some South American countries. We acknowledge 
that the evidence of the impact of such changes is disputed by some observers. 
But while we cannot say with certainty what the total impact has been, one simple 
lesson we can draw with confidence from such initiatives is that ‘the roof has 
not fallen in’ and that prevalence and consumption have not increased in these 
countries to any significant extent. Some experts indeed argue that these reforms 
have led to decreasing problems. 
It is important to note that recent research in 
Australia concluded “that decriminalizing 
cannabis shifts the age distribution of uptake 
towards younger age groups while leaving 
the proportion of those who will start using 
cannabis unchanged. This suggests that 
decriminalization affects when individuals 
start using cannabis, rather than whether or 
not they start”.147 Given the particular harm 
that drug use can cause to young people, this 
finding indicates the importance of combining any change in drug laws with 
effective drug education and treatment programmes, with close evaluation, in 
order to identify and mitigate risks of increased drug use among young people. 
Inconsistency with other substance controls
We do not have consistent and integrated laws to regulate the production, 
distribution and use of mind-altering and harmful substances, such as alcohol, 
tobacco and other potentially harmful drugs, including those for cognitive and 
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performance enhancement. Our attitudes to the public 
health consequences of tobacco and alcohol seem to 
be hardening. Smoking controls, alcohol pricing and 
sanctions for intoxication illustrate a move towards 
more controls and regulation. There appears to be 
a move in the opposite direction for some controlled 
drugs, particularly cannabis.148 With performance-
enhancing drugs, doubts have been raised about 
whether the current regulatory systems for medicines 
and medical devices can respond successfully to the 
problem. We believe all these changes represent 
a search for a new, more consistent and fairer 
equilibrium, and such moves should be welcomed and 
encouraged.
It is often argued that by reforming the law on drugs we may in fact make matters 
worse. Policy makers are understandably cautious. The concern is that, as we do 
not start from a blank sheet, relaxing the drug laws will send a message, and that 
this is likely to lead to an increase in consumption of drugs, especially amongst 
vulnerable young people. Supporters of the existing drug laws argue that they are 
drawing on the precautionary principle, which urges policymakers to be watchful 
and circumspect. 
In one analysis of the relationship between the precautionary principle and 
evidence, reference is made to an international exposition of the issue in relation 
to the environment: “Where an activity raises threats of harm to the environment 
or human health, precautionary measures should be taken even if some cause 
and effect relationships are not fully established scientifically. In this context the 
proponent of an activity, rather than the public bears the burden of proof.”149 Clearly 
for many people who are cautious of changes to drug policy, the case for change 
has not so far been adequately made to meet the burden of proof.
Yet for proponents of drug policy reform, the arguments largely rest on the 
basis that sufficient evidence has accrued to show the negative consequences 
of current policies. Thus, it might be argued that the burden of proof should 
be reversed and that the precautionary principle would indicate that it is those 
who seek to use laws to restrict drug use who need to demonstrate that such 
interventions are necessary.
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However, while there may be a strong 
case for reforming the drug control 
laws, there is still a need for caution in 
any changes. We return to this debate 
in Chapter Five, where we present our 
recommendations for how drug policy, 
including the drug laws, can be used 
most cost effectively to support responsible behaviour. 
Designing enforcement in order to meet the goal of supporting responsible 
behaviour opens up the potential to achieve additional benefits beyond that of 
merely enforcing the law and hence can bring wider benefits to communities. It 
can encourage innovation with the potential for developing more cost-effective 
interventions. 
IMPROVED RECOVERY – FOR INDIVIDUALS, FAMILIES, 
NEIGHBOURHOODS AND SOCIETY
In 2008, in response to what was becoming an increasingly polarised debate over 
what constitutes recovery from drug problems, UKDPC facilitated a consensus process 
which brought together a disparate group of people to develop a shared vision of 
recovery.150 The group included several people in recovery, and family members 
of people with drugs problems, as well as local commissioners and practitioners 
coming from services that provided a full range of types of care and support. 
Participants also came from different parts of the UK and different ages and cultural 
backgrounds. This group developed the following consensus view on recovery: 
The process of recovery from problematic substance use is characterised by voluntarily-
sustained control over substance use which maximises health and wellbeing and 
participation in the rights, roles and responsibilities of society. 
The term “control over substance use” is deliberately inclusive of both abstinence 
and maintenance approaches to recovery: both can provide the necessary control 
over substance use. However, it was agreed that neither ‘white-knuckle abstinence’, 
with a constant fear of relapse, nor being 
‘parked’ on prescribed drugs, with little 
consideration of people’s individual 
needs and aspirations (which may 
change over time), constituted recovery.
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Recovery is neither an easy, nor a linear 
process. It takes considerable time and effort to 
achieve and sustain, both for individuals and 
hard-pressed communities. Yet, there is good 
evidence that treating people who have drug 
problems can have a big impact. Treatment 
for drug dependency and addictions has a 
robust international scientific evidence base 
to justify the provision of public expenditure, 
and has proven efficacy.151 152 The use of methadone and other prescribed 
medications as part of a treatment package has substantial research evidence in 
support, including use in prisons. It is important that these treatment options are 
retained while evidence is built up for other interventions to facilitate recovery. 
But as reflected in the second half of the vision statement, it was also considered 
very important to recognise that recovery is about more than reducing or removing 
harm caused by substance misuse, as it must also encompass building a fulfilling 
life. This involves improving health and well-being, rebuilding relationships, and 
participating fully in society, for example through education, voluntary activities 
or employment. Above all, the group recognised that while the individual must be 
placed at the heart of recovery, their relationship with the wider world - family, 
peers, communities and society - is an intrinsic part of the process.
The statement also reflects the evidence about how the community, the wider 
environment and facts such as deprivation and disempowerment can influence 
recovery: something that is not often addressed. 
Recovery and communities
Our research into the stigma experienced by people with drug problems and 
their families, and the impact this has on their potential recovery highlighted the 
importance of this issue, if the vision for improved recovery in the current drug 
strategy is to become reality. 
Part of the research was a UK-wide household survey of public attitudes towards 
people with a history of drug dependence. This showed a general support for 
the idea of recovery - 81% of respondents agreed that it is important for people 
recovering from drug dependency to be part of the normal community, and 73% 
agreed that people recovering from drug dependency should have the same rights 
to a job as anyone else. However, 43% of adults said they would not want to live 
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next door to someone who had had a drugs problem, which compared with only 
9% who in a similar survey said this about someone with mental illness. Only 
two-fifths of people (41%) would be willing to work with someone with a history 
of drug dependence and 39% think someone with a history of drug dependency 
should be excluded from public office. 
This stigmatisation is also evident in many government pronouncements about 
the welfare system, in which those with drug problems, although only a small 
proportion of those on benefits, are singled out as being targets for specific action. 
This may, paradoxically, make it harder for people in recovery to obtain work.153 
The basis for this stigmatisation of those with drug problems appears to be a lack of 
understanding about addiction, and seeing it as a matter simply of personal choice. 
Our research also indicated that a large proportion of the general public believe that 
people with drug dependence are to blame for their problems, and could give up 
if they really wanted to. However, the situation is far more complex than that and 
there is a need for better information and a wider debate to address this. Our research 
also showed that press reporting of drug use is dominated by themes of crime and 
celebrity and often uses pejorative language that frames the public understanding 
of drug dependence. Recovery and integration are rarely spoken about.
The research also showed that in general, respondents who currently or 
previously had lived, worked or were close friends with someone with a history of 
drug dependence, had more positive attitudes to such people than those who had 
not had any personal experience. This suggests that stigma within communities 
might be reduced through:
•  Improving the knowledge and understanding among the general public about 
drug dependency and recovery
•  Engineering new ways to support and promote community participation 
and increased contact with recovering drug users. The Brink recovery bar 
in Liverpool established by Action on Addiction, and the Tea Room Social 
Enterprise set up by Burton Addiction Centre are examples of this sort of 
approach. These promising innovations need to be evaluated and the lessons 
disseminated.
A key aspect of participation in society involves employment. Further research 
commissioned by UKDPC to examine employers’ attitudes identified two main 
concerns for employers about hiring recovering drug users: the requirement 
for individuals to be ‘fit for the job’; and the potential risk to their business or 
other employees. Nevertheless, in many cases where recovering users had 
been employed they were seen as good 
employees. Our research found that 
experiences of employing this group are 
often very positive.
But two-thirds of employers in a survey 
said they would not consider hiring 
someone with a history of heroin or 
crack use even if they were otherwise 
suitable.154 Specific concerns described 
by employers included dealing with 
relapse, recognising the recurrent nature of the condition, risks to other 
employees, and concerns about methadone. 
The research also identified a number of legislative and administrative barriers 
which can diminish the likelihood of people recovering from drug problems to get 
a job. For example, the Equalities Act contains a specific exclusion for people with 
drug or alcohol addiction from the Disability Discrimination protections; many 
employers even within the drug sector impose arbitrary requirements for someone 
to have been two years drug free before they can be considered for employment; 
and a criminal record is becoming an ever greater barrier to work as more and 
more employers apply CRB checks for new applicants.
Parliament approved changes to the Rehabilitation of Offenders Act (ROA) in 
May 2012155 which aim to reduce the impact that having a criminal record has on 
getting a job. Given that employment can be hugely important to aid recovery from 
drug problems, this change is welcomed, even though some commentators have 
argued that it does not go far enough. As Jonathan Aitken has said, “Looking at 
the reforms there are some gains but a few disappointments”.156 We are of the view 
there is still scope for further amendments to the ROA so that there are shorter 
rehabilitation periods required where an offender has to declare their record.
Welfare reform is another government policy area which can have a major impact. 
About 80% of people entering treatment for drug problems are unemployed 
and the nature of drug addiction means 
that achieving recovery is a long-term 
process, many are in receipt of benefits 
for considerable periods of time. Evidence 
indicates that for many getting a job can 
only be a long-term goal, and is a lengthy 
process. Quite long periods of work 
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experience, such as volunteering, to help build skills, confidence and stability 
can be very valuable. Yet, pushing people into formal employment too quickly 
can create a vicious cycle of failure and relapse. It is clear that an approach 
based on using penalties within the benefit system to ‘encourage’ people with 
entrenched drug problems into work is not supported by the evidence,157 and it 
assumes that finding work is a simple matter of choice on the part of the drug 
user. So there is a risk that changes to the system will have a differential impact on 
this already disadvantaged and vulnerable group, and there is some evidence to 
suggest that this may be already happening with the current reforms, such as the 
implementation of the Work Capability Assessment.158 
Removing legislative and administrative restrictions which reinforce 
stigmatisation of people with drug dependence and addictions is therefore 
another important area to take action to develop recovery-oriented communities.
Recovery and the Criminal Justice 
System
There is evidence that certain types of 
enforcement activity may be able to reduce 
the harm to the community from certain types 
of crime and also provide a starting point for 
recovery. Operation Reduction in Brighton & 
Hove, described earlier, incorporates assertive 
outreach to encourage people dependent on 
drugs, who are dealing to support their drug 
use, to engage with treatment, and to achieve recovery with sustained support.159 
The national Drug Intervention Programme, and Integrated Offender Management 
also aim to encourage engagement with treatment.
It is important that the criminal justice system is also focused on recovery and 
supports the work done in the community. The ‘revolving door’ of short-term 
prison sentences that interrupt treatment and are too short to begin to deal with 
the complex issue of drug addiction was documented in our 2008 research review 
Reducing Drug Use Reducing Reoffending. Some progress has been made since, 
but the findings are still of relevance. We identified two broad areas where the 
evidence indicates a significant impact might be made:
1. The use of diversion and community punishments rather than imprisonment 
for most drug-dependent offenders.
Imprisonment can have unintended negative consequences for offenders 
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generally160 161 and with those who are drug-dependent, there are many practical 
issues which frustrate the delivery of successful drug treatment programmes in 
prisons, particularly for prisoners with short sentences. An environment which is 
struggling to cope with record numbers of prisoners is unlikely to be conducive 
to recovery, and custodial sentences may frequently do more harm than good. 
By creating or exacerbating problems such as housing, employment and family 
relationships and increasing health risks such as infection from blood-borne 
viruses, the chances of successful long-term outcomes are further reduced. 
Meanwhile enforced detoxification without adequate follow-up support also 
increases the risk of relapse, overdose and death, particularly on release. 
Maximising the use and cost effectiveness 
of community sentences is likely to be more 
beneficial than imprisoning problem drug-
using offenders for less serious acquisitive 
crimes and drug possession offences. This 
appears to be increasingly recognised 
by the low levels of prison sentences for 
possession alone. 
Community sentences have the potential to offer better value for money and 
deliver similar reductions in reoffending. However, we need to pay attention to 
how to make these sentences more cost effective by thinking about how they work 
with models of behaviour change and what is known about recovery processes. 
Evidence from Project Hope in the US and related projects suggest that clear, swift 
and short penalties for breaches are important for success, but the evidence is from 
a cohort of mainly stimulant-using offenders. Recent research on drug courts also 
highlighted community sentences’ potential to provide wider benefits although 
outcomes are quite variable.162 More research into ways in which community 
sentences in this country can be developed to enhance their cost effectiveness 
and recovery focus is needed.
For less problematic drug users, schemes that divert drug-using offenders in 
the early stage of offending, and before their criminality and drug problems 
have become entrenched from prosecution on condition that they address their 
substance use and other problems, may merit being expanded. Imprisonment is 
more likely to entrench some problems for the offender and their family, rather 
than solve them. Using restorative justice may be appropriate in some cases. 
Chapter 3  What a Fresh Approach Could Look Like
Imprisonment is more 
likely to entrench 
some problems for 
the offender and their 
family, rather than 
solve them.
128 129
2. Prison drug services could be improved 
further and linked into community recovery 
systems.
With so many drug-dependent offenders 
within the prison system, largely because of 
non-violent acquisitive crime offences, the 
extent and effectiveness of drug treatment 
and other interventions must be improved so that prison care is equivalent to that 
found in the community. The rollout of the Integrated Drug Treatment System 
is a positive step but continued improvement is necessary. The evaluations of 
this and of the new Drug Recovery Wings need to be used as the foundation for 
continuous improvement. 
Release is a time of particular risk as there are high rates of drug-related death and 
relapse into drug use.163 Developing support and aftercare needs to be a priority. 
The pilot at Peterborough prison using a payment by results approach may 
provide a useful model and there are initiatives elsewhere. It is important that 
these are all evaluated and good practice spread more widely. Key areas which 
could lead to significant improvements in levels of recovery include:
• The process for identifying problem drug users on reception
• Ensuring all prison healthcare adheres to NICE and other clinical guidelines
•  Enhancing performance management and clinical governance of prison 
healthcare
•  Continuity of care within the prison system and with community services before 
prison and after release.
Recovery and families
Children of drug-using parents are at particular risk; their needs were 
highlighted in the ACMD report Hidden Harm164 and since then more attention 
has been paid to them, and a number of programmes developed to try to address 
these needs. Some of these programmes are the subject of evaluation and are 
showing promising results, for example the Moving Parents and Children 
Together programme165 and the Family Drug and Alcohol Court, which seeks 
to work with families at risk of having their children taken into local authority 
care.166 It is difficult to evaluate their cost-effectiveness though because of the 
potential long-term nature of the impacts.
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Adult family members and close friends of people with drug problems can also 
experience significant stress and health problems. The impact can also spread 
more widely, for example affecting family members’ employment, their social 
lives and relationships, and the family finances.
However, adult family members affected by a relative’s substance misuse have 
been largely neglected, partly due to concerns about stigma, but also because 
the focus and that of drug treatment services has been first and foremost towards 
helping the person with the drug problem. To put this in perspective, research for 
UKDPC167 estimated that in 2008 in the UK, at the very least:
•  1.4 million adults were significantly affected by a relative’s drug use (including 
about 140,000 adult relatives of people in drug treatment)
• the cost of the harms they experienced was about £1.8 billion per year, and
•  the value of support they provide would cost about £747 million per year 
 (at 2008 prices) if it was to be delivered by health and social care providers.
Clearly, families and the support they give are a crucial asset to those needing their 
help and for the wider community. Adult family members’ support for their drug-
using relative has been shown to be important in three distinct but related ways:
• Preventing and/or influencing the course of the substance misuse problem 
•  Improving substance-related outcomes for their drug-using relative, i.e. 
reduced substance misuse, as well as promoting better engagement with 
treatment 
•  Helping to reduce the negative effects of substance misuse problems on other 
family members.
Thus adult family members may need help to meet 
their own pressing needs, but also to assist them 
to give effective help to their drug-using relative 
and to other family members. However UKDPC 
research168 has indicated that the provision of 
support to this group, although acknowledged 
often in drug policy documents, remains a 
comparatively neglected area which deserves more attention. 
There is a need to consider what recovery means for families, what White & 
Kurtz169 describe as “family recovery”, as well as for the individuals with drug 
problems themselves and support provided to family members to help them and 
the family unit adjust.
How recovery is 
achieved, and the 
time taken, differs 
from person 
to person.
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Recovery for individuals
There has been a welcome increased focus 
on recovery in drug strategies in the UK,170 
accompanied, and no doubt stimulated by, 
a burgeoning recovery movement. However, 
focusing on recovery is not simply about 
providing particular types of services, but 
rather about people directly controlling 
their own care, shifting the balance of power 
towards individuals. It also seeks to build hope and aspirations across a range 
of areas leading to the achievement of a fulfilling life, rather than focusing on 
clinical symptoms and the chronic nature of the condition. This requires a 
significant change in culture within many services, as well as the development 
of new services and new partnerships, for example developing links between 
treatment services and mutual aid groups. The challenge of this for the workforce 
should not be underestimated.
As is widely recognised,171 recovery differs between individuals. What causes the 
problems associated with substance use, and the extent of them, varies between 
individuals, as do the resources (whether personal or external) available to 
them and also their personal priorities. So how recovery is achieved, and the 
time taken, differs from person to person. Similarly, recovery may be associated 
with a number of different types of support and interventions, including medical 
treatments, or none at all.
This complexity was highlighted by the findings of a recent expert group looking 
at the role of medication-assisted treatment in recovery.172 The group highlighted 
a number of ways in which the improved outcomes resulting from the expansion 
of the treatment system over recent years can be increased further by making 
the system more recovery-orientated. These include ensuring that systems 
and services have a strong and clear vision and framework for recovery, that 
the treatment provided is optimised through proper care planning, review and 
adaptation to respond to failure and take advantage of windows of opportunity 
for improving progress. It identifies a need for ‘dynamic’ packages of care that 
deliver a range of interventions at different intensity at different times according 
to individual needs and choice. 
While the treatment itself needs to be individually tailored and follow best 
practice, the report also highlights the importance of a range of different types 
of support to facilitate recovery – whether via the person’s peers, employment 
Recovery is a process 
that takes time, 
and lapses and 
relapse must be 
expected in many 
cases, so people need 
continuing support.
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and housing, family support, and health and 
lifestyle interventions – support which will 
need to continue after treatment is completed. 
The report reflects that for most people recovery 
is an on-going process and they may always 
consider themselves ‘in recovery’ rather than 
recovered, although others may eventually feel 
that they are no longer at risk of relapse. It notes that recovery may be achieved 
in a variety of ways including through medically-maintained abstinence as 
well as for some people without professional assistance.173 Besides this tailored 
support, what is absolutely essential is a wider environment that is accepting of 
people trying to rebuild their lives, for example employers being more open and 
willing to give jobs to such people.
The development of recovery-oriented care systems is a major opportunity for 
change but this will take time. There are encouraging signs that this change 
is already beginning as increasing numbers of people leave treatment free 
from dependence, according to the most recent treatment statistics.174 There 
is an important opportunity for drug policy in fostering and developing such 
a system, but the evidence for how this can be done is still limited although 
there is useful evidence from the US and the mental health field that can 
provide some guidance.175 
Recovery is a process that takes time, and lapses and relapse must be expected in 
many cases, so people need continuing support. There are risks associated with 
relapse, which include an increased risk of overdose deaths. There is also good 
evidence that early re-entry to treatment once someone relapses is associated 
with much better long-term outcomes,176 so it is important that a focus on recovery 
outcomes does not lead to negative unintended consequences. The use of 
outcome measures that include abstinence-based discharge and no readmission 
within a particular time period may have the potential to lead to these negative 
consequences, as does an emphasis on full recovery that may make people feel 
they have failed if they relapse. 
Payment by Results systems, whereby the providers of services are paid for the 
results achieved, are being piloted and evaluated as a way of incentivising change 
to a focus on recovery in treatment services, but the evidence casts doubts on the 
likely impact and value for money of this approach.177 178  
The development 
of recovery-oriented 
care systems is a 
major opportunity 
for change.
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There are many ways in which the treatment system can be changed and 
incentivised to improve the chances of recovery and it is important that all of 
these are explored and evaluated. There are examples of innovative practice 
being developed at the grassroots, ranging from working with current 
providers to provide more integrated, recovery-focused provision, through 
the development of new services and organisations, such as recovery cafes 
and social enterprises to provide training and employment opportunities, to 
schemes that allow service users to earn credits from voluntary activities that 
can be put towards activities of their choice that may assist their recovery. The 
sharing of best practice is very important.179  
Within these new developments it is very important not to ignore the evidence 
we do have for the cost effectiveness of current treatments, such as substitute 
prescribing, as well as for new treatments such as heroin prescription for those 
for which traditional treatments have not worked. The importance of these, 
and indeed of the harm reduction services such as needle exchanges and drug 
consumption rooms for helping people begin the recovery process, should not be 
underestimated. 
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KEY POINTS
>Independent research on what works in drug policy 
receives comparatively little funding in the UK, compared 
with some other countries
>The government’s Advisory Council on the Misuse of Drugs 
(ACMD) is under-resourced and in the context of the rapid 
appearance of new drugs, this risks pushing the balance 
of its work towards classification assessments rather 
than broader policy issues
>The UK is unusual among EU countries in having the Home 
Office as the department responsible for drug policy
>There is little political space for informed debate about 
policy options
>Localism and devolution may lead to policy experimentation 
but limit the ability of the government to pursue a single drug 
strategy and to share knowledge.
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In most discussions, drug policy is presented 
as a simple struggle between two opposing 
value systems: whether to liberalise our 
approach to drugs or to wage war on the 
producers, traffickers and users. This debate 
is an extension of moral views on whether 
drug use is intrinsically wrong. Supporters 
of either outlook dominate the airwaves, the 
press, blogs and social media. 
In this environment, expert views and 
evidence get labelled as coming from either one outlook or the other and treated 
with suspicion, so we lose not only a measured review of evidence but also the 
possibility of having the kind of nuanced, practical discussion that we need. 
A crucial question is whether anything can be done to facilitate a more informed, 
objective and less sensationalist debate about drug policy in the UK. With this in 
mind, we believe that there are four areas where the ways in which we make and 
deliver drug policy are limiting our ability to have more cost-effective policies. 
THE SHORTAGE OF INDEPENDENT ADVICE AND ANALYSIS
The Advisory Council on the Misuse of Drugs (ACMD) has provided sensible and 
balanced analysis on a range of diverse drug policy issues for over 40 years.180 
In essence, the ACMD provides two types of advice to Ministers: (i) scientific 
assessment and advice about whether particular substances should be controlled 
and, if so, in which class and schedule they should be placed, and (ii) expert 
advice on a wide range of drug policy issues, drawing on research evidence and 
professional and public consultation, with the aim of improving public policy. 
In earlier years, much of the ACMD’s work was directed at this second area, such 
as its work on AIDS and drug misuse, prisons, probation, policing, treatment, 
children, and parents with drug problems; much drug policy and government-
initiated interventions stemmed from its findings. 
The very small budget of the ACMD is coming under increasing strain, with limited 
support available for the voluntary members during their work. While the ACMD’s 
work includes a recovery committee, there are significant areas of policy that are 
not being examined, such as the impact of law enforcement interventions. With 
a more devolved approach to policy beginning to emerge, it may be opportune 
to revisit the role and contribution of the ACMD in order to see whether and how 
these two functions can be optimised.
A crucial question is 
whether anything can 
be done to facilitate 
a more informed, 
objective and less 
sensationalist debate 
about drug policy 
in the UK. 
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(i) the function of assessment of harms 
The classification and scheduling of particular drugs has become the focus of 
public and political debate, and in the process the media and politicians have 
started assuming that this is the only route to exerting control over drug use. 
Yet experience suggests that this is not the case. In practice, the stage has been 
reached where there is an expectation that all new psychoactive substances 
will be subjected to legal control, while any suggestion of changing existing 
classifications has become highly controversial. 
There is a good case for now considering whether the current process for assessing 
and classifying drugs needs to be re-modelled. This was initiated by Charles Clarke 
when he was Home Secretary, but the process was dropped by his successor. 
When the Misuse of Drugs Act was passed in 1971, the principal aim of the 
classification and scheduling system was to guide the courts about sentencing. 
Subsequently, the Sentencing Council has been established in England to ensure, 
in part, better sentencing consistency. In 2012 the Sentencing Council published 
new guidelines for drug offences.181 As is discussed elsewhere, we have reached 
the conclusion that the ABC drug classification system should be reviewed. 
The ACMD has raised the possibility of a new statutory body being established, 
which would be responsible for determining whether a new substance is very 
similar (an ‘analogue’) to other controlled drugs.182 While we have concerns about 
this approach to classification,183 this idea of establishing an independent body, 
which could make decisions on levels of control, may be promising.
In New Zealand, a Law Commission review of 
their drug laws, which are very similar to those 
in the UK, proposed a different solution to the 
regulation of new drugs.184 The new regime 
would require manufacturers and importers 
of a new substance to obtain an approval for a 
substance before releasing it onto the market, 
based on trials that find it to pose a ‘low risk’. A 
new independent regulatory authority would 
determine applications for approvals. If the 
regulator decided that a substance was so harmful that it should not be approved, 
the regulator would refer the substance on to be considered for inclusion in the 
prohibited drugs regime. Prohibition would also be considered if the regulatory 
regime proved to be ineffective in minimising the harm of a regulated drug.
There is a good case 
for now considering 
whether the current 
process for assessing 
and classifying 
drugs needs to be 
re-modelled. 
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(ii) Research and policy analysis
Policy makers should be strongly in 
favour of better knowledge and evidence 
in policy making. While the government 
has established a cross-departmental drug 
research coordination group and is seeking to 
boost EU collaboration on drug research, the reality is, at a time of austerity across 
all government departments, research has been afforded a lower budget priority.
Government spending on research to support the drug strategy has declined 
over the past few years. There have been some exceptions, such as the Medical 
Research Council and Economic and Social Research Council’s joint addictions 
research programme. However, this is focused on certain research interests and 
many drug policy issues and challenges are not being examined, especially those 
relating to efficacy, cost-effectiveness and alternative policy options. The UK fares 
badly in investment in research when compared with some other countries. For 
example, in Australia there is a substantial programme of drug policy research 
carried out through a network of university research centres, some of which are 
funded by the Federal and State authorities alongside substantial independent 
foundation funding.
In a review of the lessons from one of the few independently funded research 
programmes into drug policy, the Joseph Rowntree Foundation observed, “If 
evaluations are to be impartial and if we want government-supported research to 
contribute to our wider understanding of drug issues, it may be best conducted 
elsewhere in an arm’s-length organisation that recognises and responds to the 
needs of policy-makers but also prioritises the need for us to understand more about 
drug-related problems in the UK and what the most effective responses may be”.185 
The Canadian Centre on Substance Abuse also has a legislated mandate to provide 
national leadership and evidence-informed analysis and advice to mobilise 
collaborative efforts to reduce alcohol and other drug-related harms. Its annual 
costs, principally met by the government, are about £4.7m. We believe there 
is a strong argument for establishing something similar in the UK which could 
provide authoritative independent support to policymakers in Westminster and 
the devolved governments. It would not necessarily have to be a body carrying 
out the research itself but could be responsible for commissioning research by 
other groups and then analysing and reporting the findings. 
Policy makers should 
be strongly in favour 
of better knowledge 
and evidence in policy 
making.
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CONSEQUENCES OF HOME OFFICE LEADERSHIP
There has been some debate about the merits of the Home Secretary having the 
responsibility for the coordination and leadership of drug policy. 
It was not always the case that the Home Secretary had this responsibility. 
Between 1994 and 2002, the Lord President of the Council (the senior Cabinet 
Office Minister) provided coordination and leadership. This responsibility was 
transferred to the Home Secretary in 2002. In their report, the Royal Society for Arts 
Drugs Commission recommended that responsibility for leading the drug strategy 
should be passed to the Department for Communities and Local Government.186 
An argument for this is that Home Office leadership encourages a view of drugs 
as largely a crime issue rather than a matter for health responses. As identified 
earlier, in Wales, Scotland and Northern Ireland there are differing arrangements 
about which Minister coordinates policy.
In many other countries, especially in the European Union, national leadership 
and coordination is provided by the Ministry of Health. Throughout the UK there 
has been a renewed focus and political interest in public health since 2010 and 
especially on issues such as alcohol. In England a new body, Public Health 
England is being set up which will include substantial resources being transferred 
to support drug treatment.
In some ways, the argument about who leads 
or coordinates drug policy might be seen as an 
academic one. In our study of the governance 
of drug policy, we could find little concrete 
evidence that different departmental leadership 
delivers different outcomes.187 Those people we 
interviewed felt that the quality of the leadership 
was probably more important than which Secretary of State had responsibility 
for coordination and leadership. Indeed, the argument was advanced that 
without the strong influence of the Home Office and their overriding interest in 
reducing crime, efforts to expand drug treatment and recovery services would 
never have happened. Those leading health, it is argued, will always have other 
and more pressing priorities. As one participant observed, “big political beasts 
make things happen”. 
But there remain reasons why we should consider changing the political leadership 
and coordination of drug policy, and we return to this issue in Chapter Five. 
We should consider 
changing the 
political leadership 
and coordination 
of drug policy.
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LACK OF CONSTRUCTIVE POLITICAL DEBATE
There is already substantial political consensus about drug policy across the 
UK. As one ex-Permanent Secretary pointed out to us, drug policy is largely a 
politically settled matter, with the positions of at least the two main parties in 
England converging on the need to sustain efforts against organised crime, and 
to provide help for people addicted to drugs to achieve long-term recovery. Yet 
many communities, families, treatment providers and increasingly the police do 
not agree that there is ‘no real problem’ with drug policy that requires attention. 
Or in other words, many argue that the system is in some ways at least partly 
broke and needs mending. 
Probably most politicians are of the view 
that while drug policy may be imperfect, 
the alternatives are too risky or uncertain 
and, as one ex-Home Secretary said to us, 
the case for change has not been made 
adequately made. But, by not considering 
the alternatives, we risk missing productive policy options. 
As we highlighted at the outset, politicians are now questioning whether drug 
policies are working as intended. The experience of the debate about the use of 
animals in research is instructive for policymakers. After many years of the Home 
Office avoiding public discussion of the issue on the basis that it was seen as 
too controversial, later experience showed that it was relatively simple to have 
an evidence-based debate about the subject. Across many public policy areas, 
whether GM crops, abortion, homosexuality, civil partnerships or nuclear energy, 
what was once considered a ‘no-go’ area to question still remains the subject 
of controversy. But policy alternatives are debated, and increasingly are using 
evidence and informed analysis.
It is seen as particularly controversial to suggest that drug laws should be 
amended, which is perhaps why ministers and senior professionals generally 
only speak their mind about drug policy once they have left office, or in the 
early stages of their careers. This suggests the political space for developing an 
informed consideration of options and reaching consensus is too narrow. 
In this context, the rationale for the classification of particular drugs lacks public 
transparency and is sometimes contested, particularly for cannabis. In addition, 
the relationship between the classification of different drugs and regulation of 
drugs used for medical purposes, such as heroin derivatives used for pain relief, 
can be confusing. 
By not considering 
the alternatives, we 
risk missing productive 
policy options.
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This situation is further confused by different groups using terms such as 
`legalisation’ to mean very different things. Sometimes it is used to refer to the 
complete absence of restrictions on production or sale, while at other times it is 
used to describe a system of restricted sale, such as that for alcohol or tobacco 
products. For more details of the different terms used in the debate, see Box 10.
 
Box 10: 
LEGALISATION OR DEPENALISATION?
Decriminalisation: refers to the repeal of laws that define drug use or 
possession (but not selling or distribution) as criminal offences. It does this 
through either total repeal of penal punishments (ie prison sentences) or 
shifting the basis to civil penalties, such as fines or removal of a licence, 
or administrative processes, as in Portugal. In Portugal, drug use and 
possession are still legally prohibited, but violations are deemed to be 
simply administrative offences and are dealt with by ‘Commissions for 
Dissuasions of Drug Addiction’ rather than criminal courts.
Depenalisation: refers to the reduction of the level of penalties associated 
with drug offences, usually those for personal use or possession. For 
example, ‘depenalisation’ applies to the introduction of warnings or 
cautions for cannabis possession, rather than potential time in prison.
Legalisation: refers to making drug use, possession, production and 
distribution legal. Unlike decriminalisation, legalisation would repeal 
all penalties, criminal and civil, for use, possession, production and 
distribution of a substance. However, ‘legalisation’ would most likely 
still require other types of controls and regulations to be put in place (eg 
restrictions to licensed proprietors, and age restrictions on sales).
Regulation: imposes conditions on the manufacturing, dispensing, 
approval and marketing of substances. These laws bind manufacturers and 
distributors and penalties range in severity and may be civil or criminal. 
Examples include food labelling requirements, age restrictions on sales, 
and the more stringent controls for dispensing medicines.
From ‘Taking Drugs Seriously’, UKDPC/Demos 2011
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LOCALISM AND DEVOLUTION: OPPORTUNITIES AND RISK
The devolution programme implemented since 1997 has opened up different 
approaches to drug policy throughout the UK. Although the Misuse of Drugs Act is a 
Westminster reserved power, responsibility for much of the health, educational and 
local enforcement efforts have been devolved, initially to the new administrations 
in Scotland, Wales and Northern Ireland. More recently in England, responsibilities 
are increasingly being devolved to local councils (who will have responsibility for 
the drug treatment budget which will no longer be ring-fenced) through Health and 
Wellbeing Boards and to new institutions such as Police and Crime Commissioners, 
Clinical Commissioning Groups and Academy schools. 
This new settlement appears to be enabling three connected things to happen: (i) 
subtly different interpretations of UK-wide strategies, as, for example, in Wales 
where there is a combined drug and alcohol strategy and in Brighton where a local 
commission is looking at policy alternatives (ii) policy innovation, for example in 
Scotland with minimum alcohol pricing and in many areas of England with new 
approaches to commissioning services and (iii) challenges to the implementation 
of UK-wide policies, such as the Scottish Government’s concerns about applying 
constraints on drug users claiming welfare benefits.
In the area of drug policy, there has been much concern over many years about a 
potential ‘postcode lottery’ which, by implication if not design, the new localism 
will facilitate. As reflected in the ACMD’s report on Policing,188 as far back as 1994 
there was concern about disparate local policing, prosecution and sentencing 
practices for drug offences. In drug treatment services, the pressing issue has 
been about differing access to services between localities and more recently, 
about diverse commissioning practices across the country. 
As a number of public policy commentators have observed, we appear to want 
both localism and to ensure consistency of service. It remains to be seen whether 
new approaches to improving the outcomes of public spending, such as through 
payment by results, will iron out some of these inconsistencies. In many respects 
this tension is an illustration of the inevitable challenge for a national drug strategy 
which is implemented locally through hundreds of local public institutions and 
civil society bodies via tens of thousands of professionals including police, 
teachers, doctors, nurses, prison and probation staff. 
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In this report, we have focused on identifying 
challenges, examining evidence, and 
suggesting alternative ways of approaching 
drug policy. In this final chapter, we make 
specific policy recommendations to address 
these challenges. 
Before doing so, we would like to make an 
important and perhaps surprising statement: 
we do not know definitively whether these 
proposals will work to reduce problems 
associated with drug use in the UK. As an organisation that exists to promote the 
use of evidence in drug policy, it would be inappropriate for us to assert with 
complete confidence that these proposals will achieve their objectives, without 
unacceptable costs or unintended consequences. 
However, our assessment of the current evidence supports their introduction. 
Policy success in one case may not translate to another, for example when a 
policy is introduced on a larger scale, among different groups, or implemented 
by different practitioners. This is a well-described phenomenon with the roll-out 
of pilot interventions across many public policy areas. Therefore, while we may 
be confident that these policies are worth trying, we do not claim that they would 
necessarily lead to unalloyed successes in all circumstances. But we should be 
able to move beyond creating effective policy simply by anecdote, producer 
interests, or by predetermined ideological positions.
For this reason, it is crucial that the 
introduction of these policies should be 
matched with significant efforts to monitor 
their impact. This will be valuable not only 
for demonstrating any successes in order to 
justify further expansion, but also to reduce 
the harm and costs caused by any cases where 
the changes are not beneficial. The data from 
this research should be used to shape future policies, so that the most efficient 
interventions are given the highest priority.
In presenting our recommendations, we have generally followed the structure of 
Chapters Three and Four. The one exception to this is in our recommendations on 
drug laws, which we have listed separately in recognition of the level of interest 
they may receive.
It is crucial that 
the introduction of 
these policies should 
be matched with 
significant efforts to 
monitor their impact.
While we may be 
confident that these 
policies are worth 
trying, we do not 
claim that they would 
necessarily lead to 
unalloyed successes 
in all circumstances.
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For more detailed conclusions and recommendations about issues across drug 
policy, see the reports that we have developed over our six years of work, which 
are available at www.ukdpc.org.uk.
We have already described how the traditional drug policy goals of prevention, 
treatment and enforcement are means rather than ends. This results in a narrow 
focus which restricts their effectiveness. There is a need to focus on broader goals to 
which all these policy approaches can contribute. We suggest working towards the 
goals of how society and government can support individuals to behave responsibly, 
and how they can enable and promote recovery from drug dependence.
SUPPORTING INDIVIDUALS TO BEHAVE RESPONSIBLY
The idea that wider social and environmental factors can turn an individual’s 
vulnerability to drug use into actual drug use, and to that use becoming problematic 
is well established. Equally, it is clear that there is a relationship between drug 
use and a range of other risky behaviours. This suggests that simply tackling drug 
problems and drug-using behaviour on their own will be insufficient to deliver 
responsible behaviour. Such efforts have to be integrated and coordinated with 
other social and economic policies. 
Key opportunities for policy to support these include:
• Tackle structural problems that increase risk of drug problems
Social problems, such as income inequality, lack of a sense of community, 
feelings of exclusion and disenfranchisement, are likely to have an impact on 
whether someone develops drug problems. 
It is important that this is recognised within 
social policy more widely. The potential 
impact on drug problems should therefore 
be considered in broader social policy impact 
assessments. This applies nationally and 
locally, and needs to consider particular sub-
groups within the population who may be 
disproportionately affected.
Reducing social problems like inequality in the UK may bring dividends in 
diminishing the number of people who use drugs and other substances and 
then go on to develop dependency. But such progress lies outside the immediate 
realm of drug policy. Consequently, much of drug policy appears to be a sticking 
plaster. This is in no way to denigrate its importance and contribution (as our own 
commitment to the field indicates). But if we want to make inroads into the drug 
The traditional 
drug policy goals of 
prevention, treatment 
and enforcement 
are means rather 
than ends.
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dependency that blights so many individuals, families and communities, then the 
evidence suggests that we also need to reduce inequalities and other associated 
social problems. 
• Develop and evaluate early interventions to help families and communities build 
resilience to drug problems alongside other problems
These programmes have the potential to provide a wide range of benefits beyond 
reducing drug problems but the evidence for their effectiveness is mixed. 
Nevertheless, there is some evidence for the cost effectiveness of some of these 
programmes, and this needs to be expanded and developed further. While it 
is likely that the overall impact on drug problems will be modest, there will be 
benefits in other areas as well.
• Provide evidence-based prevention 
programmes to support less risky choices
There is little evidence that drug-specific 
education makes a difference to the 
prevalence of drug taking. But we can give 
young people accurate information about 
drugs and other substances and their risks 
to influence drug-taking behaviour. While 
the evidence for cost effectiveness of drug-
specific education is weak, there is evidence 
to support broader programmes that address behaviour more generally and build 
self-efficacy, help with impulse control and teach life skills and these should be 
part of the national curriculum. 
However there are also programmes that have been shown not to work and 
these should not be supported. Schools need to be provided with the necessary 
information to make sure they are in a position to choose cost-effective programmes. 
We need also to reframe what we intend drug education to achieve. Its purpose 
ought not to be about preventing drug use, (otherwise it will be perceived to have 
failed); its value lies in helping provide a broad knowledge base for young people 
about substances and situations which they will be likely to come into contact 
with as they mature.
• Promote interventions which reduce the harms of drug use 
There will always be some use of psychoactive substances, and some people will 
become dependent on them. There is good evidence supporting a number of ways 
in which people who use drugs can be enabled to do so in such a way that the harm 
to themselves and nearby community are minimised. These include traditional 
Schools need to be 
provided with the 
necessary information 
to make sure they 
are in a position to 
choose cost-effective 
programmes. 
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harm-reduction programmes, such as needle and syringe exchanges to reduce 
the spread of blood-borne viruses, and drug consumption rooms, where those 
continuing to use drugs can do so with medical support to hand, and promising 
innovative approaches relating to recreational use, such as pill-testing services 
available in or near nightclubs.
• Involve local communities in law enforcement 
and assess its impacts
The evidence is weak for the efficacy of 
most traditional drug enforcement activity, 
especially that directed at major and middle-
level drug dealers and criminal networks as 
well as border interdictions. But what there 
is supports interventions that take a problem-solving approach and that involve 
local communities. The traditional indicators, of numbers of arrests and amount 
of drugs seized, do not necessarily reflect success in reducing the availability of 
drugs and the damage to communities. 
A smart approach to enforcement that more clearly focuses on harm and 
differentiates between offenders at different levels in the supply chain and 
according to the harm they cause also has growing support from the evidence. 
But a more systematic approach to monitoring and research is needed.
All drug enforcement operations should be 
assessed to demonstrate their proven impact 
on communities, to allow for continuous 
improvements and better value for money. 
At the community level, enforcement should 
involve the affected communities in identifying 
problems and setting priorities to help focus 
on the most harmful aspects of drug markets. 
Research on the impact of different approaches 
to enforcement on drug-related harms should 
also be undertaken to show what works under 
what circumstances and what approaches provide best value for money. 
Many attempts at enforcement such as crackdowns, intelligence gathering 
operations, border interceptions and so on have never been subject to robust 
independent appraisal as to their value for money. Relying on numbers of people 
arrested or volume of drugs seized are poor proxies for understanding whether 
such enforcement activity is making a sustainable difference. 
Enforcement should 
involve the affected 
communities in 
identifying problems 
and setting priorities.
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STIMULATING AND PROMOTING RECOVERY 
FROM DRUG DEPENDENCE
The new focus on recovery from drug dependence provides an important opportunity 
to increase the effectiveness of drug policy. However, as is recognised in the drug 
strategies across the UK, improved rates of recovery from dependence require the 
involvement of more than just treatment systems and government services.
National and local efforts to provide stable accommodation and get people into 
work are commendable, even if many professionals doubt that this will be easily 
achieved given the current economic circumstances and the limited housing 
stock. But it is also about more than just government services, although it is 
important that all policies work together to promote recovery, something that is 
not always the case at present. 
• Tackle stigma towards people with drug 
problems and their families
Society as a whole needs to be engaged if we 
are to achieve the goal of reintegrating people 
with drug problems. For this to be successful, 
tackling the damaging stigma towards people 
with drug problems will be vital to provide a 
foundation and then an environment in which 
recovery is possible. This needs to be wide-ranging and government can set an 
example, including through its announcements. A wider stigma ‘campaign’ 
could improve public and professional knowledge and understanding of drug 
dependence and recovery. If recovering drug users relapse, it will not be simply 
that they have ‘failed’ but rather, we will have failed them.
There is also a need for work with employers, to promote the benefits of employing 
people in recovery from drug dependence. The public sector should set an example 
by employing more people in recovery.
• Make the criminal justice system more focused on recovery
Different policies need to work together rather than against each other to promote 
recovery. There needs to be more support for smart enforcement programmes, such 
as Operation Reduction, that divert drug-dependent offenders into the treatment 
system instead of the criminal justice system and that work with communities to 
support them to reintegrate.
If recovering drug 
users relapse, it will 
not be simply that 
they have ‘failed’ but 
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Reducing the numbers of those sent to prison 
and improving integration between services 
in prisons and as part of community sentences 
and community-based services, can also 
contribute to a criminal justice system that is 
more recovery-focused.
The period when someone is released from 
prison is a particularly difficult time and while 
various efforts over many years have sought to improve outcomes in this vital 
phase, the goal of better reintegration remains a distant one. There is much that 
could be done to enhance policy and practice in this area. 
• Provide greater support to families of people with drug problems
People with drug problems are more likely to achieve recovery if they have a 
supported and supportive family. The involvement of adult family members of 
people with drug problems can promote recovery for their drug-using relative, 
but they also need support in their own right. This needs to be reflected in local 
area planning processes as well as in service development alongside the need 
to support children of drug-misusing parents. For families where substance 
misuse is intergenerational, new models of family intervention should be further 
developed and evaluated. 
• Continue to develop treatment systems, 
mutual aid networks and communities that 
support those recovering from drug dependence
To support recovery, a wide range of treatment, 
mutual aid and supportive local community 
approaches is required. Opportunities for action 
include promoting recovery through balanced 
treatment systems, which take account of 
the varied and individual nature of recovery, recognise diverse needs, and are 
underpinned by a competent workforce. The role of local communities including 
employers, faith groups and generic services should be enhanced, particularly if 
stigma among these groups is reduced. 
This requires investment in a skilled and competent workforce, as well as 
sustaining the level of spending on treatment and recovery services by the 
government and local councils. There is some evidence that mutual aid really 
helps recovery, and local groups should be supported. 
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THE LAWS ON DRUG PRODUCTION, SUPPLY AND POSSESSION
Our conclusions about how the law might be changed are structured in a possible 
order in which they could be introduced. We are aware that some are shorter 
term and some longer term adjustments. We do not seek to describe how they 
could work in detail, as we anticipate this to be the responsibility of others to 
progress, particularly given our proposal for a political forum to recommend next 
steps for drug policy. Our concern has been to consider how the control systems 
could be changed at a strategic level. Of most importance is careful monitoring 
and evaluation of the impacts of any reforms.
• Review the process for classifying controlled drugs
Given the challenges to the way in which drugs are currently classified, including 
the rejection of expert advice on some classifications, such as for ecstasy and 
cannabis, we have concluded that the 40-year-old ABC classification system 
and the process of providing advice to ministers and parliament has significant 
weaknesses. For many people it has lost credibility. 
There should be a wholesale review both of 
the Misuse of Drugs Act and the underpinning 
classification system. Such a review ought 
to examine the possibility of devolving 
decision-making responsibility to an expert 
body which could be accorded a statutory 
role to make classification decisions, with appropriate democratic safeguards.
This could enable it to revisit the relative classification of individual drugs, based 
on assessed relative harms, in order to end up with a more coherent framework. 
The ABC system is not perfect but it has an inherent logic, even if there is often 
only limited evidence upon which decisions can be based. The Misuse of Drugs 
Act could be amended to confer delegated decision-making powers either to the 
ACMD or to a new statutory body.
• Reduce sanctions for drug possession
For the reasons outlined in Chapter 3, the law on the possession of small amounts 
of controlled drugs, for personal use only, could be changed so that it is no 
longer a criminal offence. Criminal sanctions could be replaced with simple civil 
penalties, such as a fine, perhaps a referral to a drug awareness session run by 
a public health body, or if there was a demonstrable need, to a drug treatment 
programme. The evidence from other countries that have done this is that it 
would not necessarily lead to any significant increase in use, while providing 
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opportunities to address some of the harms 
associated with existing drug laws.
Given its relatively low level of harm, its wide 
usage, and international developments, 
the obvious drug to focus on as a first step 
is cannabis, which is already subject to 
lesser sanctions than previously with the 
use of cannabis warnings. This is something 
which has been gathering momentum in 
other countries. If evaluations indicated that there were no substantial negative 
consequences, similar incremental measures could be considered, with caution 
and careful further evaluation, for other drugs. 
These changes could potentially result in less demand on police and criminal 
justice time and resources. Given the experience of other countries, our 
assessment is that we do not believe this would materially alter prevalence 
levels, while allowing resources to be spent on more cost-effective measures 
to reduce the harms associated with drug use. We would expect the net effect 
to be positive.
• Address production and supply
Some people argue for the removal of criminal sanctions not only for possessing 
drugs but also for their production, trafficking and supply. Among the suggested 
advantages of this are increased tax revenues, putting a potential end to the 
criminal control of supply chains and associated violence, and an increased level 
of safety for users of controlled drugs.
However, other than possibly for 
cannabis, we do not believe there is 
sufficient evidence at the moment to 
support the case for removing criminal 
penalties for the major production or 
supply offences of most drugs. One of 
the lessons from the tobacco and alcohol 
markets is that commercialisation can 
lead to some disastrous consequences 
for the health and wellbeing of the public. As a result there have been moves in 
the alcohol and tobacco markets to put more trading restraints and regulations in 
place to reduce the effects of commercialisation. 
One of the lessons 
from the tobacco and 
alcohol markets is that 
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We appreciate that some will argue that the risks of the commercialisation 
of controlled drugs could be contained with careful regulation and that our 
position does nothing to deal with the negative consequences of the current 
system in places such as South or Central America, Central and South-East Asia 
or increasingly parts of Africa. It also would not address existing problems with 
drug contamination and unpredictable dosage levels. But our assessment is that 
such a change could lead to some hugely negative unintended consequences, and 
should be treated with caution.
For the most ubiquitous drug, cannabis, 
it is worth considering whether there are 
alternative approaches which might be more 
effective at reducing harm. For example, there 
is an argument that amending the law relating 
to the growing of it, at least for personal use, 
might go some way to undermining the commercialisation of production, with 
the associated involvement of organised crime and the development of stronger 
strains of cannabis (‘skunk’), that we have seen in the UK and other countries in 
recent years.
Fragmenting production could undermine organised crime networks. Perhaps the 
most expedient course to take here would be to re-examine sentence levels and 
sentencing practice to ensure that those growing below a certain volume of plants 
face no - or only minimal - sanctions. The impact of any such move would need 
to be carefully measured and evaluated so policymakers could make informed 
decisions about future actions.
• Review penalties for all drug offences
More generally there is a case for Parliament to revisit the level of penalties applied 
to all drug offences and particularly those concerned with production and supply. 
Even though maximum sentences are rarely applied, in recent years there has 
been a clear drift upwards in the length of imprisonment for drug production and 
supply offences. This incurs costs in terms of burden on the taxpayer, yet there 
is little evidence to support the idea this is a deterrent, or more importantly, any 
long-term impact on drug supply. 
We conclude that there ought to be a major review of the sentence framework 
under the Misuse of Drugs Act. Such a review lies outside the remit of the 
Sentencing Council which anyway has recently developed new guidelines for 
the courts. We propose a more fundamental review of the Misuse of Drugs Act 
including the justification for punishment levels across all types of drug offences. 
Fragmenting 
production could 
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We suggest that Parliament could do this itself or could look to a body such as the 
Law Commission. The priority for such a review should be to collect and evaluate 
evidence to ensure that penalties are working effectively to deliver proportionate 
justice for victims of drug-related crime, and to act as a deterrent for those whose 
activities are causing the most harm.
• Establish consistency in controls over all 
psychoactive drugs
Our final conclusion related to the law is 
more fundamental. One of the strongest 
criticisms of current policy is that harmful 
substances are dealt with through a range 
of legislative frameworks. For example, 
solvents are regulated through the 
Intoxicating Substances Act; alcohol and 
tobacco are regulated through trading 
standards and licensing as well as through 
taxation policies; while cannabis is classified under the Misuse of Drugs Act. 
This is not only inefficient, but because of such inconsistent control measures, 
it is sending confusing messages about the potential harms of such substances, 
especially to young people who have access to a plethora of information. 
It is hard to continue to ignore many of the contradictions inherent in current 
approaches to potentially harmful substances that also can confer some benefits. 
We therefore recommend a review to consider the implications of consolidating all 
legislation that covers potentially harmful substances, including alcohol, tobacco 
and solvents, as well as other drugs that are used for cognitive, appearance or 
performance enhancement, such as modafinil as a study aid or anabolic steroids 
for building muscle mass, into one Harmful Substances Control Act. 
IMPROVING STRUCTURES AND PROCESSES
It is over 40 years since the Misuse of Drugs Act became law and the UK’s drug 
problem is now much more severe than it was in 1971, even though in recent years 
there have been some significant gains. We have previously argued that drug 
consumption patterns are, in large part, driven by cultural and socio-economic 
factors rather than drug policy in itself. New psychoactive substances pose new 
challenges while at the same time our understanding of the problems associated 
with licit substances has grown. 
It is hard to continue 
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The debate about drugs is a hotly contested and polarised area and anyone 
entering it runs the risk of being characterised as being on one side or the other. 
However, it is clear that the UK’s drug problem is complex and multi-faceted, 
and simple solutions will not be cost effective. But we can do better in helping 
people behave more responsibly and when they fail to do so, assist them recover 
and reintegrate into society, or, if they are involved in serious crime, to punish 
them more effectively and proportionately. It is time to consider new legislative 
approaches fit for 21st Century problems.
• Introduce independent decision-making 
on drug harms
Both the Advisory Council on the Misuse 
of Drugs (ACMD) and the New Zealand 
Law Commission have proposed that an 
independent body could be empowered to 
take delegated decisions about controlling 
new drugs. There is some debate about the 
merits and downsides of setting up a body 
to take such decisions and whether such a 
body might be entrusted with reviewing 
the current arrangements for controlling 
existing drugs. 
Some experts have argued that either the ACMD or a new statutory body, with 
democratic safeguards, might assume delegated responsibility for taking 
decisions about the classification and scheduling of all substances, whether new 
or existing. The National Institute for Health and Clinical Excellence (NICE) and 
the Medicines and Healthcare products Regulatory Agency (MHRA) operate in 
this manner and although there are inevitable controversies, by and large the 
systems work well and are respected. With appropriate parliamentary oversight 
and accountability, we see no reason in principle why decision making over the 
process of classification might not be delegated in its entirety to a new statutory 
body. This might avoid some of the more inaccurate headlines which accompany 
the process of drug control. 
We therefore recommend that the government should initiate a formal review of 
the powers and remit of the ACMD and explore different options for the assessment 
of harms and the classification process.
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• Improve research and policy analysis
We need a new mechanism for embedding evidence and knowledge development 
into the drug policy process, incorporating evaluation of the drug strategy, and a 
coordinated programme of research and knowledge dissemination to politicians, 
policy-makers, practitioners, the media and the wider public.
If drug policy is to be effective and provide 
value for money, it is important to build 
learning and evaluation into the process. 
This needs to include learning from when 
things fail: if something is not working it 
should be stopped or changed and then re-
evaluated. 
While the ACMD has conducted some 
influential reviews and is respected internationally, we believe there is a need 
for a new independent body to build on this success, which could take on new 
functions to provide independent leadership and coordination of research and 
policy analysis. 
Working in collaboration with new bodies such as the College of Policing 
and National Institute for Health Research (NIHR), School for Public Health 
Research, as well as the established research councils and the devolved 
administrations, a new body could be charged with commissioning and 
managing research alongside evaluating the impacts of drug and alcohol 
strategies and intervention programmes. Such a body could take a role 
across the UK, which would allow it to exploit the opportunities for natural 
experiments arising from diverging drug policies.
The argument for a successor body to ACMD is strong, both to develop our 
knowledge and to respond to the pressures of the economic situation. The 
issue arises, of course, about how such a body might be funded. In addition to 
applications being made to the various research councils there may be a strong 
case for some of the resources being raised through the forfeiture of assets 
from drug-related crime. Perhaps some £10 million a year could be redirected 
for this purpose. We believe that the principle of re-channelling seized assets 
to help develop and improve our knowledge and understanding is a sound 
one, and a strong business case could easily be built to validate this. Such a 
body might be attractive also to some charitable trusts and foundations, given 
its independent status.
If drug policy is to be 
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• Move the political lead for drug policy
In the longer term, the prevailing policy and 
public debate needs to shift to one that is 
predicated on fostering an environment that 
values responsible behaviours, and which 
promotes recovery for those who develop 
drink or drug problems. This national 
conversation is best led by those dedicated to promoting better public health. This 
does not diminish the need to take strong action against those who break the law, 
such as those involved in serious or organised crime. It is the commercialisation 
of the production, distribution and sale of psychoactive substances about which 
we must remain vigilant. 
Transferring responsibility for coordinating and leading national drug policy from 
the Home Office to the Department of Health would facilitate the development of a 
more active public health approach to drugs, that can improve public and political 
understanding about how the UK should best respond to the drugs challenges 
over the next few decades.
We do not think that transferring leadership will bring substantial change, at 
least in the short or medium term. But as a symbolic measure it would signal a 
fresh attitude to drug policy. 
• Create a cross-party political forum to progress discussion about future policy 
We have already suggested that more independent research and analysis 
coordinated by a new body could provide more informed factual and analytical 
contributions to the debate about drug policy. In the past, one route for 
examining issues of major public concern would have been to set up a Royal 
Commission, but this approach has fallen out of favour in recent years. 
Parliamentary Committees provide valuable insights and challenge policies. 
This has happened with drug policy through both the Home Affairs Committee 
and the Science and Technology Committees.
In recent years, ad hoc expert commissions have been established, often chaired 
by a leading public figure, for example, on pension reform. Very occasionally, 
efforts have been made to achieve cross-party consensus on key issues, such as 
the establishment of the Commission on Funding of Care and Support, chaired by 
Andrew Dilnot. More recently, the Coalition Government has enlisted the services 
of a former Labour minister (eg Alan Milburn and Frank Field), to advise them on 
issues such as poverty. Recently, Peter Mandelson made a similar recommendation 
with regard to airport policy: “My proposal would be for the parties to hand the 
The national 
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issue to an independent panel of wise people which, working to a clear timetable, 
would assess the evidence and recommend the best approach”.189 All of these 
are designed in one way or other to put contentious issues into a more politically 
neutral space, with the aim of identifying new policies and forging a wider debate.
We believe that fundamental questions 
about the direction of drug policy need 
to be considered in a similar cross-party 
environment. The most productive way of 
making substantial improvements to drug 
policies may be for the leaders of the main 
parties in the Westminster and devolved 
governments to commit personally to setting up a cross-party forum tasked with 
exploring the question of ‘what next for UK drug policy?’. This body should also 
seek to engage the public, with the goal of both reflecting and informing public 
opinion on these issues.
When some serious questions are being asked about the cost effectiveness of 
current policies, we need to try and create a fresh national conversation to achieve 
progress.
• Evaluate local approaches
Devolution and localism should be seen as unique opportunities for natural 
experiments in drug policy which can, and should, be properly evaluated. 
Unfortunately we can find little evidence that either national or local public service 
bodies are considering this opportunity, except where they are initiated by central 
government, such as the payment by results programme or the Randomised 
Injectable Opioid Treatment Trial (RIOTT).
Across the fields of policing and healthcare, 
innovative approaches are both possible 
and desirable, for example whether and 
how the drug law is implemented, such as 
for possession of cannabis, or public health 
based efforts to provide help for those that 
continue to inject drugs. In the UK, we are 
poor at systematically developing independent knowledge about the impact of 
different approaches and transferring this knowledge into wider networks.
We have already mentioned the pressing need for an enhanced independent 
drug policy research capacity in the UK. But to complement this in a devolved 
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environment, there is also a need to ensure 
that knowledge is spread more widely. In the 
US, the Federal Government funds a major 
programme of grants of over $10 million 
for regional Addiction Technology Transfer 
Centres. The purpose of this programme is to 
develop and strengthen the workforce that 
provides addictions treatment and recovery 
support services to those in need. 
If we continue to pursue national policies of devolution and localism in policing, 
heath care and education, we can no longer rely on osmosis or the market to 
ensure that the evidence about the impacts of different approaches is spread and 
acted upon. National drug strategies must pay attention to the crucial need to 
build our research and knowledge base, and provide a mechanism to ensure this 
is transferred to the people that matter at the local level, whether these are local 
councillors, Health and Wellbeing Boards, Police and Crime Commissioners or 
professionals in a range of disciplines. 
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CONCLUSION
Conclusion
We cannot ignore the fact that there are various markets for certain drugs, which 
are governed by the normal rules of supply and demand. Governments across the 
world have sought to manage these markets by prohibiting these drugs, except 
in certain circumstances such as for medicines or research. But the markets have 
not behaved in the way governments intended. The full panoply of control and 
regulatory tools, with substantial enforcement resources to back them up, have 
not been able to significantly reduce drug problems, and in some cases to prevent 
them increasing. At best, controls may have kept the lid on the scale of the market. 
At worst, they may have exacerbated drug problems. 
This is not an argument for abandoning any attempts to control mind-altering 
drugs or to limit the harm that can be caused by their production, supply and 
use. The real challenge is in the development of drug policies that are based on 
the best evidence we can generate, and which can balance competing demands 
and interests. It is something on which our political leaders, domestically and 
internationally should seek to make new progress.
We think that six years of work by the UK Drug Policy Commission have not 
only contributed to the development of policies that will be more cost effective 
in addressing the UK’s drug problems, but have also demonstrated the value of 
independent analysis of evidence.
Our research has identified a number of specific 
policy proposals, which we are confident could 
be incorporated into practice for everyone’s 
benefit. But more valuable would be a change 
in UK drug policy’s relationship with evidence. 
A commitment to the use of evidence to inform 
which policies are adopted, combined with 
rigorous trials of new and existing policies, 
and a willingness to act on the results of this research, would go a long way 
towards ensuring that the UK has an effective and good value response to the use 
of mind-altering drugs. 
Our aim is that this, above all, will be the legacy of the UK Drug Policy Commission.
The real challenge 
is in the development 
of drug policies that 
are based on the 
best evidence we can 
generate.
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We all have an interest in knowing which policies work in tackling 
problems associated with drug use. Many members of the public, and 
many politicians, believe that our drug policies are not working. But 
the debate about how we address the challenges of mind-altering drugs 
is polarised in a way not seen in most other policy areas.
 
The UK Drug Policy Commission was established to address these problems 
in a different way. Its aim has been to show how independent scrutiny 
of evidence can produce both better results and more effective use of 
resources in drug policy and practice.
 
Existing drug policies have struggled to limit the damage drug use can 
cause, and now new challenges are emerging. The rapid development 
of new drugs is changing drug markets too quickly for the traditional 
methods we use to control drugs to be effective. The economic crisis may 
be impacting on the nature of drug use and drug problems and, with 
fewer resources, the capacity of services to respond will be limited further. 
Added to that, the speed and scale at which services are being devolved 
to a local level may create increasing and unpredictable variations in the 
kind of services offered in different parts of the UK.
 
In this report, UKDPC proposes a radical rethink of how we structure our 
response to drug problems.  It provides an analysis of the evidence for 
how policies and interventions could be improved, with recommendations 
for policymakers and practitioners to address the new and established 
challenges associated with drug use. 
 
UKDPC aims to foster a fresh approach to drug policy: one in which 
evidence takes priority, creating light rather than heat in the debate 
on drugs, so that we can create an environment that works to reduce 
dependence on drugs, safeguards communities and delivers value 
for money.
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